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Abstract 
 
Background 
The vascular endothelial growth factor (VEGF) inhibitor ranibizumab is emerging as 
an  efficacious  treatment  for  diabetic  macular  oedema.  Large  clinical  trials  have 
shown improvements in visual acuity and reduced central retinal thickness. Details of 
its effect on other retinal functional parameters are lacking. There is a concern that 
repeated ranibizumab treatment could exacerbate macular ischaemia or lead to global 
retinal dysfunction by inhibiting physiological isoforms of VEGF.  
 
Outcomes  of  surgery  for  advanced  proliferative  retinopathy  remain  variable  and 
post-operative  complications  including  recurrent  haemorrhage  can  limit  visual 
recovery. VEGF is strongly implicated in the pathogenesis of advanced retinopathy, 
so VEGF inhibition prior to surgery may improve outcomes. Trials have failed to 
demonstrate  a  clear  benefit  for  bevacizumab,  so  investigation  of  the  licensed 
intraocular agent ranibizumab represents a logical next step. 
 
Aims 
To investigate the effects of ranibizumab and laser treatment in diabetic macular 
oedema on the following parameters: visual acuity, protan and tritan colour contrast 
sensitivity, 4° and 12° macular sensitivity by microperimetry, electrophysiological 
indices  from  pattern and full  field  electroretinograms.  To report structural  retinal 
changes  following  ranibizumab  and  laser  treatment  in  terms  of  qualitative  and 
quantitative  optical  coherence  tomography  outcomes,  and  to  quantify  macular 
ischaemia by fluorescein angiography. 
To  investigate  the  effect  on  visual  acuity  at  three  months  post-surgery  of 
ranibizumab  pre-treatment  in  patients  undergoing  vitrectomy  for  advanced 
proliferative diabetic retinopathy. 
 
Methods 
Randomised clinical trial of intravitreal ranibizumab vs. laser in 36 subjects with 
centre-involving diabetic macular oedema (The LUCIDATE study).  4 
 
Randomised  clinical  trial  of  pre-operative  intravitreal  ranibizumab  vs. 
subconjunctival saline injection in 30 subjects undergoing vitrectomy-delamination 
for advanced proliferative diabetic retinopathy (The RaDiVit study).  
 
Results 
Thirty six subjects with diabetic macular oedema were recruited and 33 completed 
the trial. Ranibizumab treated subjects gained a mean of 6 letters compared with 0.9 
letter loss for laser at 48 weeks. Retinal sensitivity improved in the central macular 
4° and 12° in both groups but to a greater extent with ranibizumab. There was no 
evidence  of  worsening  global  retinal  dysfunction  by  electroretinograms  in  either 
group. Retinal thickness decreased in both groups: there was a 132 µm reduction in 
central  macular  thickness  with  ranibizumab  compared  with  103  µm  for  laser. 
Fluorescein  angiography  showed  no  evidence  of  significantly  increased  macular 
ischaemia in either group. 
 
Thirty  subjects  with  advanced  proliferative  diabetic  retinopathy  were  recruited, 
underwent surgery, and completed the study. At three months post-surgery, visual 
acuity  in  the  ranibizumab  group  was  53  letters  compared  with  47  letters  in  the 
control group. 
 
Conclusion 
In  diabetic  macular  oedema,  there  is  evidence  that  ranibizumab  leads  to  greater 
improvements in visual acuity and retinal sensitivity than laser, with a corresponding 
greater reduction in retinal thickness. There is no evidence that it worsens macular 
ischaemia or indices of global retinal electrophysiological function, but larger trials 
designed to address each of the outcomes investigated here would be required to 
confirm these findings. 
In proliferative diabetic retinopathy, there is evidence from this small pilot study that 
ranibizumab treatment  leads  to  better visual  acuity at  3 months  post-surgery. An 
appropriately powered trial would be required to confirm this.  5 
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1 Introduction 
 
Diabetes mellitus will become more prevalent over the next century and therefore 
presents  a significant  public health problem. Diabetic eye disease  will ultimately 
affect a considerable proportion of patients with diabetes and, if untreated, will cause 
sight  loss  from  diabetic  macular  oedema  and  proliferative  diabetic  retinopathy. 
Research into treatments for these two main causes of loss of vision in diabetes is 
therefore of critical importance. 22 
 
1.1   Diabetes mellitus and epidemiology 
Diabetes mellitus is a chronic disorder of glucose metabolism characterised by a 
deficit in insulin production or lack of response to insulin. In type 1 diabetes, there is 
an absolute deficit in insulin production by the pancreas, whereas type 2 diabetes is a 
syndrome  of  insulin  resistance  associated  with  obesity,  hypertension  and 
hyperlipidaemia, termed “the metabolic syndrome”.  Other types of diabetes include 
gestational diabetes or steroid-induced diabetes. In common to all types of diabetes is 
sustained  hyperglycaemia,  which  left  untreated  leads  to  complications  caused  by 
damage to the vascular and nervous systems. 
 
The  World  Health  Organisation  reported  on  World  Diabetes  Day  2012  that  an 
estimated 347 million  people worldwide had diabetes (defined by  fasting plasma 
glucose ≥ 7.0 mmol/l, or on medication for diabetes) and of these, 80% lived in low 
to middle income countries [1]. Numbers of people with diabetes are expected to 
increase enormously in the first third of the current century, fuelled in part by the 
accompanying rise in obesity and resultant increase in type 2 diabetes. Estimates for 
the prevalence of diabetes in 2000 stood at 2.8% with a predicted rise to 4.4% by 
2030 [2]. The predicted future global burden is shown in Figure 1.  
 
Exploring the likely age breakdown of those affected by diabetes shows that the 
largest increase will occur in the 45-64 age group in developing countries, shown in 
Figure  2,  demonstrating  that  this  disease  will  continue  to  affect  working  age 
populations and create a significant economic burden, particularly in those countries 
with  the  fewest  resources  to  deal  with  this.  In  developed  countries,  an  ageing 
population  means  that  the  largest  increase  will  occur  in  the  over  65s,  so  cost-
effective interventions for the management of diabetes and its complications will be 
important for health services in these countries. 23 
 
 
Figure 1 – World Health Organization data showing increased prevalence of diabetes 
by 2030 (data from Wild et al. [2]). 
 
 
Figure 2 – Numbers projected to be affected by diabetes broken down by age and 
development level (from [2]). 24 
 
 
In  the  United  Kingdom  (UK),  the  latest  estimate  for  the  number  of  people  with 
diabetes is derived from data arising from General Practice as part of the Quality and 
Outcomes Framework. This was reported by Diabetes UK, the leading UK diabetes 
charity, as 2.9 million in October 2011 [3], giving an overall prevalence of 4.45%. 
The breakdown for different countries of the UK is shown in Table 1; note that this 
data  is  for  the  adult  population  and  depends  on  general  practitioners  correctly 
recording the diabetic status of their patients and so is likely to be an underestimate. 
 
Country  Prevalence / %  Number of people 
England  5.5  2,455,937 
Northern Ireland  3.8  72,693 
Scotland  4.3  223,494 
Wales  5.0  160,533 
 
Table 1 – 2011 estimates for prevalence of diabetes in the adult population of the 
UK, taken from [3]. 
 
This high prevalence of diabetes in the UK means that approximately 10% of the 
NHS budget is spent on the care of persons with diabetes. 25 
 
1.2  Diabetic retinopathy 
The retina is the thin, transparent tissue lining the inner surface of the eye and is 
responsible for transducing light focussed by the optical structures of the eye into 
electrical  signals  that  pass  along  the  optic  nerve  to  the  brain.  Histologically,  the 
retina is traditionally divided into ten layers, shown in Figure 3, and receives a dual 
blood supply. The highly vascular choroid supplies the outer retina, consisting of the 
rod and cone photoreceptors, while the inner retina is supplied by capillaries arising 
from branches of the central retinal artery. 
 
Figure 3 – Histology of the retina. Adapted from “histology-world.com”. 
 
The macula, found only in primates, is a specialised region of the retina containing 
xanthophyll  pigment  and  is  responsible  for  the  fine,  detailed  vision  required  for 
reading and face recognition. It has a number of anatomical adaptations that allow it 
to perform this role: a dense concentration of photoreceptors and two or more layers 
of ganglion cells. Retinal capillaries are displaced from the specialised central area of 
the  macula  termed  the  fovea,  with  an  avascular  zone  approximately  500  µm  in 
diameter identifiable in normal subjects.   
 
The  microvascular  disorder  of  the  retina  occurring  in  patients  with  diabetes  and 
including features of vascular occlusion and leakage is termed diabetic retinopathy.  26 
 
1.2.1  Non-proliferative diabetic retinopathy 
The earliest features of diabetic retinopathy are the manifestations of damage to the 
retinal capillaries, including their supporting cells - the pericytes, and the capillary 
basement  membrane.  The  first  lesions  visible  clinically  are  typically 
microaneurysms: microscopic dilations of retinal capillaries that can be filled with 
blood. The capillary disease can lead to leakage of exudates from the vasculature and 
retinal haemorrhages. Capillary loss in areas of the retina results in ischaemia, visible 
clinically as cotton wool spots which are caused by impaired axoplasmic flow in the 
retinal nerve fibre layer.  
Figure 4 shows the typical fundus appearance of this stage of the disease. In more 
severe  forms  of  non-proliferative  retinopathy,  increasing  tissue  hypoxia  and 
ischaemia leads to extensive retinal haemorrhages and changes in vascular calibre, 
notably  venous  dilatation  from  impaired  autoregulation.  Abnormal  connections 
between  the  arterial  and  venous  sides  of  the  circulation  termed  intraretinal 
microvascular abnormalities (IRMA) develop. Further details on the pathogenesis of 
diabetic retinopathy are discussed in Section 1.3.  
 
 
Figure 4 – Colour fundus photograph showing the changes of non-proliferative 
diabetic retinopathy. CWS – cotton wool spot. 27 
 
1.2.2  Proliferative diabetic retinopathy 
Increasing tissue hypoxia and impaired blood flow leads to the release of angiogenic 
growth factors and the formation of new blood vessels at various sites in the eye, 
termed proliferative diabetic retinopathy. In the posterior segment of the eye, new 
blood vessels form typically at the optic disc (new vessels  at the disc, NVD) or 
elsewhere in the retina (new vessels elsewhere, NVE), shown in Figure 5. Severe 
ischaemia leads to the diffusion of angiogenic factors to the anterior segment of the 
eye  and  the  development  of  new  vessels  on  the  iris  or  in  the  anterior  chamber 
drainage  angle,  NVI  or  NVA.  Left  untreated,  this  anterior  segment 
neovascularisation can lead to neovascular glaucoma and loss of vision. 
 
 
Figure 5 – Colour fundus photograph to show proliferative diabetic retinopathy. New 
vessels at the disc and new vessels elsewhere are visible, with preretinal 
haemorrhage at the superior and inferior arcades. Photocoagulation scars are present. 
 
The  vitreous  gel  of  the  eye  provides  a  scaffold  that  can  support  the  growth  of 
abnormal new vessels from the retinal circulation. Traction on these vessels can lead 
to vitreous haemorrhage and uncontrolled fibrovascular proliferation can result in 28 
 
tractional retinal detachment, shown in Figure 6. Breaks in the retina can occur and 
this  is  termed  combined  tractional-rhegmatogenous  retinal  detachment;  ultimately 
vision can be lost. There is therefore the potential for considerable visual morbidity 
in patients with proliferative diabetic retinopathy. 
 
 
Figure 6 – Colour fundus photograph of a right eye with advanced fibrovascular 
proliferation and tractional retinal detachment involving the macula. 
1.2.3  Diabetic maculopathy and diabetic macular oedema 
The microvascular changes of diabetic retinopathy as described above are frequently 
present in the macular area and this is termed diabetic maculopathy. Typical patterns 
seen  include  clusters  of  microaneurysms  around  the  foveal  avascular  zone  and 
exudate arranged in a circinate pattern around leaking microaneurysms. 
 
Breakdown of the inner blood-retinal barrier leads to increased vascular permeability 
and  the  leakage  of  fluid  into  the  retina;  this  is  termed  diabetic  macular  oedema 
(DMO).  Clinical  examination  reveals  retinal  thickening.  The  Early  Treatment 
Diabetic Retinopathy Study (ETDRS) provided three definitions of what they termed 
clinically significant macular oedema (CSMO), used as criteria for laser treatment in 29 
 
the initial study [4], and shown diagrammatically in Figure 7. CSMO was defined as 
1) any oedema occurring within 500 µm of the centre of the fovea (A); 2) oedema 
associated with exudates lying within 500 µm of the centre of the fovea (B); 3) 
oedema of area one disc diameter or greater, any part of which lies within one disc 
diameter of the foveal centre (C). Visual loss in DMO occurs because of disruption 
of  the  retinal  architecture  leading  to  neuronal  dysfunction,  but  pre-existing 
pathological changes that are present before the clinically visible lesions probably 
also contribute. 
 
 
Figure 7 – Diagrammatic representation of CSMO as defined in the ETDRS. Inner 
circle shows 500 µm radius from fovea; outer circle shows radius of one disc 
diameter. A – oedema within 500 µm; B – exudates within 500 µm with associated 
thickening; C – oedema of greater than one disc diameter area, any part lying within 
one disc diameter of the fovea. 
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1.2.4  Epidemiology of diabetic retinopathy and maculopathy 
Population-based studies have reported the prevalence of diabetic retinopathy among 
diabetic  patients  and  have  further  broken  this  down  to  report  the  prevalence  of 
different  grades  of  retinopathy  and  sight-threatening  retinopathy  necessitating 
referral to an ophthalmologist. The studies show that significant numbers of patients 
with diabetes have retinopathy and that this may present at an advanced stage. 
 
The  Wisconsin  Epidemiologic  Study  of  Diabetic  Retinopathy  (WESDR)  was 
designed to report the prevalence of retinopathy and identify risk factors for eye 
disease  by  studying  patients  with  diabetes  in  southern  Wisconsin.  From  10,135 
eligible patients, a sample of 2990 was studied, comprising a younger onset group 
taking insulin (approximately equivalent to type 1) and a group diagnosed over the 
age of 30 (approximately equivalent to type 2). Prevalence of retinopathy and of 
maculopathy in these two groups is shown in Table 2. 
 
  Young onset (diagnosis 
before 30 years, taking 
insulin) n=1210 / % 
Older onset 
(diagnosis over 30 
years of age) 
n=1780 /% 
Any retinopathy  71  50 
Proliferative retinopathy  23  5 
Diabetic Retinopathy Study high-
risk characteristics for visual loss 
10  2 
 
Table 2 – Prevalence of retinopathy in the WESDR at baseline [5, 6] summarised in 
[7]. 
 
A major finding from the study was that the prevalence of retinopathy increased with 
increasing duration of diabetes. This applied to both the younger and older onset 
groups and to severity of retinopathy. Duration of disease was also found to be a risk 
factor for the prevalence of DMO, again in both younger and older onset groups, 
shown in Figure 8A and B. 31 
 
 
 
A 
B  
Figure 8 – Increase in prevalence of retinopathy and proliferative retinopathy (A) and 
clinically significant macular oedema (B) with increasing duration of diabetes in both 
groups from WESDR. Taken from [7].  
 
In the UK, one of the earliest population-based studies arose from examining the 
population of Melton Mowbray in Leicestershire. This research examined the eyes of 
diabetic  patients  requiring  insulin  in  1987  and  found  a  population  prevalence  of 
10.9/1000 for any diabetes. Of the 113 patients examined, 50% had no evidence of 
retinopathy, but amongst the remaining patients 9% had evidence of proliferative or 
advanced diabetic eye disease and 8% had untreated maculopathy [8]. This study 
found that risk factors for severity of retinopathy were duration of diabetes, elevated 
blood pressure and age at examination. 
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The Liverpool  Diabetic Eye Study reported the prevalence of different grades of 
diabetic  retinopathy  and  maculopathy  before  the  introduction  of  a  retinopathy 
screening programme. The point prevalence of diabetes was 12.4/1000 and 33.6% of 
patients examined had retinopathy [9]. Of note, significant levels of retinopathy that 
could require treatment or maculopathy were present in 4.5% and 9.2% of patients 
respectively, with 13.4% of patients examined graded as having sight-threatening eye 
disease. At entry into the screening programme in Liverpool, diabetic retinopathy 
status was evaluated in 8062 patients with diabetes. Prevalence of diabetes overall 
was 1.8% and prevalence of different categories of retinopathy is shown in Table 3. 
 
  Type 1 diabetes (%)   Type 2 diabetes (%)  
Any retinopathy   45.7   25.3  
Proliferative retinopathy   3.7   0.5  
Sight-threatening disease   16.4   6.0  
 
Table 3 – Prevalence of retinopathy at entry into screening in Liverpool, UK [10] 
 
Screening for diabetic retinopathy and its impact are discussed further in Section 
1.5.1. It is clear, however, from the findings of the Liverpool Diabetic Eye Disease 
Study and the Melton Mowbray study, that without a systematic programme to detect 
early diabetic eye disease, a significant number of patients will miss out on treatment 
for sight-threatening disease. 33 
 
1.3  Pathophysiology of diabetic retinopathy 
Studies into the epidemiology of diabetes demonstrated that duration of diabetes was 
a major risk factor for diabetic retinopathy. This important finding sheds light on the 
possible pathogenic mechanisms underlying the development of retinopathy. While 
previously  it  had  been  thought  that  hypertension  co-existing  with  diabetes  was 
responsible for the development of vascular abnormalities, it now became apparent 
that  changes  in  the  vasculature  develop  as  a  result  of  the  cumulative  effects  of 
hyperglycaemia. The WESDR aimed to establish this link between hyperglycaemia 
and progression of retinopathy and showed that the relationship between increasing 
glycosylated haemoglobin level and retinopathy severity was present in both younger 
and older onset groups with diabetes, providing evidence that glycaemic level was 
more important than type of diabetes in the development of this complication [7, 11]. 
Although  the  initiating  event  in  the  development  of  diabetic  retinopathy  may  be 
chronic  hyperglycaemia,  the  exact  pathophysiology  is  complex  and  controversies 
exist concerning the most important factors and events. Hyperglycaemia leads to the 
accumulation of advanced glycation end-products such as sorbitol and the activation 
of a number of interconnected biochemical mechanisms. Some of these are shown in 
Figure 9. Implicated biochemical pathways include oxidative stress, the polyol and 
hexosamine pathway, and the activation of protein kinase C isoforms. 
 
Figure 9 – Interaction between biochemical pathways in the pathophysiology of 
diabetic retinopathy. From [12]. 34 
 
The biochemical pathways activated by hyperglycaemia alter the cytokine profile in 
the retina, recruiting leukocytes as part of the inflammatory response, and in turn 
mediate damage to endothelial cells and pericytes, which leads to the visible clinical 
lesions  of  microvascular  disease.  Thickening  of  the  basement  membrane  of 
capillaries in the inner and outer retina leads to a loss of their barrier function and 
leakage of plasma into the retina. However, the metabolic and biochemical changes 
that are present in the retina do not only affect blood vessels, but also affect the 
network of retinal neurons. Therefore, it is helpful to think of pathological changes in 
diabetic retinopathy as affecting the entire neurovascular unit, defined as the physical 
and  biochemical  relationship  among  the  retinal  neurons,  glia  and  associated 
vasculature [13]. Disturbance in the retinal vasculature is likely to lead to neuronal 
dysfunction because of  the high metabolic activity of the  retina, which makes  it 
susceptible to  changes  in the supply of oxygen  [14, 15]. Oxygen sensing occurs 
through activation of transcription factors such as the hypoxia inducible factor (HIF) 
which in turn alters cytokine activation with further downstream effects. The dual 
blood supply of the retina means that changes to oxygen supply may affect the inner 
and outer retina differently. Photoreceptors receive a copious blood supply from the 
highly  vascular  choroid,  but  the  inner  retina  containing  second  and  third  order 
neurons  and  glial  cells  has  a  comparatively  sparse  blood  supply.  Biochemical 
disruptions  leading to  vascular changes  in  the inner retina are therefore liable to 
affect  inner  retinal  neurons.  The  resulting  dysfunction  may  manifest  as  reduced 
vision and reduced indices of other tests which depend on inner retinal neuronal 
function such as colour vision and electrophysiology, discussed further in section 
2.1. 
Retinal structure and function is maintained in part by intact inner and outer blood-
retinal barriers. The outer blood-retinal barrier is formed by the tight junctions of the 
zonula occludens of the retinal pigment epithelial cells, while the inner blood-retinal 
barrier  is  formed  from  the  tight  junctions  of  capillary  endothelial  cells.  When 
vascular disease leads to the breakdown of this inner blood-retinal barrier, macular 
oedema occurs. The increase in permeability of retinal capillaries is mediated by an 
activated cytokine network and in particular a rise in vascular endothelial growth 
factor (VEGF), discussed further below. Protein kinase C (PKC) is  an important 35 
 
mediator of this aspect of the pathology: phosphorylation of isoforms such as PKC-β 
activated by VEGF result in breakdown of the tight junctions required to maintain 
vascular  integrity,  through  endocytosis  of  occludin  proteins  [16].  PKC  inhibitors 
such  as  ruboxistaurin  have  been  investigated  as  possible  therapies  for  macular 
oedema. 
The prolonged biochemical insult of hyperglycaemia leads to vascular occlusion and 
progressive capillary loss. This results in impaired oxygen delivery and gives rise to 
the clinical situation of macular ischaemia. This manifests clinically as enlargement 
of  the  foveal  avascular  zone  (FAZ)  and  loss  of  the  perifoveal  capillary  network 
which can be seen on fluorescein angiography, for example in  Figure 10. Visual 
acuity is likely to be reduced and other indices of retinal function similarly affected.  
 
Figure 10 – Detail of macula from fundus fluorescein angiogram to show partial loss 
of perifoveal capillary network in patient with diabetic macular oedema and macular 
ischaemia. Foveal avascular zone size is 650 µm – upper limit of normal. 
In parallel  to  the changes  in  blood-retinal  barrier status  that are seen in diabetic 
retinopathy, the accumulation of pro-angiogenic growth factors such as VEGF leads 
to the formation of new blood vessels which are abnormal in both structure and 
permeability. These are the hallmark of proliferative diabetic retinopathy.  36 
 
In summary, although complex pathways and multifactorial biochemical changes are 
implicated in the pathogenesis of diabetic retinopathy, VEGF has emerged as a key 
cytokine released in response to hypoxia and ischaemia. It has been shown to be an 
activator of inflammatory pathways and some of the biochemical pathways noted 
above such as protein kinase C. Its biology and role in angiogenesis and increased 
vascular permeability is discussed below. 37 
 
1.4  Vascular  endothelial  growth  factor  –  a  mediator  of 
angiogenesis and vascular permeability 
Vascular endothelial growth factor-A (VEGF-A, subsequently referred to as VEGF) 
is one member of a family of growth factor proteins including VEGF-B, -C, -D, -E 
and placental growth factor (PlGF). It is an angiogenic and vascular permeability 
factor, and because these processes underlie pathological changes in a number of 
ocular  diseases  including  diabetic  retinopathy,  VEGF  inhibition  has  become  an 
important therapeutic modality in their treatment. 
1.4.1  VEGF biology 
The  discovery  of  VEGF  arose  through  the  observation  that  angiogenesis  was  an 
inherently important factor in the growth of tumours. Michaelson proposed that a 
diffusible factor (“Factor X”) in the eye was responsible for neovascularisation in 
diabetic eye disease  [17], and in  parallel  investigations,  Ashton  and Cook at  the 
Institute of Ophthalmology in London demonstrated that a diffusible factor could 
induce corneal neovascularisation [18]. It was subsequently shown that a diffusible 
factor was also implicated in angiogenesis in tumours. Initial candidate molecules for 
angiogenesis  included  epidermal  growth  factor,  tumour  necrosis  factor  and 
transforming  growth  factors  α  and  β.  These  molecules  are  all  important  in  the 
landscape of angiogenesis but were not able to induce endothelial cell proliferation 
alone. The basic and acidic fibroblast growth factors (FGF) were found to be capable 
of inducing angiogenesis through an action on endothelial cells, but importantly are 
not secreted by cells and so do not fit with observations of a diffusible factor. 
The search for a diffusible factor led to the first identified function of the molecule 
now known as VEGF: as a vascular permeability factor, when it was demonstrated 
that ascites fluid collected from guinea pigs with liver tumours could induce vascular 
permeability [19]. Ferrara et al. discovered and sequenced a heparin binding growth 
factor that fulfilled the criteria for a soluble growth factor and was able to induce 
angiogenesis through mitogenic activity on endothelial cells [20]. They termed this 38 
 
VEGF. At the same time, sequencing of the vascular permeability factor previously 
described revealed that this was the same molecule [21].  
VEGF exerts its action through two main tyrosine kinase receptors: VEGFR-1 (flt-1), 
VEGFR-2  (KDR)  and  neuropilin  co-receptors.  Interaction  with  the  different 
receptors conveys different functions in physiological and pathological angiogenesis, 
comprehensively reviewed in [22]. 
VEGF exists in different isoforms achieved by differential splicing of mRNA, shown 
in Figure 11. Different isoforms are referred to as VEGFxxx, where xxx refers to the 
number  of  amino  acids  present  in  the  protein,  ranging  from  121  to  206,  with 
VEGF165  being  a  particularly  common  form.  Exons  1-4  are  conserved  between 
isoforms  while  variations  in  exons  5-8  affect  the  properties  of  the  molecule.  In 
particular, exon 8 controls endothelial cell mitogenic activitiy, illustrating that some 
of the activities of VEGF may be isoform dependent. A change in the distal splice 
acceptor site in exon 8 gives rise to new variants of the VEGFxxx molecules which 
have been termed VEGFxxxb, and were first identified in a renal cell carcinoma line 
[23]. These may have different properties from the conventional VEGFxxx isoforms 
and may play a role in the maintenance of vascular physiology in health rather than 
disease. 
 
Figure 11 – Exon structure of different VEGF isoforms to show how differential 
splicing leads to their formation. UTR – untranslated region. From  [24]. 39 
 
1.4.2  VEGF in diabetic retinopathy 
Experimental evidence specific to diabetic retinopathy showed that VEGF activity in 
the  eye  reprises  its  role  elsewhere  in  the  body  as  an  angiogenic  and  vascular 
permeability factor. Additional evidence for a neuroprotective action in the retina 
reinforces  the  link  between  neurons  and  vasculature  in  the  concept  of  the 
neurovascular unit. 
Aiello et al. first showed that VEGF was present in the ocular fluid of patients with 
neovascular disorders including diabetic retinopathy [25]. Concentrations of VEGF 
correlated  with  the  severity  of  the  ocular  disease,  with  highest  levels  present  in 
subjects  with  active  proliferative  diabetic  retinopathy  or  active  iris 
neovascularisation. In subjects who had undergone laser photocoagulation to reduce 
disease activity, VEGF levels were raised in the early phase and then lowered.  This 
correlation  between  activity  and  VEGF  level  suggested  that  inhibition  of  VEGF 
might be a possible therapeutic modality. In a mouse model of ischaemia-induced 
retinal  neovascularisation,  neutralising  VEGF  using  a  chimeric  receptor  protein 
significantly reduced the area of neovascularisation compared with control eyes [26], 
and  in  non-human  primates,  inhibiting  VEGF  blocked  the  development  of  iris 
neovascularisation [27]. The observation that a state identical to diabetic retinopathy 
could be induced in the eyes of primates by injections of VEGF provided further 
evidence that VEGF is a causative factor in diabetic eye disease [28]. 
While  neovascularisation  is  an  important  cause  of  visual  loss  in  retinal  vascular 
disease, macular oedema from breakdown of the inner blood retinal barrier leads to 
reduced  vision  in  greater  numbers  of  patients  with  diabetes,  as  shown  by  the 
epidemiological studies discussed above. VEGF as a vascular permeability factor is 
also  implicated  in  the  development  of  macular  oedema.  Immunohistochemical 
studies demonstrate the presence of VEGF in retinal capillaries affected by diabetes 
[29],  and  show  that  these  capillaries  have  increased  permeability.  Qaum  et  al. 
demonstrated  that  it  had  a  direct  causative  role  in  the  induction  of  vascular 
permeability in diabetes by showing that messenger RNA levels for VEGF were 
elevated  in  rats  with  early  diabetes  and  that  this  corresponded  temporally  to 
breakdown  in  the  inner  blood  retinal  barrier  [30].  Furthermore,  this  increased 40 
 
vascular permeability could be reversed in a dose-dependent fashion by systemic 
administration of a high affinity chimeric protein known as VEGF-Trap, comprised 
of soluble VEGF receptor and Fc proteins. This represents compelling evidence for 
the direct involvement of VEGF in blood-retinal barrier breakdown. 
While these findings demonstrate the direct role of VEGF on the vasculature, both in 
terms of leading to neovascularisation and inducing vascular permeability, there is 
also evidence that VEGF acts on retinal neurons which adds a new dimension to the 
understanding  of  the  pathological  effects  of  its  upregulation  and  possible 
consequences of inhibition. For example,  in vivo work in the rat has shown that 
administering VEGF isoforms following an ischaemia-reperfusion injury leads to a 
reduced number of apoptotic cells in the retina [31]. In addition to a reduction in 
apoptosis,  increased  blood  flow  resulted  and  an  importance  in  ischaemic 
preconditioning was demonstrated. Secondly, systemic neutralisation of VEGF by 
sFlt1  (soluble  VEGF  receptor  expressed  by  adenoviral  vectors)  led  to  increased 
apoptosis of retinal neurons in the mouse [32]. 
1.4.3  Activation of VEGF pathways by hypoxia and ischaemia  
VEGF  is  of  critical  importance  in  physiological  angiogenesis  as  VEGF  receptor 
knockouts are lethal and even knockout of a single allele of the Vegf gene in mice is 
lethal  embryonically.  While  physiological  angiogenesis  represents  a  large  and 
important area of study, it is the activation of VEGF and its role in pathological 
angiogenesis, such as in cancerous tumours and ocular disease that is relevant to the 
current  study.  For  example,  in  human  glioblastoma  cell  lines,  VEGF  and  its  flt 
receptor are both upregulated and are present around areas of tumour necrosis [33].  
Furthermore, demonstration that VEGF mRNA upregulation occurs in response to 
hypoxia in these tumours and in other cell lines [34] suggests that hypoxia sensing is 
an important component of the angiogenic response. Investigation into the effect of 
hypoxia on human retinal pigment epithelial cells demonstrated a similar response: 
these cells synthesise increased levels of mRNA for VEGF and release soluble forms 
of VEGF after a hypoxic stimulus [35]. 
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The  link  between  hypoxia  in  tumour  tissue  or  in  the  retina  and  the  increased 
expression  of  VEGF  seen  in  these  tissues  is  now  understood  to  be  mediated  by 
transcription factors which are altered in the presence of hypoxia, termed hypoxia 
inducible factors (HIFs). HIF-1, for example has been shown to be responsible for 
increased transcription of VEGF in hypoxic conditions [36]. HIF-1α dissociates from 
the  product  of  the  Von  Hippel  Lindau  tumour  suppressor  gene  in  conditions  of 
hypoxia and is then able to bind to hypoxia responsive elements of nuclear DNA 
together with HIF-1β. This in turn leads to activation of a number of target genes 
including those connected with angiogenesis. While hypoxia is an important factor in 
activating the HIF pathway, inflammation also leads to downstream effects mediated 
by this mechanism. Therefore in diabetic retinopathy, where vascular disease leads to 
tissue hypoxia and the upregulation of inflammatory pathways also occurs, the HIF 
pathway may be central to the pathophysiology. 
 
Greater  understanding  of  the  signalling  pathway  for  hypoxia  and  the  cytokines 
involved in this gives rise to the possibility of new therapeutic targets in diabetic 
retinopathy. For example, the mammalian Target Of Rapamycin protein (mTOR) is a 
tyrosine kinase that induces expression of the hypoxia inducible factor and hence 
VEGF further downstream, and so inhibition of this target could potentially reduce 
VEGF activity. Rapamycin (sirolimus) inhibits the mTOR binding complex and a 
Phase  1  study  of  50 patients  receiving  sirolimus  either  subconjunctivally  or  by 
intravitreal  injection  revealed  no  significant  safety  concerns  [37].  Further  results 
from  study of this  drug are awaited, to  better understand its  possible role in the 
treatment of diabetic retinopathy.  
1.4.4  Summary 
VEGF  is  the  soluble  mediator  of  angiogenesis  and  vascular  permeability  first 
proposed over sixty years ago. Oxygen sensing in the retina leads to its upregulation 
through changes in the structure of transcription factors which also activate other 
cytokines involved in the complex angiogenic pathway. VEGF is strongly implicated 
in  the  pathogenesis  of  diabetic  retinopathy  and  so  inhibition  of  its  activity  is  a 
potential therapeutic target. Its role in health and disease is complex, meaning that 42 
 
VEGF inhibition risks blocking important physiological functions. The evidence for 
VEGF  as  a  neuroprotective  factor  and  its  possible  role  in  maintaining  a  healthy 
circulation in the retina means that in macular ischaemia in particular, there is a 
theoretical risk that VEGF blockade could accelerate the disease process.  43 
 
1.5  Treatment of diabetic eye disease 
Successfully treating diabetic eye disease begins with prevention through appropriate 
systemic management of the patient. Early retinopathy changes may not cause visual 
loss and may be present for considerable time. Screening programmes are therefore 
necessary to identify the development of potentially sight-threatening retinopathy, 
which is frequently asymptomatic in its initial stages but requires prompt treatment if 
visual  loss  is  to  be  prevented.    Continued  systemic  control  of  diabetes  remains 
important  as  eye  disease  is  treated;  retinopathy  may  be  the  first  indicator  of 
microvascular disease elsewhere in the body and may occur following sub-optimal 
control. Historic treatment of retinopathy included pituitary ablation [38] while the 
introduction of laser treatment  for proliferative  retinopathy  and maculopathy was 
shown to prevent sight loss. Drugs delivered by the intraocular route include steroids 
and anti-VEGF agents; these address the molecular cause of the disease. 
1.5.1  Screening 
There is now a well-established national programme in the UK to screen patients 
with diabetes over the age of 12 for retinopathy. The National Health Service (NHS) 
Diabetic Eye Screening Programme offers annual digital fundus photography to all 
patients with diabetes over the age of 12 years. Two images of 45° field are captured 
by the photographer for grading. The clinical  grading of retinopathy used by the 
screening programme is based on the original ETDRS grading scheme and consists 
of  mild  and  moderate  non-proliferative  diabetic  retinopathy  (previously  termed 
background  diabetic  retinopathy),  severe  non-proliferative  retinopathy  (pre-
proliferative  diabetic  retinopathy)  and  non-high-risk  and  high-risk  proliferative 
diabetic retinopathy. If potentially sight-threatening retinopathy is identified, referral 
to a specialist eye unit for further assessment and treatment is organised to take place 
within a pre-specified time frame. 
  
Clinical outcomes for screened patients 
Patients with diabetes but without evidence of retinopathy are graded as R0. Those 
with  retinopathy  not  meeting  the  criteria  for  referral  to  ophthalmology  (“non-
referable retinopathy”) are graded as  R1 and both  of these groups are invited to 44 
 
return for annual photography. The main purpose of the screening programme is to 
identify  those  with  the  potential  for  sight-threatening  diabetic  retinopathy,  which 
includes severe non-proliferative and proliferative retinopathy (grades R2, R3) with 
or without the additional presence of maculopathy (M1). These patients are either 
referred to a Hospital Eye Service, to a digital imaging surveillance clinic, or for 
clinical examination in a dedicated Slit Lamp Bio-microscopy Service [39]. 
 
Standards  are  in  place  to  ensure  the  prompt  assessment  of  patients  identified  as 
having sight-threatening retinopathy depending on the severity: in cases of active 
proliferative diabetic retinopathy (R3a), patients must be seen in an eye clinic within 
a maximum of 4 weeks and, if needed, treated by laser panretinal photocoagulation 
within  another  2 weeks.  In  the  presence  of  M1  (referable  maculopathy),  R2 
(referable  retinopathy)  or  treated  proliferative  diabetic  retinopathy  with  no  active 
lesions (R3s), an appointment within 13 weeks must be offered in the hospital eye 
service  or  a  surveillance  clinic.,  in  order  to  confirm  the  diagnosis  and  instigate 
treatment if necessary.  
1.5.2  Systemic control in the treatment of diabetic eye disease 
There is persuasive evidence from large, well-designed randomised controlled trials 
that  improved  glycaemic  control  has  beneficial  effects  on  the  development  and 
progression of retinopathy in both Type 1 and Type 2 diabetes. 
 
The Diabetes Control  and Complications  Trial (DCCT) established that intensive 
glycaemic control in Type 1 diabetes reduced the risk of development of retinopathy 
(primary prevention) and slowed its progression in a group with mild retinopathy at 
baseline (secondary prevention) [40]. A total of 1441 patients with no retinopathy or 
mild  non-proliferative  changes  were  randomised  in  two  cohorts  to  either  insulin 
pump  therapy  or  regular  insulin  injection.  In  the  primary  prevention  cohort,  the 
adjusted  mean  risk  of  retinopathy  was  reduced  by  76%  with  intensive  therapy, 
although the two groups were similar for the first 36 months [40]. Intensive therapy 
in the secondary progression group reduced the risk of three-step progression by 45 
 
54%,  also  reducing  the  risk  of  proliferative  disease  and  the  need  for  laser 
photocoagulation.  
For patients with Type 2 diabetes, the UK Prospective Diabetes Study (UKPDS) 
showed  that  intensive  diabetic  control  reduced  the  risk  of  needing  retinal 
photocoagulation (relative risk ratio compared with conventional treatment = 0.71). 
Additionally,  a  smaller  proportion  of  patients  treated  intensively  had  a  two-step 
progression in retinopathy after 6 years of follow-up [41]. 
 
Observational studies following both of these trials showed that the beneficial effect 
of  strict  glycaemic  control  is  maintained  even  if  metabolic  control  subsequently 
deteriorates.  In  the  Epidemiology  of  Diabetes  Interventions  and  Complications 
(EDIC) study, which followed the Diabetes Control and Complications Trial cohort, 
there continued to be a significantly lower risk of retinopathy progression in the 
group  previously  receiving  intensive  control.  Despite  HbA1c  (glycosylated 
haemoglobin) levels converging, the risk of a 3-step progression in retinopathy was 
reduced by 75% after 4 years [42]. In the UKPDS, differences in HbA1c levels had 
been lost after 1 year of extended follow-up, but after 10 years there was still a 24% 
risk  reduction  for  microvascular  disease  in  the  sulphonylurea–insulin  group  [43]. 
This  ‘metabolic  memory’  phenomenon  or  ‘legacy  effect’,  where  early  optimal 
glycaemic  control  has  long-term  beneficial  effects,  may  be  related  to  reduced 
accumulation of advanced glycation end products that are formed during periods of 
hyperglycaemia and lead to vascular stiffness and dysfunction [44]. 
 
The  UKPDS  also  examined  the  effect  of  intensive  blood  pressure  control 
(< 150/85 mmHg) with captopril or atenolol on microvascular complications in 1148 
hypertensive patients with Type 2 diabetes [45]. By a median of 7.5 years, there was 
a  34%  reduction  in  risk  of  a  two-step  deterioration  in  retinopathy  grade  in  the 
intensively  treated  group.  All  of  the  studies  discussed  used  standard  ETDRS 
photographs assessed by masked graders to determine retinopathy progression. In 
contrast to the legacy effect seen following intensive glycaemic control, there was 
not a persistent reduction in risk of microvascular disease when strict blood pressure 
control was not maintained after the end of the randomised study [46]. 
 46 
 
Angiotensin-converting enzyme inhibitors have also been shown to have a beneficial 
effect on retinopathy development in patients with Type 1 diabetes independently of 
their reduction in blood pressure. The EURODIAB Controlled Trial of Lisinopril in 
Insulin-Dependent Diabetes Mellitus (EUCLID) study demonstrated a 50% reduction 
in risk of a one-step retinopathy progression in patients treated with lisinopril [47]. 
Retinopathy progression was a secondary endpoint in the Renin Angiotensin System 
Study (RASS), which demonstrated 65 and 70% reductions in risk of progression for 
normotensive  patients  with  Type 1  diabetes  treated  with  enalapril  and  losartan, 
respectively  [48].  The  Diabetic  Retinopathy  Candesartan  Trials  Programme 
(DIRECT)  was  specifically  designed  to  investigate  the  effect  of  an  angiotensin 
receptor blocker on the incidence and progression of retinopathy. In patients with 
Type 1  diabetes,  candesartan  reduced  the  incidence  of  retinopathy  but  did  not 
significantly affect progression [49]. Similarly, in DIRECT-Protect 2, there was no 
reduction in progression of retinopathy in patients with Type 2 diabetes receiving 
candesartan, but regression was increased in this group by 34% [50]. 
 
Studies  such  as  the  Heart  Protection  Study  have  demonstrated  conclusively  that 
statins reduce the risk of cardiovascular events in patients with diabetes [51], so trials 
of statins specifically to look at their effect on retinopathy are lacking. However, 
evidence is emerging that the addition of a fibrate to pre-existing statin therapy does 
have a beneficial effect on diabetic retinopathy. The Fenofibrate Intervention and 
Event Lowering in Diabetes (FIELD) study examined need for laser retinopathy as a 
tertiary outcome in a trial of fenofibrate therapy to reduce cardiovascular disease; 
more patients in the control arm required one or more laser treatments  [52]. The 
ACCORD-Eye study not only demonstrated reduced risk of retinopathy progression 
with intensive glycaemic control in patients with Type 2 diabetes, but also showed a 
40%  reduction  in  relative  risk  of  retinopathy  progression  with  the  addition  of 
fenofibrate to simvastatin [53]. 
 
Taken  together,  the  extensive  investigations  into  systemic  glycaemic  control  in 
diabetes  accompanied  by  good  blood  pressure  and  lipid  management  show  that 
biochemical changes in the whole body can influence the degree and progression of 
diabetic  retinopathy.  This  provides  indirect  clinical  confirmation  of  laboratory 47 
 
studies  which  reveal  the  multifactorial  nature  of  the  pathophysiology  of  diabetic 
retinopathy. 
1.5.3  Laser treatment for diabetic retinopathy 
Mild  to  moderate  non-proliferative  diabetic  retinopathy  is  typically  managed  by 
observation. The development of sight-threatening lesions in the form of proliferative 
diabetic retinopathy or macular oedema is an indication for treatment; for 30 years 
laser photocoagulation of the retina was the mainstay of this and continues to have a 
role today. 
1.5.3.1  Proliferative retinopathy 
The  Diabetic  Retinopathy  Study  (DRS)  showed  that  performing  panretinal  laser 
photocoagulation was an effective treatment for patients with high risk proliferative 
retinopathy, as subjects who were randomised to peripheral scatter laser treatment 
had a 50% lower risk of severe visual loss after five years [54]. The DRS defined 
high risk characteristics for visual loss as moderate or severe new vessels on the disc 
or  nearby;  mild  new  vessels  on  the  disc  associated  with  haemorrhage,  and  new 
vessels elsewhere associated with haemorrhage. This study still informs treatment 
today, although the technique of laser has changed so that direct treatment to new 
vessels is no longer performed. 
 
Laser photocoagulation exerts its effects by a number of mechanisms, reviewed in 
detail  by  Stefánsson  [55].  The  destruction  of  photoreceptors  in  ischaemic  retina 
reduces peripheral retinal oxygen demand and rebalances the circulation to improve 
blood flow to the central retina. It is also probable that improved diffusion from the 
choroid through laser scars contributes to improved oxygenation of the retina and 
downstream  effects  on  the  vasculature  that  not  only  reduces  the  stimulus  for 
neovascularisation but decreases macular oedema by reducing vessel permeability. 
1.5.3.2  Diabetic macular oedema 
The  ETDRS  demonstrated  that  laser  treatment  for  clinically  significant  macular 
oedema, as defined above, reduced the chance of moderate visual loss at 3 years by 
half, with 12% of treated eyes experiencing a drop in acuity of two lines compared to 48 
 
24%  of  untreated  eyes  [4].  Fluorescein  angiography  can  be  used  to  guide  laser 
treatment which is now performed in a modified manner to the original grid method 
described  in  the  ETDRS.  Focal  laser  is  applied  to  focal  leaks  such  as 
microaneurysms while a grid pattern is applied to diffuse leaks and areas of capillary 
non-perfusion that are not contiguous with the foveal avascular zone. Focal laser 
causes  heating  of  the  retinal  pigment  epithelium  (RPE),  activation  of  matrix 
metalloproteinases and may lead to gliosis and scarring. Closure of microaneurysms 
directly by laser is not required as the changes in the RPE may be sufficient to alter 
the retinal capillaries by improved oxygenation and autoregulation. Treatment should 
be applied with caution in macular ischaemia and should generally be performed at 
least 500-750 µm from the foveal centre [56, 57].  
 
Recent evidence for the long term benefit of laser came from the extended follow up 
of patients in the Diabetic Retinopathy Clinical Research network’s (DRCR.net) trial 
of  triamcinolone  versus  laser  for  DMO  [58].  In  this  study,  laser-treated  patients 
gained 5 letters (one line on the standard ETDRS chart) of visual acuity at three years 
from randomisation, although this analysis only included the subset of patients who 
continued participation in the trial [59]. 
 
Lasers used can be in the green-yellow range of wavelengths or in the infrared range 
when using the diode laser. Conventional laser treatment can cause scars in the retina 
and theoretically can lead to the development of a scotoma, so there has been recent 
interest in the micropulse diode laser as a means of limiting collateral damage. A 
randomised clinical trial investigating this showed that visual acuity outcomes were 
equivalent  with  micropulsed  laser  to  conventional  green  laser,  but  visible  retinal 
scars  occurred  less  frequently  [60].  The  choice  between  green  and  yellow 
wavelengths for conventional laser has also been shown by the DRCR.net not to 
affect outcomes [61]. 
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1.5.4  Medical agents for the treatment of diabetic macular oedema 
The complicated pathogenesis of DMO, with interconnected biochemical pathways 
leading to the activation of a number of different cytokines presents numerous targets 
for  pharmaceutical  intervention.  Results  of  trials  for  some  of  these,  such  as  the 
protein kinase C inhibitor ruboxistaurin, have been disappointing, perhaps because of 
the multifactorial nature of the disease. Mixed evidence exists for the use of steroids, 
but a growing number of phase 3 trials have demonstrated the efficacy of anti-VEGF 
agents in this condition. 
1.5.4.1  Glucocorticoids / steroids 
Steroids  exert  their  effects  through  multiple  pathways.  They  have  a  direct  anti-
inflammatory  effect  as  they  inhibit  the  formation  of  arachidonic  acid  by 
phospolipase-A2  and  subsequently  reduce  activity  in  the  cyclo-oxygenase  and 
lipoxygenase pathways, but they also exert effects on numerous cytokines through 
intracellular action. They alter vascular permeability through effects on endothelial 
cell tight junctions and VEGF production. They are therefore attractive agents in 
theory for a disease like DMO with multiple biochemical pathways involved in the 
pathogenesis. However, they also cause cataract and raised intraocular pressure in a 
proportion  of  patients  and  this  is  their  principle  drawback.  The  steroids 
triamcinolone, dexamethasone and fluocinolone acetonide have been investigated as 
treatments for DMO, with the latter two now available as slow release intravitreal 
implants, recently reviewed [62]. 
 
The DRCR.net laser vs. triamcinolone study randomised participants to 1mg or 4mg 
triamcinolone or laser treatment, with the primary outcome at two years. Retreatment 
was performed if indicated every four months. Although the triamcinolone treated 
patients initially appeared to do better in terms of visual acuity at 4 months, there 
was no difference between treatment groups after one year. At the two-year primary 
endpoint laser was found to be superior to triamcinolone treatment with a gain of 
1±17 letters in the laser group compared to 2 or 3 letter losses in the 1mg and 4mg 
triamcinolone groups respectively [58]. This difference was not solely attributable to 
the development of cataract.  
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The dexamethasone drug delivery system marketed as Ozurdex® (Allergan; Irvine, 
California, USA) consists of dexamethasone bound with a biodegradable copolymer 
of lactic and glycolic acids [63]. Injected through the pars plana of the ciliary body 
using a 22G injection system, it releases 700 µg of dexamethasone as the polymer 
degrades, so therapy can be repeated as required. Ozurdex is approved for macular 
oedema caused by central and branch retinal vein occlusion and for non-infectious 
uveitis of the posterior segment of the eye, but has also been evaluated for DMO; 
further studies are underway. 
 
A subgroup analysis of a randomized trial of Ozurdex in multiple causes of macular 
edema showed in 171 patients with DMO that Ozurdex resulted in a statistically 
significant difference in the proportion of patients gaining two or more lines at 90 
days (33% vs. 12% for untreated controls) [64]. A trial of 55 patients with DMO who 
had undergone vitrectomy showed statistically significant visual acuity increases of 
6.0 and 3.0 letters at 3 and 6 months respectively [65]. To date no trials have been 
published reporting the longer term efficacy and safety outcomes following repeated 
administration. Two Allergan-sponsored, prospective trials are in progress to achieve 
a  licence  for  this  formulation  of  dexamethasone  in  DMO  (NCT00168389, 
NCT00168337, www.clinictrials.gov). 
 
Iluvien® (Alimera Sciences; Alpharetta, Georgia, USA) is an injectable intravitreal 
insert, delivered using a 25G injector system and designed to release fluocinolone 
acetonide for up to three years, which has been evaluated for the treatment of DMO 
at  two  doses:    0.2  µg/day  and  0.5  µg/day  [66].  It  has  received  a  marketing 
authorisation  for  this  indication  in  a  number  of  European  Union  member  states 
including the United Kingdom and France. 
  
The FAME study was a sham-controlled double-masked trial to investigate Iluvien in 
its two different dosages that recruited 951 subjects with persistent DMO. At the 24 
month primary endpoint, 28% of patients receiving either dose of the implant had an 
improvement of 3 or more lines, compared to 16% with sham [67]. Visual acuity 
improvements were 4.4 or 5.4 ETDRS letters compared to 1.7 with sham. The rate of 
glaucoma  filtration  surgery  was  8.1%.    However,  approaching  90%  of  phakic 51 
 
patients required cataract surgery, which did not limit their benefit from the implant 
in terms of final visual acuity. Results from this study mean that Iluvien has recently 
been  approved  by  the  National  Institute  for  Health  and  Care  Excellence  for  the 
treatment of chronic DMO, only in pseudophakic patients. 
 
Results of the studies of three agents discussed above show that a visual acuity gain 
of approximately one line can be achieved with steroid treatment. It appears that 
longer-acting implants are required for this as triamcinolone injection did not have 
long-term  benefits  over  laser.  The  side  effects  of  cataract  and  raised  intraocular 
pressure  make  further  surgical  procedures  likely  during  the  course  of  a  patient’s 
disease if steroid treatment is used. 
 
1.5.4.2  Inhibitors of VEGF 
The  importance  of  VEGF  in  the  pathogenesis  of  ocular  diseases  where 
neovascularisation is a prominent feature led to the development of agents to inhibit 
VEGF  action.  These  inhibitors  were  shown  in  animal  models  to  reverse 
neovascularisation  and  blood-retinal  barrier  breakdown,  suggesting  a  possible 
therapeutic use in diabetes against both PDR and DMO. Four VEGF inhibitors are 
currently  commercially  available  and  have  been  investigated  in  the  treatment  of 
diabetic eye disease. 
Pegaptanib 
Pegaptanib  (Macugen®,  Pfizer  UK  Ltd)  is  a  nucleotide  apatmer  modified  by 
pegylation, designed to bind to VEGF165. There is limited evidence for its efficacy in 
DMO as the manufacturers chose not to continue the process to obtain a licence after 
the early phase trials. 
A phase II study showed in 2005 that pegaptanib injections could improve visual 
acuity in subjects with DMO, as 34% of those treated with a 0.3mg injection gained 
at least 10 letters (two lines) at the 36 week primary endpoint [68]. A larger study 
randomising participants to 0.3mg or sham injection showed similar results, with 
36.8% gaining two lines compared to 19.7% receiving sham injection. This study 52 
 
also showed sustained effectiveness for pegaptanib with a mean gain of 6.1 letters at 
2 years [69]. 
One  further  noteworthy  point  is  that  pegaptanib  was  the  first  anti-VEGF  agent 
reported to induce regression of neovascularisation in diabetic retinopathy. In a small 
subgroup analysis of patients in the phase II trial with neovascularisation at trial 
entry, 8 of 13 were shown to have regression of new vessels following pegaptanib 
treatment [70]. This additional effect of anti-VEGF agents has been explored further 
in analyses of the larger trials of ranibizumab discussed below; a trial in progress is 
also evaluating ranibizumab for the primary treatment of proliferative retinopathy 
(DRCR.net protocol R study). 
Bevacizumab 
Bevacizumab  (Avastin®;  Genentech,  South  San  Francisco,  CA,  USA)  is  a 
recombinant,  humanised  mouse  monoclonal  antibody  directed  at  all  isoforms  of 
VEGF. It is an IgG antibody with a molecular weight of 149 kDa and is synthesised 
in a Chinese hamster ovary cell line expression system. It was initially demonstrated 
in tumour cell lines that application of this antibody could inhibit VEGF-mediated 
angiogenesis and tumour growth, leading to the possibility of its use as a therapeutic 
agent in the control of tumours and neovascular diseases [71]. The vitreous half-life 
of bevacizumab in rabbits was found to be 4.32 days, while in the aqueous and serum 
the  half-life  was  4.88  and  6.86  days  respectively  [72].  Maximum  serum 
concentration of bevacizumab occurred 8 days after injection and levels remained 
above 1μg/ml for 29 days. Trans-retinal transport mediated by the Fc portion of the 
antibody results in the presence of bevacizumab in the systemic circulation. 
 
A  randomised  controlled  trial  of  repeated  bevacizumab  therapy  compared  with 
standard macular laser therapy for DMO (The BOLT study) suggested bevacizumab 
treatment to be superior. This trial recruited 80 subjects with centre-involving DMO 
and randomised them 1:1 to receive either bevacizumab injections six weekly, with 
three loading injections and then retreatment as required, or macular laser therapy 
every four months. Bevacizumab treatment resulted in a median gain of 8 ETDRS 
letters at one year, compared with a drop of a 0.5 letters with laser [73]. Central 53 
 
macular thickness decreased in both groups and was significantly lower at 12 months 
than baseline. This decrease was greater in the bevacizumab treated group (-130 µm 
vs. -68 µm for laser) although this did not reach statistical significance. There was 
also limited evidence for a beneficial effect of bevacizumab on grade of diabetic 
retinopathy. 
A  secondary  aim  of  the  study  was  to  investigate  the  effect  of  bevacizumab  on 
macular  ischaemia,  given  the  theoretical  concerns  with  VEGF  inhibition  in  this 
condition.  Subjects  were  only  included  if  they  did  not  have  significant  macular 
ischaemia at baseline as the greatest linear dimension (GLD) of the foveal avascular 
zone (FAZ) was required to be less than 1000 µm and perifoveal capillary dropout 
graded as less than “severe” by the reading centre. After four months of therapy with 
bevacizumab, there was no detectable increase in macular ischaemia. The FAZ GLD 
and FAZ area remained the same, with no change in the grade of perifoveal capillary 
loss in either group [74]. Two year data from the study showed that visual acuity 
improvements could be sustained with a median of 13 injections over 24 months; 
bevacizumab treated subjects gained a mean 8.6 letters with almost half gaining two 
lines [75]. No new safety concerns were identified over two years of the study. 
Ranibizumab 
Ranibizumab (Lucentis®; Genentech, South San Francisco, CA, USA and Novartis 
Pharma AG, Basel, Switzerland) is a recombinant, humanised monoclonal antibody 
fragment, Fab (IgG1 kappa isotype) to all isoforms of VEGF. It is produced by an 
Escherichia coli expression system and has a molecular weight of 48 kDa. Affinity 
maturation  studies  carried  out  on  the  native  Fab,  V12,  derived  a  variant  termed 
Y0317 which has a 22-fold higher binding affinity to VEGF [76]. This protein differs 
by six amino acid residues from the parent antibody and was at least 30 times more 
potent at inhibiting mitogenic activity in human umbilical vein endothelial cells. 
 
Pharmacokinetic  studies  for  ranibizumab  were  carried  out  using  the  same  rabbit 
model as bevacizumab and it was found to have a half life in the vitreous of 2.88 
days  [77].  No  ranibizumab  was  detected  in  the  serum  or  the  fellow  eye  in  this 
experiment.  A  study  to  investigate  the  pharmacokinetics  of  ranibizumab  in 
cynomolgus monkeys found a half-life of 2.6 days in the vitreous following bilateral 54 
 
intravitreal injection of 0.5mg [78]. Ranibizumab was detected in the serum at a 
concentration of 150ng/ml  at  6 hours but declined rapidly thereafter.  It was  also 
detected in both neural retina and RPE, with a pharmacokinetic profile suggesting 
levels sufficient to inhibit VEGF activity from monthly dosing. 
 
The clinical evidence base for ranibizumab is now considerably larger than for the 
previous two agents with a number of phase III trials reporting the effects in a total 
of thousands of patients; ranibizumab is now licensed in Europe and the USA for 
DMO.  The  pivotal  trials  on  which  recommendations  for  treatment  are  based  are 
discussed below. In addition to the visual acuity improvements seen in the usual 
primary outcome measures, a number of other useful findings have emerged as part 
of exploratory outcome data. 
 
The RESTORE study was a randomised, double masked, sham controlled trial that 
took place in multiple centres across Australia, Europe, Turkey and Canada, and was 
designed to compare ranibizumab treatment to laser.  Patients with visual impairment 
due to DMO (n=345) were randomised to receive ranibizumab, ranibizumab plus 
laser or laser alone. The two ranibizumab-treated arms had improvements in acuity 
of 6.4 or 6.8 letters at 12 months compared to 0.9 letters with laser alone, following a 
regimen  of  three  initial  injections  then  treatment  on  an  as-required  basis. 
Approximately 23% of patients in the two ranibizumab arms had gained three lines 
(15 or more letters) of visual acuity compared with 8.2% in the laser arm [79]. In the 
extension phase of this study when all three groups received ranibizumab, visual 
acuity was maintained in year 2 with on average a further three or four ranibizumab 
injections  for  those  previously  treated  with  ranibizumab;  previous  laser-treated 
patients gained vision from the 12 month primary endpoint to month 24 (+5.4 letters) 
[80]. 
The DRCR.net protocol I study of laser, ranibizumab and triamcinolone included 854 
eyes from patients with centre-involving DMO. In this randomised trial an eye could 
receive  ranibizumab  with  either  prompt  or  deferred  laser,  laser  alone  or 
triamcinolone with prompt laser treatment. “Prompt” in this trial meant around the 
time of initial treatment, and “deferred” prevented laser from occurring prior to 24 55 
 
weeks. The two ranibizumab treated groups each gained a mean 9 letters by the one 
year primary outcome compared with 4 letters for triamcinolone and 3 letters for 
laser alone [81]. The difference was sustained at two years, shown in  
Figure 12. In addition to the superior gain in terms of absolute number of letters, the 
two ranibizumab groups had the greatest chance of a 10 letter gain (around 40%) and 
the  lowest  chance  of  a  10  letter  drop  in  visual  acuity  (around  5%).  A  planned 
subgroup analysis explored factors that might be associated with improved outcomes. 
In the ranibizumab groups, visual acuity at baseline was predictive of response as 
subjects with visual acuity of 65 letters or fewer gained on average more letters than 
those  with  better  visual  acuity  at  baseline  (13  vs.  5  letter  gain).  This  may  be 
attributable to a “ceiling effect”: as visual acuity has a theoretical maximum, subjects 
with better acuity at baseline have less scope to improve. Change in retinal thickness 
over the study was evaluated by optical coherence tomography (OCT) scanning. At 
one  year,  subjects  treated  with  ranibizumab  had  a  retinal  thickness  reduction  of 
approximately  140  µm  from  baseline.  Retinal  thickness  at  trial  entry  was  also 
predictive  of  response:  subjects  with  greater  central  retinal  thickness  (≥400  µm) 
responded better (11 letters vs. 7 letters) to ranibizumab than those with thicknesses 
<400 µm. 
A further finding from the exploratory analysis is worthy of note: triamcinolone with 
prompt  laser  treatment  was  as  effective  as  ranibizumab  for  subjects  who  were 
pseudophakic at baseline. This result, achieved with a median of three injections of 
triamcinolone,  suggests  that  this  relatively  cheap  drug  still  has  a  role  in  the 
management of patients with DMO. 
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Figure 12 – Change in visual acuity in the DRCR.net protocol I study of 
ranibizumab, laser and triamcinolone in DMO. From [81]. 
 
The separately published two-year results of the trial are complicated by a protocol 
amendment  that  occurred  subsequent  to  the  publication  of  the  one  year  primary 
endpoint  meaning  that  all  subjects  could  switch  to  receive  ranibizumab  if  they 
desired. However, they confirmed that the one-year gains with ranibizumab were 
sustained and suggested a marginal benefit for the group with deferred laser [82]. 
The sustained visual acuity benefits were achieved with only a further 1-2 injections 
in the ranibizumab arms, but more subjects in the deferred laser group began to need 
at least one session of focal/grid laser (investigators judging this were masked to 
treatment allocation). Therefore, while it appears that performing laser at the outset 
of treatment confers no additional benefit, it is not possible to infer with certainty 
that it has no role at all. By three years, evaluating only subjects initially assigned to 
ranibizumab to provide details of long term effects, the benefit was again sustained 
with  the  difference  between  prompt  and  deferred  laser  groups  becoming  more 
apparent. If laser were deferred initially, the visual acuity gain at three years was 9.7 
letters compared to 6.8 if laser were performed promptly [83]. The trial continues 
and five year results are awaited. 
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RISE and RIDE were two identical, randomised, sham-controlled trials of 0.3 mg 
and 0.5 mg ranibizumab in DMO that formed the manufacturer’s application for a 
licence for the condition in the USA. In contrast to the DRCR.net protocol I study 
they  did  not  use  laser  or  triamcinolone  as  controls  and  they  featured  mandatory 
monthly  dosing  to  the  primary  endpoint  at  24  months.  The  trials  showed  that 
monthly dosing with ranibizumab was superior to sham treatment as between 30 and 
40% (slight differences between trials and ranibizumab dose) gained three lines by 
two years; the mean visual acuity gain was 8.5 to 9.9 letters [84]. The visual acuity 
and OCT results from these two pivotal trials are shown for information in Figure 13. 
 
Figure 13 – Visual acuity and OCT results from RISE and RIDE, taken from [84]. 
CFT = central foveal thickness; * = P<0.0001 compared with sham. 
 
Although not powered to detect a difference between the two doses of ranibizumab 
used, RISE and RIDE showed no additional benefit for 0.5 mg compared to 0.3 mg 
so  this  lower  dose  is  that  used  in  the  USA  for  DMO,  while  in  Europe  0.5  mg 
continues  to  be  used.  The  RESOLVE  study  was  an  earlier  randomised  trial  that 
investigated ranibizumab in DMO at these two doses but also allowed the dose to be 
doubled to 0.6 mg or 1.0 mg based on response; although relatively small numbers 
were involved it did not show significant differences between doses [85].  
 
In  summary,  randomised  trials  of  ranibizumab  in  DMO  have  demonstrated  its 
superiority over laser. Subjects treated over two years can expect to gain on average 
between 8 and 10 letters; 30-40% of treated patients should gain two lines. This can 58 
 
be achieved with injections on an as-required basis as subjects in the DRCR.net trial 
received approximately 7 injections in year 1 and 2-3 in year 2. Improvements in 
visual acuity are mirrored by reductions in retinal thickness. Subjects with worse 
visual  acuity  and increased macular thickness  at  baseline  are likely to  do better. 
Combining treatment with laser appears to confer no additional benefit and actually 
may reduce visual acuity gains. The optimal dose and retreatment strategy are not yet 
fully  defined.  Grade  of  diabetic  retinopathy  is  likely  to  improve  in  a  number  of 
subjects treated with long-term ranibizumab as shown by sub-analyses in RESTORE, 
DRCR.net and RISE/RIDE trials. 
 
Aflibercept 
Aflibercept,  formerly  known  as  VEGF  Trap-Eye  and  now  marked  as  Eyelea® 
(Regeneron Pharmaceuticals, New York, USA) is a fusion protein consisting of the 
key binding domains of VEGF Receptors 1 and 2 fused with the Fc portion of IgG. It 
possesses  a tight  binding affinity for  all VEGF-A isoforms  and placental  growth 
factor (PlGF). 
 
The DA VINCI trial was a Phase II study that compared four dosing regimens of 
aflibercept with standard laser therapy in patients with centre involving DMO. At the 
six month primary endpoint, improvements in the aflibercept groups ranged from 8.5 
to 11.4 letters compared to a 2.5 letter improvement in the laser group [86]. Two 
phase III trials of aflibercept in DMO are currently underway and it is likely that it 
will have a role in the management of DMO. 
Differences between the anti-VEGF agents 
 
Pegaptanib is specific to VEGF165 while bevacizumab, ranibizumab and aflibercept 
bind  all  isoforms  of  VEGF.  Compared  with  ranibizumab,  bevacizumab  is 
approximately  three  times  larger  and  has  different  pharmacokinetic  properties.  It 
lasts longer in the vitreous and is present in higher concentrations in the peripheral 
circulation following intravitreal injection. It also appears to be present in the fellow 
eye of rabbits receiving a uniocular injection. Ranibizumab, in contrast, has a higher 59 
 
binding affinity for VEGF and higher potency for inhibiting its action in in vitro 
studies. It is found in all layers of the retina after intravitreal injection. A study in 
rhesus monkeys to compare the retinal penetration of the Fab form of the VEGF 
antibody  with  a  full-length  antibody  showed  that  the  rhuMab  HER2  antibody 
(Herceptin,  trastuzumab)  did  not  penetrate  further  than  the  internal  limiting 
membrane [87], suggesting that this may also be the case with bevacizumab. The 
differences in binding between the agents may explain differences in clinical efficacy 
and safety profile. Aflibercept is designed to have a high affinity for VEGF and has 
been  marketed  as  being  suitable  for  two-monthly  dosing  in  age-related  macular 
degeneration. Ongoing phase III trials will investigate whether this is the case in 
DMO, but head-to-head trials of all the agents to evaluate clinical efficacy and safety 
are desirable. 
 
Safety of anti-VEGF agents 
 
The randomised trials carried out investigating anti-VEGF agents in DMO have not 
identified  any  risks  particular  to  the  condition.  Endophthalmitis  occurs  in 
approximately 1 in 1000 injections despite the use of povidone iodine pre-injection 
[88]. This will likely significantly worsen vision if it does occur. There has been 
concern in the ophthalmic community for some years about the theoretical risk of 
anti-VEGF agents entering the systemic circulation and increasing the risk of heart 
attack and stroke. Pharmacokinetic evidence presented above suggests that this risk 
is likely to be higher with bevacizumab and aflibercept than ranibizumab. A recent 
review of rates of stroke from the largest randomised controlled trials in age-related 
macular degeneration (AMD) provided some evidence of increased risk that was not 
statistically significant [89]. Subjects receiving bevacizumab in the Comparison of 
AMD  Treatments  Trials  (CATT)  did  not  have  an  increased  risk  of  arterial 
thromboembolic events compared with ranibizumab treated subjects, but did have a 
higher rate of other serious systemic adverse events not known to be associated with 
systemic anti-VEGF therapy. However, these occurred in greater numbers in the as-
required (prn) treatment group. A large, population-based nested case control study 
examining factors associated with heart attack and stroke in 91,000 patients with 60 
 
retinal disease did not find that prior treatment with anti-VEGF agents was a risk 
factor [90].  
1.5.5  Surgical treatment of diabetic retinopathy 
1.5.5.1  Vitrectomy for diabetic macular oedema 
Vitrectomy has been advocated for patients with reduced visual acuity due to DMO. 
Initially it was thought it may be effective in patients with diffuse DMO and without 
macular  traction  due  to  removal  of  the  VEGF  reservoir  from  the  vitreous  gel. 
However, it is likely only effective in patients with DMO and co-existent macular 
traction; when release of the latter during surgery allows the macula to resume a 
more normal contour which may in turn improve visual acuity. A review of patients 
in  the  USA  undergoing  such  surgery  found  two  factors  predictive  of  visual 
improvement,  namely  eyes  undergoing  epiretinal  membrane  removal  (i.e.  with 
traction) and poor initial visual acuity [91], although the latter may have arisen due to 
a ceiling effect on visual acuity for those with a better level of vision at baseline. 
However, although the chance of a two-line improvement was 26%, there was a 22% 
risk  of  a  two-line  loss  of  visual  acuity,  so  the  risks  and  benefits  are  delicately 
balanced and surgery may not be in the patient’s best interests. 
 
1.5.5.2  Surgical treatment for proliferative diabetic retinopathy 
As discussed above, the DRS showed that panretinal laser photocoagulation reduced 
the risk of visual loss in proliferative diabetic retinopathy. However, some patients 
with proliferative retinopathy may not receive timely treatment, while others may 
continue to progress without treatment, so that features of advanced diabetic eye 
disease  such  as  fibrovascular  proliferation,  vitreous  haemorrhage  and  tractional 
retinal  detachment  may  develop.  If  left  untreated,  these  conditions  will  lead  to 
irreversible loss of vision, so in this situation surgery may be required to prevent this. 
The Diabetic Retinopathy Vitrectomy Study (DRVS) investigated the outcome of 
performing  early  vitrectomy  for  non-clearing  vitreous  haemorrhage  and 
demonstrated for the first time an advantage in performing surgery promptly rather 
than  deferring  for  a  year  [92].  Since  then,  advances  in  surgical  technique  and  a 61 
 
clearer understanding of the indications for surgery has led to improved outcomes, 
discussed further in Chapter 3. 
 
The  indications  for  performing  vitrectomy  surgery  in  proliferative  diabetic 
retinopathy  are:  non-clearing  vitreous  haemorrhage;  tractional  retinal  detachment 
threatening the macula; combined tractional-rhegmatogenous retinal detachment; and 
subhyaloid  haemorrhage  obscuring  the  macula  [93].  The  objectives  of  diabetic 
vitrectomy surgery are to clear the ocular media and relieve antero-posterior traction 
on the retina. Firstly, core vitrectomy is performed to clear vitreous haemorrhage and 
remove  the  vitreous  gel.  Dissection  of  fibrovascular  membranes  either  by 
segmentation  or  delamination  relieves  traction  and  releases  tractional  retinal 
detachment.  In  some  cases  the  tractional  process  leads  to  retinal  breaks  before 
surgery (combined tractional rhegmatogenous retinal detachment) although creating 
further breaks during the separation of delicate tissues is very common. Tamponnade 
agents are used to secure any retinal breaks, and laser is applied to the  retina to 
prevent further neovascularisation [94]. One of the factors determining the likely 
success of diabetic vitrectomy is the status of the posterior vitreous in terms of its 
attachment to the retina. Fibrovascular attachments develop through proliferation of 
new  vessels  and  associated  fibrous  tissue.  This  can  result  in  focal  or  broad 
vitreoretinal attachments which require careful separation. While surgery for cases 
with  a  complete  posterior  vitreous  detachment  and  hence  no  fibrovascular 
attachments may be technically straightforward, in cases where broad vitreoretinal 
adhesions are present the outcome may not be as successful. Pre-existing macular 
ischaemia may also compromise visual results. Pharmacological therapies such as 
anti-VEGF  agents  have  been  used  as  adjuncts  to  surgery  and  their  role  is  also 
discussed further in Chapter 3. 62 
 
1.6  Problems and Aims 
 
The  preceding  chapter  outlined  the  clinical  problem  of  diabetic  retinopathy  and 
reviewed  the  pathophysiology  and  treatment  of  the  two  most  common  sight-
threatening  complications:  diabetic  macular  oedema  and  proliferative  diabetic 
retinopathy. 
 
The work presented in this thesis attempts to address some of the clinical issues that 
remained unresolved, at the time of commencing the work, in  these two clinical 
areas. 
1.6.1  Diabetic macular oedema 
Modified  ETDRS  macular  grid  and  focal  laser  therapy  can  stabilise  vision  and 
reduce the chance of moderate visual loss in subjects with diabetic macular oedema, 
and if presenting visual acuity is worse than 6/12, carries a 40% chance of a one-line 
gain in visual acuity [4] and a 20% chance of gaining two lines [58]. However, the 
RESOLVE study and READ-2 studies were phase 2 trials investigating ranibizumab 
that  suggested  the  potential  for  significant  visual  improvement  greater  than  that 
achieved with laser [85, 95]. Phase 3 trials were subsequently commenced to assess 
efficacy,  but  were  not  designed  specifically  to  address  certain  concerns  in  the 
medical  retina  community  about  the  safety  of  long-term  ranibizumab  therapy. 
Therefore  the  specific  aims  of  the  clinical  trial  presented  in  Chapter  2  were  to 
address some of these clinical problems. 
 
Problem  1:  The  effect  of  repeated  anti-VEGF  therapy  in  diabetic  macular 
oedema 
Diabetic maculopathy and retinopathy are diseases associated with focal and global 
retinal  ischaemia  and  animal  studies  have  shown  that  bevacizumab  can  lead  to 
ultrastructural  changes  in  the  choriocapillaris  of  non-human  primates  [96]  and 
increased capillary non-perfusion in rabbits [97]. It is therefore possible that repeated 
anti-VEGF therapy with the biologically similar agent ranibizumab could lead to 
changes in peripheral retinal structure via these choriocapillaris alterations and have 63 
 
a resulting effect on peripheral retinal function. Follow-up from phase 2 studies was 
not of sufficient duration to exclude the possibility of long-term retinal dysfunction 
resulting from repeated ranibizumab use. 
 
Aim  1:  To  investigate  the  effect  on  peripheral  retinal  function  of  repeated 
ranibizumab 
Reports of electrophysiology following anti-VEGF treatment for DMO are lacking in 
the  literature,  with  small  case  series  only  reporting  effects  of  bevacizumab  or 
ranibizumab on pattern and multifocal ERG (see Section 2.1.1.4). Repeated full-field 
electroretinography in this trial would allow the effect of ranibizumab on peripheral 
retinal  photoreceptor  and  neuronal  function  to  be  investigated.  This  investigation 
should be performed at baseline and at one year to establish the longer term effects of 
repeated treatment. 
 
Problem  2:  Could  anti-VEGF  agents  exacerbate  pre-existing  macular 
ischaemia? 
Ischaemic diabetic maculopathy is a difficult disease to treat as permanent structural 
damage has  occurred to the fine perifoveal  capillary network  responsible for the 
oxygen supply to the inner retina at the macula. The possibility that constitutively 
expressed physiological isoforms of VEGF exist that may be neuroprotective has 
been postulated [98]. This raises the possibility that pan-anti-VEGF inhibition by an 
agent  such  as  ranibizumab  could  exacerbate  macular  ischaemia.  The  first 
commercially  available  anti-VEGF  agent  for  intraocular  use,  pegaptanib,  was  a 
selective VEGF165 inhibitor, and it was hoped that greater selectivity might obviate 
potential  problems  arising  from  pan  anti-VEGF  inhibition.  Unfortunately  clinical 
experience  with  this  agent  is  limited  in  DMO  so  it  is  not  possible  to  determine 
whether this is the case or not. One case report identified progression of disease in a 
patient  with  pre-existing  ischaemia  who  received  bevacizumab  [99],  but  a  report 
from a randomised trial of bevacizumab in DMO did not find an adverse effect on 
the foveal avascular zone [74]. 64 
 
Aim 2: To investigate the effect of ranibizumab on macular ischaemia 
Carrying  out  serial  fundus  fluorescein  angiography  with  grading  of  the  foveal 
avascular zone size and area, with recording of perifoveal capillary loss, after the 
methods of Michaelides et al., would address this question.  
 
Problem 3: Visual acuity is only one measure of retinal function in DMO 
The changes of diabetic retinopathy affect the entire neurovascular unit, so changes 
to neuronal function coincide with the vascular pathology that is the hallmark of the 
disease. Visual acuity tests the function of the retina at the fovea, but does not give 
information on the function of the surrounding macula. Measures of retinal function 
that to a greater extent rely on function of the entire macula such as colour vision, 
pattern  electroretinograms  and  retinal  sensitivity  from  microperimetry  have  been 
reported to be reduced in diabetic macular oedema (see Section 2.1). To date these 
have been assumed to be irreversible, as there is little evidence of changed function 
following laser treatment. 
 
Aim 3: To investigate the effect of ranibizumab on different retinal functional 
modalities 
Suitable tests to achieve this aim include colour contrast sensitivity, fundus-related 
microperimetry and pattern electroretinography. 
 
Problem 4: How can clinical retreatment decisions be made based on retinal 
thickness in DMO?  
Phase 3 trials of ranibizumab in DMO and other diseases either adopt a mandatory 
monthly  retreatment  schedule  (e.g.  RISE/RIDE  [84])  or  employ  some  form  of 
algorithm based on clinical status to guide retreatment. Such algorithms typically 
include visual acuity as one measure, but also may employ automated measures of 
retinal  thickness  from  OCT  scans  (e.g.  DRCR.net  protocol  i  trial  [81]).  When 
fixation is poor and OCT devices do not employ eye-tracking software, significant 
measurement variability can occur between scans and this has been demonstrated in 
age-related macular degeneration  [100]. It  is  necessary to  establish  the test-retest 
variability, or repeatability, of newer spectral domain OCT devices as these are used 
with increasing frequency in clinic settings. 65 
 
 
Aim  4:  To  determine  the  repeatability  of  retinal  thickness  and  volume 
measurements using Spectralis SD-OCT 
Recruiting patients for a clinical trial offers the opportunity to carry out repeated 
imaging studies, so with multiple scans taken at baseline and subsequently analysed, 
coefficients of repeatability for scans from this device can be calculated. This will be 
a first step to developing possible algorithms for guiding clinical practice. 
 
Problem 5: The uncertain role of the choroid in the pathogenesis of DMO and 
diabetic retinopathy 
The choroid supplies oxygen to the outer retina and changes in its thickness have 
been  reported  with  increasing  severity  of  diabetic  retinopathy  by  several 
investigators [101-103]. Furthermore, animal studies have shown that permeability of 
the choroidal vasculature may be altered by VEGF inhibition [96]. Therefore it is 
plausible that ranibizumab treatment may lead to measurable changes in the choroid 
which could be relevant to understanding its mechanism of action in DMO. 
 
Aim  5:  To  investigate  the  effect  of  ranibizumab  treatment  for  DMO  on 
choroidal thickness 
Using the enhanced depth imaging mode of the Spectralis OCT device, the choroid 
can  be  imaged.  A  preliminary  study  of  changes  in  choroidal  thickness  over  the 
course of the trial may help determine whether there is an effect of VEGF inhibition 
on choroidal thickness, which has been claimed by other investigators [104]. 
 
1.6.2  Advanced proliferative diabetic retinopathy 
For advanced proliferative diabetic retinopathy, vitrectomy surgery can lead to good 
visual results, but is technically very challenging and outcomes can be compromised 
by  recurrent  post-operative  haemorrhage.  In  this  clinical  situation,  an  agent  that 
could facilitate safer and effective surgery and prevent post-operative haemorrhage 
could lead to better vision for patients. Trials that have investigated bevacizumab 
have suffered from methodological flaws and have chosen a variety of endpoints. 66 
 
Chapter 3 presents a clinical trial designed to address the main clinical problems 
facing surgeons carrying out vitrectomy for advanced PDR and avoid some of the 
methodological problems seen in earlier trials with bevacizumab. 
 
Problem 1: Patients after surgery may still have poor vision 
Longitudinal data from cohorts of patients undergoing vitrectomy for advanced PDR 
show that a significant number do not regain functional vision in the operated eye 
[93].  This  may  be  due  to  recurrent  post-operative  vitreous  cavity  haemorrhage, 
advanced retinal ischaemia or recurrent detachment. There is interest therefore in 
optimising surgery to improve vision for patients. 
 
Aim 1: To investigate the effect on visual acuity of a pre-operative injection of 
ranibizumab  in  patients  undergoing  vitrectomy  for  advanced  proliferative 
retinopathy 
Choosing visual acuity as the primary outcome measure for the trial is appropriate 
because  it  is  likely  to  correlate  best  with  the  patient’s  functional  outcome  and 
satisfaction. 
 
Problem  2:  Recurrent  bleeding  can  occur  both  during  and  after  vitrectomy 
surgery in this condition. 
A number of studies have attempted to quantify intra-operative haemorrhage during 
diabetic  vitrectomy  using  both  qualitative  and  quantitative  methods  with  varying 
results [105, 106]. There is not convincing evidence to support the routine use of pre-
operative  bevacizumab  or  ranibizumab  in  this  condition,  so  further  study  to 
determine a potential benefit for patients is required. 
 
Aim  2:  To  investigate  intra-operative  haemorrhage  and  post-operative 
haemorrhage 
As a secondary outcome measure in the clinical trial, the degree of intraoperative 
haemorrhage as reported by the surgeon and as measured by quantitative techniques 
will be reported. 
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Problem 3: Exacerbation of tractional retinal detachment by pre-operative use 
of anti-VEGF agents 
Investigators have reported new tractional retinal detachments and exacerbation of 
existing  tractional  pathology  in  subjects  undergoing  pre-operative  bevacizumab 
injection  [107,  108].  Again,  methodology  for  identifying  this  progression  and 
masking of surgeons reporting it has been variable. It is therefore unclear whether 
this represents a genuine effect of bevacizumab or natural progression of disease. 
 
Aim 3: To investigate the effect of ranibizumab on progression of tractional 
retinal detachment 
Ultrasound evaluation provides an objective means of measuring tractional retinal 
detachment that can be undertaken even in the presence of significant media opacity. 
With  appropriate  masking  of  the  sonographer,  measurements  before  and  after 
administration  of  ranibizumab  will  help  establish  whether  the  contraction  of 
fibrovascular membranes leads to new pathology. 
 
Problem  4:  The  pathophysiology  of  proliferative  retinopathy  involves  many 
cytokines in addition to VEGF 
Diabetic  retinopathy  includes  vascular  leakage,  occlusion  and  angiogenesis  in 
addition  to  chronic  inflammation.  Numerous  cytokines  have  been  found  to  be 
upregulated in diabetic retinopathy, with VEGF arguably the most important of these 
(see Section 3.1.3). There are few opportunities to study the vitreous in these patients 
and the effect of ranibizumab has not been studied. It is therefore hypothesized that 
ranibizumab treatment may lead to measurable changes in the cytokine profile. 
 
Aim  4:  To  record  the  level  of  VEGF  and  related  cytokines  in  patients 
undergoing vitrectomy for advanced PDR 
Sampling of vitreous and plasma and subjecting this to cytometric bead array allows 
the  simultaneous  quantification  of  many  vitreous  cytokines.  This  preliminary 
investigation may highlight cytokines worthy of further study. 
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2 The LUCIDATE
* Study  
This  chapter  outlines  the  backgrounds,  methods,  results  and  discussion  of  the 
LUCIDATE study: a randomised controlled trial exploring the detailed functional 
and structural effects of repeated ranibizumab therapy on diabetic macular oedema. 
 
*LUCIDATE – LUCentis In Diabetic macular oedema – A Treatment Evaluation 
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2.1  Background 
As discussed in chapter 1, diabetic macular oedema (DMO) is an important cause of 
visual  loss  and  treatments  until  recently  have  been  limited  to  laser  with  some 
evidence  for  the  efficacy  of  steroids.  Now,  there  is  good  evidence  for  the 
effectiveness of anti-VEGF treatments in this condition from large, well-designed 
randomised controlled trials. These phase 3 trials, typically involving hundreds of 
patients,  are  limited  in  the  number  of  investigations  that  can  be  carried  out  on 
individual subjects. They generally take visual acuity as a primary endpoint, often 
with central retinal thickness from optical coherence tomography (OCT) imaging as 
a secondary endpoint. To date, there is little knowledge of the results that can be 
expected from other tests of visual function such as microperimetry, colour contrast 
sensitivity  and  electrophysiology  following  anti-VEGF  therapy.  The  advent  of 
spectral domain OCT imaging means that morphological features of DMO can be 
identified and changes to these features following treatment can be assessed. Macular 
ischaemia  remains  a  theoretical  concern  with  anti-VEGF  agents  so  fluorescein 
angiography continues to be a useful modality for evaluating this. A trial to evaluate 
the functional  and structural  effects  of ranibizumab in  DMO may provide useful 
information and the answers to some of these questions. 
2.1.1  Functional tests to evaluate diabetic macular oedema 
In contrast to tests that evaluate retinal anatomy and structure, tests of function are 
generally  more  time  consuming,  require  greater  patient  co-operation  and  may  be 
subject to more test-retest variability. Aside from widely used visual acuity testing, 
which is very strongly influenced by foveal function, they are not routinely employed 
in  clinical  trials  or  standard  clinical  practice.  However,  in  the  absence  of  an 
unambiguous  structural  biomarker  which  is  known  to  correlate  well  with  retinal 
function,  these  functional  tests  may  be  useful  in  establishing  the  effects  of 
treatments. Having accurate and reproducible measures is therefore important for the 
diagnosis  and  monitoring  of  macular  disease  and  for  assessing  responses  to 
treatments in clinical trials. 70 
 
2.1.1.1  Visual acuity testing 
High contrast visual acuity is typically chosen as the primary endpoint for the large 
clinical trials of treatments for DMO discussed in Chapter 1. Several charts are used 
in routine clinical practice to assess visual acuity. Although used very commonly, the 
Snellen chart, created by Hermann Snellen in 1862 has a number of disadvantages 
that make it less suitable for clinical trials work. This chart utilises black letters, 
termed “optotypes”, on a white background for maximal contrast. Each optotype is 
arranged on a 5x5 grid subtending 5 minutes of arc, with gaps in the letter structure 
required for discrimination subtending a visual angle of 1 minute of arc. However, 
there are different numbers of letters on each line and the spacing is not regular. Thus 
the  chart  is  poor  for  accurate  assessment  of  the  lower  end  of  the  visual  acuity 
spectrum and does not provide a continuous analysis of acuity. In 1976, Ian Bailey 
and Jan Lovie published their eponymously named chart featuring a new layout of 5 
letters per row with spacing between letters and rows equivalent to the letter size.  
This was created to eliminate the crowding effect and standardise the number of 
errors that could be made on each line. The character size change is a logarithmic 
progression  of  letter  sizes  and  the  chart  output  is  given  as  the  logarithm  of  the 
minimum angle of resolution (LogMAR). 
 
The  advantages  of  the  Bailey-Lovie  LogMAR  chart  led  to  the  development  of 
standardised visual acuity charts for clinical trials use. Designed for use in the Early 
Treatment  Diabetic  Retinopathy  Study,  these  “ETDRS”  charts  consist  of  three 
separate  sets  of  Sloan  letters  based  on  the  LogMAR  chart  characteristics  [109]. 
Different charts are provided for right and left eyes and a third chart can be used 
during refraction prior to testing best-corrected acuity. These charts are now widely 
used in clinical trials and visual acuity is typically reported as a letter score from 0 to 
approximately 95. 
2.1.1.2  Colour vision testing 
Colour vision defects are an important cause of reduced visual function and have 
occupational implications for patients with diabetes. Reports of reduced colour vision 
in diabetes date from the 1970s. 71 
 
The  Farnsworth-Munsell  100-Hue  test  has  been  used  for  several  decades  to 
document colour vision defects and was employed in the ETDRS [110]. The test 
consists of arranging 85 numbered caps of equal contrast and saturation in a regular 
colour series. Following the method proposed by Kinnear [111], the square root of 
the error score generated by the test is used to normalise the results. Only 8.1% of 
subjects in the ETDRS had a SQRT 100-Hue score <7.5 (normal), and all of these 
had a visual acuity better than 20/40. Almost half of the patients investigated in this 
ETDRS sub-study had hue discrimination scores worse than the 95
th percentile of a 
group of normal subjects. These findings suggest that even with relatively preserved 
visual acuity, colour vision may be impaired. Clinically significant macular oedema 
was reported as being associated with a worse hue discrimination score. However, 
this study also reports that even in eyes with no detectable macular oedema, over one 
third of eyes had abnormal hue discrimination. This suggests that neuronal changes 
are  present  even  before  the  characteristic  microvascular  changes  of  diabetic 
retinopathy are visible and the concept of the “neurovascular unit” of the retina as an 
important concept in the pathogenesis of diabetic retinopathy is recalled. The defect 
in colour vision most commonly occurring in diabetic retinopathy has been reported 
to be in the tritan, or blue-yellow axis of colour discrimination [112]. A follow up 
report from the ETDRS population further classifies the colour vision defects seen in 
this group of patients [113], confirming that the commonest specific defect seen, in 
26% of eyes studied, was a defect in discrimination in the blue-yellow axis. The 
severity of this was associated with increasing age and severity of macular oedema. 
10% of eyes had a generalised reduction in hue discrimination with no specific axis. 
Therefore evidence suggests that colour vision defects are present early in diabetic 
macular disease and are very common. 
 
Alternative methods  for investigating colour contrast  sensitivity using  automated, 
screen based techniques have been explored. Arden et al. described in 1988 a system 
to generate gratings on a computer display and use these to establish thresholds of 
colour  contrast  sensitivity  [114].  This  system  demonstrated  that  ophthalmologists 
using blue wavelengths of argon laser for retinal treatment developed reduced colour 
contrast  thresholds  [115].  This  computer-linked  technique  evolved  into  the 
ChromaTest, which projects digital optotypes of different colour contrast, but equal 72 
 
size and luminance, over the central 6.5° of the retina to measure protan and tritan 
sensitivities [116]. The Sussex Gratings Machine test is a cathode-ray tube based 
colour vision test that displays sinusoidal gratings along different colour confusion 
axes  on  a  standard  cathode  ray  tube  television  monitor.  It  has  been  used  to 
investigate  impairment  in  colour  contrast  thresholds  in  diabetic  retinopathy  [117, 
118] and has corroborated previous findings of impairment in the tritan axis in this 
disease. It is known that accelerated lens ageing occurs in diabetes and this offers an 
alternative explanation for decreased tritan contrast sensitivity. Tregear et al. showed 
that for subjects with diabetes but no retinopathy, the reduced tritan sensitivity could 
be explained by correcting for increased yellowing of the lens [117]. However, even 
after this correction was made, subjects with background retinopathy were shown to 
have  reduction  in  tritan  sensitivity  even  in  the  absence  of  macular  oedema. 
Furthermore,  the  presence  of  ischaemia  as  defined  by  clinical  examination  was 
shown to reduce red/green (protan) sensitivity as well as the expected reduction in 
tritan sensitivity. 
 
The finding of reduced colour sensitivity preceding the development of significant 
diabetic eye disease has led investigators to explore the possibility of using colour 
vision testing as a screening tool for diabetic retinopathy [116, 118]. Detecting a 
functional impairment before structural disease has occurred could be advantageous 
in allowing patients access to clinical examination and treatment at an earlier stage. 
Ong et al. showed that the automated cathode ray tube technique employed by the 
Sussex  Gratings  Machine  could  yield  a  94%  sensitivity  and  95%  specificity  for 
detecting  sight-threatening  diabetic  retinopathy  by  measuring  tritan  contrast 
sensitivity [118]. The ChromaTest was investigated in a pilot study of subjects with 
type  2  diabetes  and  either  untreated  non-proliferative  retinopathy  or  untreated 
clinically  significant  macular  oedema  [116].  Of  subjects  with  non-proliferative 
retinopathy, 30% had tritan thresholds greater than normal and this figure in subjects 
with CSMO was 71%. However, this did not reach a high enough level of sensitivity 
or specificity from this preliminary study to justify its use as a screening tool. A 
recent  systematic  review  of  colour  vision  testing  for  screening  for  diabetic  eye 
disease  concluded  that  there  was  insufficient  evidence  to  justify  its  inclusion  in 
screening programmes at present [119]. 73 
 
2.1.1.3  Microperimetry 
Conventional  visual  field  examination,  or  perimetry,  generally  is  unable  to 
compensate  for  fixation  that  is  eccentric,  or  that  may  be  unstable;  this  limits  its 
usefulness in macular disease where central scotomata may be present compromising 
the patient’s ability to minimise eye movements during examination. It is therefore 
desirable  to  have  a  method  of  performing  perimetry  that  allows  stimuli  to  be 
projected onto known retinal locations with a greater degree of confidence, in order 
to evaluate more accurately retinal sensitivity in macular disease.  This technique is 
termed fundus-related perimetry, or microperimetry. 
 
Development of microperimetry 
Early methods for carrying out this test utilised a scanning laser ophthalmoscope 
(SLO) connected to a monitor to enable visualisation of the retina while targets were 
presented [120]. Techniques evolved to include a computer on which the operator 
could select retinal targets to test, and which allowed some compensation for eye 
movements  during  testing  [121],  but  the  procedure  remained  relatively  time-
consuming and was not generally available in a clinical setting. The Nidek MP1 
(Nidek technologies, Padua, Italy) was the first commercially available device that 
allowed automation of this type of examination, and has been validated against the 
pre-existing SLO-based techniques that had been in use for many years [122]. This 
machine projects a fixation target and stimuli on a liquid crystal display while the 
fundus is imaged in infra-red, under standard illumination conditions. The automatic 
eye tracker frequently monitors and corrects for eye movements so that the stimulus 
is projected with accuracy onto the known retinal location; allowing the matching of 
locational sensitivity to areas of visualised pathology [123]. 
 
Effect of DMO on retinal sensitivity 
The automated nature of the Nidek MP1 device and the relative ease of performing 
examinations have led to a number of studies reporting retinal sensitivity in DMO, 
with attempts being made to correlate findings with structural changes present in the 
macula. In a study comparing normal subjects with 32 eyes of subjects with DMO, 74 
 
MP1-determined retinal sensitivity was shown to be significantly lower (2.0dB and 
2.8dB in the central 2° and 10° respectively, compared with 15.0dB and 14.8dB) 
when DMO was present [124]. This study also demonstrated correlations between 
retinal sensitivity and both visual acuity and foveal thickness. However, only a single 
thickness measurement from the central fovea was taken from OCT, so this finding 
has questionable significance. Further criticisms of this study include the omission of 
demographic data regarding the subjects and the lack of age-matched controls [125], 
although the magnitude of the disparity between sensitivity in normals and in those 
with DMO suggest that a genuine difference does exist. 
 
Vujosevic and co-workers conducted a more detailed study to examine correlation 
between  visual  acuity,  retinal  thickness  and  retinal  sensitivity.  In  subjects  with 
CSMO,  there  was  a  significant  correlation  between  retinal  thickness  in  the  five 
central OCT subfields and retinal sensitivity (r=-0.48, p<0.0001), but this correlation 
was not seen in subjects without macular oedema or with oedema that did not meet 
the criteria for CSMO [126]. This study utilised a customised 45-stimulus radial grid 
covering  the  central  12°  of  the  macula;  from  this  can  be  determined  the 
microperimetry test loci that lie in corresponding OCT subfields. They demonstrated 
that in the presence of diabetes central macular sensitivity was lower than normal 
even in eyes with no macular oedema (11.9 ±3.4dB), and when macular oedema was 
present sensitivity was reduced further (4.7 ±3.5dB in the group with CSMO). 
 
In a study evaluating 20 eyes with capillary non-perfusion as a result of diabetic 
retinopathy, MP1-determined retinal sensitivity was significantly reduced in areas of 
non-perfusion  compared  with  immediately  adjacent  retina  [127].  Average  retinal 
sensitivity ranged from 0 to 1.7dB in non-perfused areas, whereas in perfused retina, 
sensitivities increased up to 13.3dB for some patients (overall mean not presented). 
This suggests that retinal non-perfusion identified by fluorescein angiography merits 
further exploration as a correlate of retinal function. 
 
Retinal sensitivity changes reported by microperimetry following treatment for DMO 
There are a number of reports describing the effect of treatments for DMO on retinal 
function as determined by microperimetry using the Nidek MP1. However, many of 75 
 
these studies are uncontrolled, so results reporting changes in sensitivity should be 
interpreted with caution given the learning effect associated with the machine and the 
inherent test-retest variability present. Mean macular sensitivity has been shown to 
have a  coefficient of  repeatability (CR) of 1.81dB, but  higher in  the  central  10° 
(2.13dB), with a CR for individual point sensitivity of 5.56dB [128]. 
 
Two  uncontrolled  studies  report  a  modest  increase  in  mean  retinal  sensitivity 
following intravitreal triamcinolone injection for DMO. Twenty eyes treated with 
8mg triamcinolone had an improvement in mean macular sensitivity of 1.69dB at 3 
months [129], while 11 eyes that received 4mg in a separate study showed a slight 
increase in retinal sensitivity of 3.23dB [130]. Without a control group it is difficult 
to  ascertain  whether  this  represents  a  true  clinical  change  or  is  attributable  to  a 
learning effect.  
 
A randomised trial has reported the effect of two different methods of laser treatment 
on retinal sensitivity in DMO. Subjects were randomised to either standard modified 
ETDRS macular laser or sub-threshold micropulse diode laser (MPDL). While visual 
acuity was stable in both groups, retinal sensitivity decreased in the group receiving 
standard ETDRS laser by 1.69 dB in the central 12° of the macula, but improved by 
0.87 dB in the same area after MPDL. This change was accompanied by no increase 
in fundus autofluorescence with MPDL but evidence of increased autofluorescence 
with ETDRS laser, suggesting the newer technique may be less damaging to the 
retinal pigment epithelium [131]. A novel laser with even shorter pulse duration in 
the  nanosecond  range  has  shown  promise  in  DMO.  Retinal  rejuvenation  therapy 
(2RT) selectively targets individual RPE cells to ensure sufficient numbers of cells 
survive  to  prevent  accompanying  photoreceptor  death.  A  pilot  study  in  28  eyes 
suggested  the  potential  for  improved  visual  acuity  and  reduced  central  macular 
thickness with this technique; further investigations are awaited [132]. 
 
Only one small prospective study reports the effect of an anti-VEGF agent on retinal 
sensitivity. A series  of  26 eyes  receiving three bevacizumab injections for DMO 
showed  an  improvement  in  retinal  sensitivity  of  around  6  dB  following  three 
injections [133]. The investigators report parallel improvements in visual acuity and 76 
 
retinal thickness, and therefore suggest that these changes may correlate with each 
other. A further study reports correlations between visual acuity and morphological 
features of DMO on OCT in subjects who had received a series of three ranibizumab 
injections.  However,  there  is  no  mention  in  the  published  paper  of  the  actual 
microperimetry results in the study [134]. 
 
Little can be therefore concluded about the long term functional effects of treatments 
on  retinal  sensitivity  measured  in  this  manner.  Conventional  laser  appears  to 
decrease retinal sensitivity as shown in the one well-designed randomised, masked 
trial, but it is not  yet known with any certainty what the effect on sensitivity of 
medical agents for treating diabetic macular oedema might be. 
2.1.1.4  Electrophysiology 
Pattern electroretinogram 
The pattern electroretinogram (PERG) is an electrophysiological recording that is 
used to investigate function of the macula. It is produced by a subject observing a 
reversing  stimulus,  such  as  a  checkerboard,  which  retains  a  constant  luminance 
throughout the reversal. Because there is no change in overall mean luminance, the 
response originates only from the area stimulated by the reversing pattern, which 
typically covers a 10-16° field. The main components of the PERG are a positive 
deflection  at  approximately  50  ms  termed  the  P50  and  a  negative  deflection  at 
approximately 95 ms, the N95 component. The precise cellular origin of the P50 is 
unknown,  but  it  arises  partly  in  retinal  ganglion  cells  and  is  driven  by  macular 
photoreceptors, so represents a true test of macular function [135, 136]. The typical 
PERG waveform is shown in Figure 14. Although the PERG is commonly used in a 
clinical setting to help distinguish between optic nerve and retinal disease, it has also 
been used a research tool and has found to be abnormal in diabetic retinopathy. 77 
 
 
Figure 14 – The typical PERG waveform to illustrate the major components 
described above. A small early negative deflection is also recognised (N35). From 
[136]. 
 
Arden et al. recorded the PERG in subjects with normal visual acuity and varying 
grades  of  diabetic  retinopathy.  They  showed  that  the  amplitude  of  the  PERG 
decreased depending on the severity of the retinal disease. Subjects with only a few 
microaneurysms present typically had normal  PERG amplitudes,  but  by  the time 
significant  ischaemia  was  present  as  shown  by  capillary  dropout  on  fluorescein 
angiograms, the PERG P50 amplitude had reduced by over 50% [137]. Coupland et 
al. also found that when there was no photographic evidence of diabetic retinopathy 
there was no PERG abnormality, but when retinal changes appeared the amplitude 
reduced [138]. Jenkins et  al.  provide supporting evidence for P50 amplitudes no 
different from normals in subjects with minimal diabetic retinopathy changes [139]. 
However, a different  research  group employed  a slight  variation in  technique by 
using  sinusoidal  gratings  instead  of  a  checkerboard;  this  suggested  that  PERG 
changes  were  present  even  when  no  retinopathy  was  present  [140].  Evidence 
therefore supports the conclusion that PERG amplitude reduces in diabetes when 
visible retinopathy is present. 
 
These studies provide evidence of early retinal dysfunction in diabetic retinopathy 
and maculopathy, even in the absence of reduced visual acuity. The appearance of 
functional  changes  like  PERG  P50  amplitude  reduction  when  retinal  signs  are 78 
 
minimal provides further evidence for the effect of diabetes on the retinal neuronal 
network; suggesting again that it is not only a vascular disease but one affecting the 
whole neurovascular unit. 
 
Effects of treatment for DMO on the pattern electroretinogram 
Laser was shown in the ETDRS to reduce risk of visual loss when performed for 
CSMO, so is at best able to preserve vision with acuity improvements less likely. 
However, it has been shown that after macular photocoagulation for DMO there is a 
reduction  in  the  PERG  amplitude,  reflecting  the  contribution  of  the  paramacular 
neurons,  located in  the region  where laser is  performed, to  the PERG waveform 
[141]. Although this study reported a decrease in the order of 40%, it only studied six 
eyes from three patients and did follow these patients for any period of time, so it 
possible that there may have been recovery of function later or that it could have 
worsened.  As  this  study  pre-dated  the  widespread  availability  of  OCT  it  is  not 
possible to know to what extent structural changes in the macula accompanied this 
functional change. However, evidence therefore exists for worsening retinal function 
even with preserved visual acuity. 
 
Two longitudinal, uncontrolled studies report an increase in the PERG P50 amplitude 
after injections of triamcinolone and bevacizumab. In 40 eyes that received a single 
triamcinolone injection, visual acuity improved and there was an increase in P50 
amplitude from 1.5 µv to 2.1 µv after six months [142]. Again, there is no correlation 
made with OCT. Patients in this study had relatively poor visual acuities at baseline 
(worse than 6/60 on average) so it is possible that fixation may have been impaired 
which may have reduced the PERG response. It is therefore possible that improved 
amplitudes at six months simply reflect better fixation as acuity improves. Similar 
results were reported by the same group after a single bevacizumab injection to 35 
treatment-naïve eyes. In this study P50 amplitude increased from 1.4 to 2.2 µv at 6 
months [143]. The same caveats apply about the lack of a control group and the 
possibility  of  PERG  improvement  being  driven  by  improved  acuity  and  hence 
fixation. It is also surprising given what is known about the pharmacokinetics of 
bevacizumab and the retreatment schedules used for anti-VEGF agents in clinical 
trials that a single injection could have an effect for six months. 79 
 
In summary, the PERG may be an early indicator of neuronal dysfunction in diabetic 
retinopathy. As it evaluates the response of the macula, it may be employed usefully 
as a tool for evaluating the functional effects of treatment. There is some evidence 
that P50 amplitude may be reduced after laser treatment and increased after either 
steroid or anti-VEGF therapy, but randomised trials are lacking and there is little 
long-term follow-up data. 
 
Full-field electroretinogram 
The full-field electroretinogram (ERG) records the massed responses of the rods and 
cones to retinal stimulation. It is obtained using a Ganzfeld bowl which is designed 
to provide uniform illumination to the entire visual field. In scotopic conditions it 
measures the rod responses, and after light adaptation it is able to measure cone 
responses by using a background illumination to saturate rod responses. The 30 Hz 
flicker ERG is specific to cone responses as this flicker frequency is beyond the 
temporal resolution of rods. A typical ERG waveform consists of an a wave, which is 
generated by hyperpolarisation of the photoreceptors, and a b wave arising in ON-
bipolar cells [135]. A standard set of ERGs consists of a number of rod- and cone-
specific  responses  obtained  in  lighting  conditions  specified  by  the  International 
Society for the Clinical Electrophysiology of Vision (ISCEV) [144]. Evaluation of 
ERG recordings comprises measurement of the amplitudes and implicit times of a 
and b waves. Wave amplitude generally reflects the functional integrity of the retina 
and is reduced when loss of function has occurred. Increased implicit times imply 
that retinal dysfunction is present. Oscillatory potentials are a further component of 
the electroretinogram that have been studied in diabetes. They are small oscillations 
superimposed on the ascending limb of the b wave, the source of which may be 
amacrine  cells,  although  other  investigators  have  reported  contributions  from 
photoreceptors and ON-bipolar cells [145]. 
 
In diabetes, the changes in the electroretinogram may correlate with disease severity 
and duration. Similarly to the findings from studies of the PERG in diabetes, subjects 
with  early  diabetes  and  no  retinopathy  may  have  no  alteration  in  the  ERG.  For 
example, Uccioli et al. showed that subjects with less than six months’ duration of 80 
 
disease did not have a reduction in the electroretinogram [146]. Interestingly, other 
researchers have reported a bimodal distribution in amplitudes of ERG b waves in 
subjects with either no retinopathy or minimal disease: while one group of subjects 
had decreased amplitudes another group had an increase in magnitude  [139]. No 
obvious cause for this in terms of correlation with age or duration of disease was 
found. 
 
Full-field  ERG  represents  the  massed  response  of  retinal  neurons  and  so  it  is 
unsurprising  that  amplitude  declines  following  panretinal  photocoagulation, 
reflecting  the  loss  of  functional  retina  from  laser  burns  aiming  to  destroy 
photoreceptors.  This  has  been  observed  for  many  years  [147].    Recently, 
investigators  have  evaluated  the  impact  of  ranibizumab  treatment  combined  with 
PRP  on  electroretinograms  in  high  risk  proliferative  retinopathy  [148].  In  this 
randomised  study,  subjects  in  the  PRP  +  ranibizumab  group  could  receive 
retreatment  with  ranibizumab if new vessels  persisted;  at  the study endpoint this 
group had fewer laser burns and less decline in retinal function based on rod and 
cone response b wave amplitudes. There was a small increase in b wave implicit 
time, but no difference between groups. Increases to the implicit time of the b wave 
represent evidence of retinal dysfunction, so changes seen after a particular treatment 
may  represent  evidence  of  increasing  ischaemia.  Evaluating  the  full-field 
electroretinogram in a study where ranibizumab is given in the absence of significant 
retinal  laser  yields  the  opportunity  to  evaluate  further  its  long  term  effects  on 
generalised retinal function. 
 
Multifocal electroretinogram 
The  multifocal  ERG  (mfERG)  provides  a  means  of  evaluating  localised  retinal 
function. To record a mfERG the subject views an array of either 61 or 103 hexagons 
on  a  display  screen,  while  fixating  centrally,  so  that  these  hexagons  fall  on  the 
posterior pole of the eye and stimulate the macula together with mid-peripheral retina 
out to 20-25°. The hexagons flicker in a pseudo-random sequence and a continuous 
ERG is recorded. Mathematical analysis then allows the extraction of an individual 
ERG from each hexagonal component. A typical mfERG is shown in Figure 15. The 81 
 
individual components of the wave are similar to the typical waveform of the full 
field ERG but as they represent a mathematical construction they cannot be thought 
of as analogous. A standard for recording mfERGs has been published by ISCEV 
[149]. 
 
Figure 15 – Multifocal ERG recording from a normal subject. (A) shows the 
individual extracted ERGs from each of the 61 hexagonal stimuli. (C) shows this in 
graphical form. This recording is from a left eye as the decreased sensitivity from the 
blind spot nasal to the macula can be identified. From ISCEV standard [149]. 
 
Yamamoto et al. investigated the mfERG in subjects with diabetic macular oedema 
and found that when cystoid oedema was present, central responses were decreased. 
Additionally, they established that foveal thickness measured by OCT correlated to 
an  extent  with  mfERG  response  amplitude  [150].  Conflicting  results  for  mfERG 
amplitude change following triamcinolone injection for DMO have been reported. A 
study of 15 patients receiving triamcinolone found an improvement in visual acuity 
together with increased mfERG amplitudes in the central and peripheral hexagons 
with no accompanying change in implicit time [151]. However, a similar study of 24 
patients with DMO treated with triamcinolone failed to replicate this finding and did 
not  detect  a  difference  in  mfERG  amplitudes  despite  visual  acuity  improvement 
[152]. While it is possible that irreversible retinal dysfunction may be present in 
subjects with longstanding DMO, it is also possible that the signal to noise ratio of 
mfERG  is  too  low  to  record  changes  in  retinal  function  related  to  resolution  of 
macular oedema. It may be that visual acuity improvements result from a highly 
localised improvement in function at the fovea that is not reflected in the mfERG 82 
 
measurement. Multifocal ERG remains a research tool rather than a core diagnostic 
tool in electrophysiology and may be of some use in the evaluation of DMO. 
 
2.1.2  Structural tests to evaluate diabetic macular oedema 
Non-invasive imaging techniques have now become widespread in the management 
of  DMO.  Colour  photography  and  fluorescein  angiography  have  been  in  use  for 
decades, but the decrease in cost and subsequent increase in availability of OCT 
scanning has  meant  that research into this  modality has  attracted a  great  deal  of 
attention. 
2.1.2.1  Optical coherence tomography 
First described by David Huang at the Massachusetts Institute of Technology in 1991 
[153], and developed for clinical use by Carmen Puliafito and James Fujimoto [154], 
OCT scanning allows the generation of cross-sectional images of the retina rapidly 
and non-invasively. It achieves this by interferometry and involves comparing the 
time delay of light reflected from the retina with a reference beam and analysing the 
interference patterns between the two beams; this has been extensively described in 
the literature [155]. OCT became commercially available in the 1990s with devices 
produced by Zeiss and now many different devices are available. OCT images are 
conventionally displayed as a cross-sectional B-scan image derived from combining 
several thousand axial or “A” scans (see Figure 17 below for example). Recently, 
interest has developed in combining several B-scans into an en face image (or C-
scan).  
 
The older, time-domain (TD) OCT machines obtained images by way of a movable 
mirror that scanned the imaging beam across the retina and acquired 400 A-scans per 
second. The Zeiss OCT1 had an axial resolution of around 15 µm, improved by 
about 7 µm in later devices such as the Zeiss Stratus OCT [156]. Spectral-domain 
(SD) OCT devices use a spectrometer to measure light reflectance across the spectral 
range so do not require a moving mirror, and are much faster than TD OCT; typically 
they are able to obtain 20-40,000 A-scans per second with a higher resolution of 4-7 
µm  axially.    Examples  include  the  Zeiss  Cirrus  device  and  the  Spectralis  OCT 83 
 
(Heidelberg Engineering GmbH; Heidelberg, Germany), shown in Figure 16, which 
also incorporates eye tracking software and improved signal-to-noise ratio with the 
ability  to  superimpose  multiple  images  from  the  same  retinal  location  (see  also 
section 2.1.2.2). 
 
 
 
Figure 16 – The Heidelberg Spectralis OCT system (Image courtesy of Heidelberg 
Engineering GmbH, Germany). 
 
OCT in diabetic macular oedema 
Quantitative and qualitative approaches to measuring and characterising the OCT 
features of DMO have been adopted. Hee et al. demonstrated the viability of using 
OCT to image the retina of patients with DMO [157] and showed increased foveal 
thickness when macular oedema was present. They mapped the macular region using 
the nine ETDRS subfields, which has now become an accepted standard for OCT of 
the  macula  and  thickness  in  the  central  subfield  has  been  used  as  an  outcome 
measure  in  clinical  trials.  Otani  et  al.  described  three  different  morphological 
features  of  DMO  visualised  on  TD  OCT:  sponge-like  retinal  swelling,  cystoid 
oedema  and  serous  retinal  detachment;  they  also  identified  the  presence  of  hard 
exudates as hyper-reflective foci [158]. Both these early reports also found a negative 
correlation  between  central  retinal  thickness  on  OCT  and  visual  acuity  in  this 
condition. 
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Increased OCT resolution has led to better identification of the OCT correlates of the 
anatomical retinal layers using newer SD OCT devices. Following on from the early 
descriptions  of  the  patterns  seen  in  DMO,  it  has  now  become  easier  to  link  the 
pathophysiological changes of blood-retina barrier breakdown with the accumulation 
of fluid in the layers of the retina, with typical appearances from a SD OCT image in 
DMO shown in Figure 17. 
 
 
Figure 17 – OCT scan from patient with diabetic macular oedema, to show retinal 
thickening, fluid in inner and outer retina, and hyperreflective foci. 
 
Angiographic  appearances  of  macular  oedema  include  petaloid  and  honeycomb 
patterns,  as  fluid  accumulates  in  the  fibre  layer  of  Henle  and  the  inner  retina 
respectively.  However,  the  appearance  of  apparent  cysts  on  OCT  imaging  is 
misleading, as electron micrographic studies have shown that the fluid present in the 
retina  occupies  interconnected  spaces,  and  the  walls  of  these  spaces  represent 
stretched  neuronal  elements  as  retinal  layers  become  separated  by  fluid 
accumulation.  The  cross-sectional  area  of  retinal  tissue  crossing  these  spaces 
correlates with visual acuity in DMO [159]. 
 
Deak et al. correlated retinal sensitivity from microperimetry with morphological 
features on OCT scans in DMO to try and establish the link between observed OCT 
features and their functional effect. They found that large outer nuclear layer cysts 
and serous retinal detachment had the greatest effect on retinal sensitivity (-3.86 and 85 
 
-3.65 dB), but retinal swelling alone did not have a detectable effect on sensitivity 
[160]. 
 
Investigating  the  longitudinal  effect  of  treatment  for  DMO  on  some  of  the 
morphological  changes  present  on  OCT  affords  the  opportunity  to  identify  those 
which may be useful as markers of a good response to treatment, and which may 
signify irreversible retinal damage and hence a likely poor response to treatment. 
Choroidal thickness evaluation by OCT 
Limitations to the resolution of OCT at increasing retinal depth previously meant that 
even  deeper  structures  such  as  the  choroid  were  very  difficult  to  image.  Spaide 
described  the  technique  of  enhanced  depth  imaging  (EDI),  where  pushing  a 
conventional Spectralis OCT device closer to the subject’s eye to obtain an inverted 
image allowed the choroid to be imaged. The device’s eye tracking function and 
ability to average the signal from up to 100 images (automatic real time, ART) meant 
that  high  resolution  images  of  the  choroid  could  be  obtained  [161].  Now, 
conventional SD OCT devices incorporate an EDI setting that obviates the need to 
invert  the  image  manually  and  is  optimised  for  imaging  the  choroid.  Choroidal 
thickness has been studied in healthy subjects and it is now widely accepted that it is 
influenced by  axial length  and refractive error;  increasing in  thickness  in longer, 
myopic eyes and also decreasing in thickness with age [162]. Across the macula, the 
choroid is thinnest nasal to the fovea and does not correspond with the typical retinal 
thickness map seen in normal subjects. 
 
The role of the choroid in the pathophysiology of diabetic retinopathy and DMO is 
not well understood, but the high oxygen requirements of the photoreceptors and the 
supply of these requirements by choroidal blood flow makes it a valid target for 
investigation. Indeed, reduced choroidal thickness has been reported in subjects with 
both type 1 and type 2 diabetes [101, 163], and there is a growing body of evidence 
that this may be related to severity of retinopathy or disease duration. It is possible 
that changes in choroidal thickness affect oxygen delivery to photoreceptors and may 
influence the production of VEGF and hence development of macular oedema. 
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Querques et al. investigated 63 subjects with diabetes with and without retinopathy 
and CSMO and also  found decreased choroidal  thickness  in  all diabetic subjects 
compared to normal controls. Although their results demonstrated a trend towards 
decreasing choroidal thickness with increased retinopathy severity and presence of 
macular oedema, they did not reach statistical significance [164]. Regatieri et al. in a 
similar study found no reduction in thickness if only non-proliferative retinopathy 
was present, but for subjects with macular oedema or treated proliferative disease the 
choroid  was  thinner  [102].  A  large  study  from  Vujosevic  et  al.  provides  further 
evidence  that  increasing  severity  of  retinopathy  is  associated  with  increased 
choroidal thinning [103]. 
 
The  relative  novelty  of  choroidal  thickness  measurement  has  meant  that  a 
standardised technique for obtaining measurements across the macula has not been 
defined,  making  comparison  between  studies  difficult.  Furthermore,  the  above 
studies, which have found decreased choroidal thickness in diabetes with an apparent 
progression  as  retinopathy  worsens,  have  been  cross-sectional  in  design.  A 
prospective study to investigate the effect on choroidal thickness of treatment for 
DMO may contribute to understanding the role of the choroid in this condition. 
2.1.2.2  Repeatability of OCT measures of macular oedema 
Measurement variation is an important concept in subjective, functional tests where 
patient performance can impact upon results such that there may be a difference 
between outcomes when a test is repeated even when no clinical change can have 
occurred. Measurement variation also occurs with tests that are not dependent on 
subjective responses, such as OCT scanning. In this situation, patient factors such as 
head position or ocular fixation may affect the computer-driven algorithms used to 
generate  retinal  thickness  measurements  and  introduce  measurement  variability. 
Inclusion criteria for clinical trials and retreatment protocols in trials of intravitreal 
agents for macular disease frequently incorporate a quantitative OCT parameter such 
as central macular thickness to drive retreatment. Studying repeatability allows true 
clinical change to be distinguished from naturally occurring measurement variability. 
Clinicians can then define a threshold to recognise when a condition has changed, 87 
 
which can subsequently be used in clinical trials and clinical practice to determine 
the need for further treatment or to identify a therapeutic response. 
 
Repeatability  of  OCT  retinal  thickness  measurements  has  been  studied  in  DMO 
using time domain devices,  with  estimates  for the coefficient  of repeatability for 
retinal  thickness  in  the  central  subfield  of  21  µm  and  38  µm  from  different 
investigators  [165,  166].  Studies  comparing  time  domain  with  spectral  domain 
devices  have  failed  to  demonstrate  a  statistically  significant  improvement  in 
coefficient of repeatability for the newer devices evaluating retinal thickness in DMO 
[167, 168]. The Spectralis SD OCT device has the capability to track eye movement 
and can automatically place follow-up scans in the same retinal location potentially 
leading to highly repeatable measurements of retinal thickness. However, this device 
had not been used to evaluate the repeatability of retinal thickness measurements in 
DMO when this programme of investigation commenced.  
2.1.2.3  Colour photography for diabetic retinopathy grading 
The gold standard for grading of diabetic retinopathy was established by the ETDRS 
as  seven-field  stereoscopic  fundus  photography  with  classification  based  on  a 
modification  to  the  Airlie  House  criteria  for  grading  retinopathy  [169].  Careful 
examination of the features of retinopathy that were predictive for progression led to 
the  development  of  a  numerical  scale  for  the  classification  of  retinopathy  and 
macular oedema [170]. This scale ranges from level 10 (no retinopathy present) to 
level 85 (advanced PDR with macular detachment) with stages between representing 
different  severities  of  non-proliferative  and  proliferative  retinopathy.  Seven-field 
stereoscopic grading is particularly time-consuming and uncomfortable for patients, 
so  investigators  have  sought  other  methods  to  grade  retinopathy  based  on  fewer 
images. Evaluation of agreement in grading when either two or four fields were used 
showed high levels of agreement for four field photography across most grades of 
retinopathy [171]. More recently it has been shown that ophthalmic examination by 
an experienced clinician compares favourably with the gold standard, and even with 
two  field  photography  (which  is  used  in  the  UK  diabetic  screening  programme) 
grading shows good agreement with seven field imaging [172]. Using an established 
Reading Centre to grade retinopathy provides another potential clinical trial outcome. 88 
 
2.1.2.4  Fundus fluorescein angiography 
Imaging  the  vasculature  of  the  posterior  pole  of  the  eye  using  cameras  and 
appropriate  filters  following  a  bolus  intravenous  injection  of  either  10%  or  20% 
sodium fluorescein is termed fundus fluorescein angiography (FFA). The ETDRS 
established the value of FFA in the diagnosis and management of DMO and defined 
grades of capillary loss indicative of macular ischaemia with reference to standard 
photographs [173]. This study also described methodology for grading the foveal 
avascular zone and suggested an upper limit of normal for FAZ diameter of 1000 
µm.  However, inter-grader repeatability  for this  measure was  low, typically with 
kappa values of 0.4 to 0.5, indicating only moderate agreement. 
 
As  discussed  in  Chapter  1,  macular  ischaemia  remains  a  theoretical  concern 
following anti-VEGF administration. Although the results from the BOLT study at 4 
months and 12 months did not show any evidence of worsening macular perfusion 
following  either  bevacizumab  or  laser  treatment  [73,  74],  there  has  not  been  a 
systematic  evaluation  of  the  effects  of  ranibizumab  on  these  parameters.  In  the 
DRCR.net protocol I trial for example, fluorescein angiography was only obtained at 
the  investigator’s  discretion,  so  there  was  limited  opportunity  to  assess  for 
progression of macular ischaemia. A prospective clinical trial evaluating the effect of 
ranibizumab on macular ischaemia may yield useful data. 
 
2.1.3  Structure-function correlation in diabetic macular oedema 
Imaging techniques employed in patients with DMO allow retinal structure to be 
evaluated. These currently include: 
  OCT 
o  Retinal thickness 
o  Retinal morphology 
  Colour fundus imaging 
  Fluorescein angiography 
o  Size of foveal avascular zone 
o  Degree of perifoveal capillary loss 89 
 
 
Tests evaluating the function of macula include visual acuity and microperimetry to 
measure  retinal  sensitivity.  Correlation  between  these  different  modalities  of 
investigation attempts to measure the effect of a structural change in the retina on the 
function of the retina in that area. 
 
In  DMO,  the  link  between  a  structural  change  and  a  corresponding  functional 
alteration has not been well demonstrated. It has been established in early studies of 
OCT  in  DMO  that  retinal  thickness  correlates  negatively  with  visual  acuity.  For 
example,  the  DRCR.net  evaluated  OCT  and  visual  acuity  results  from  a  large 
randomised trial to estimate the size of the effect of increased retinal thickness on 
acuity. They reported a 4.4 letter change in visual acuity for every 100 µm change in 
retinal thickness, but recognised that a variety of OCT results could be associated 
with the same visual acuity [174].  
 
Studies of morphological changes and their effect on retinal function have suggested 
that different patterns of oedema have different effects on retinal function (e.g. Deak 
et al. investigating microperimetry and OCT morphology [160]). Pelosini et al. have 
shown in DMO that a better correlate of visual acuity is the cross sectional area of 
retinal  tissue  bridging  across  apparent  cystic  spaces  visible  on  OCT  [159].  New 
techniques of simultaneous microperimetry and OCT are becoming available that 
may make it easier to correlate these findings: Charbel Issa et al. describe the use of 
such  a  technique  to  correlate  microperimetry  findings  with  OCT  in  macular 
telangiectasia, for example [175]. 
 
The disadvantages of the functional tests used to evaluate the macula include their 
time-consuming nature, test-retest variability, and in the case of electrophysiology 
low signal to noise ratios. Structural imaging studies by contrast are rapidly acquired 
and  subject  to  less  test-retest  variability.  Therefore  the  demonstration  of  reliable 
structure-function  correlation  would  allow  structural  tests  to  provide  information 
about the function of the retina and may allow the identification of patients more 
likely to respond to treatment. 
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2.1.4  Aims and objectives of the study 
At the time of commencing this study, ranibizumab had not received a licence for the 
treatment  of  DMO  but  phase  III  clinical  trials  with  this  aim  were  in  progress. 
Standard treatment for DMO in the UK was laser photocoagulation. 
As ranibizumab inhibits all isoforms of VEGF, there was concern that repeated use 
may lead to alterations in normal retinal physiology that might manifest in a number 
of ways, including reduced colour vision, reduced macular sensitivity and reduced 
electrophysiological indices. 
Spectral domain OCT technology was also not widely available at the start of the 
study and changes in retinal structure seen with this imaging technique had not been 
reported.  
Primary objectives 
-  To  investigate  the  effect  of  ranibizumab  on  colour  contrast  sensitivity 
changes in DMO 
-  To  investigate  the  effect  of  ranibizumab  on  macular  sensitivity  by 
microperimetry 
-  To  investigate  the  effect  of  ranibizumab  on  the  pattern  and  full-field 
electroretinogram 
-  To  investigate  structural  changes  seen  on  SD-OCT  scans  following 
ranibizumab treatment 
Secondary objectives 
-  To establish the repeatability of retinal thickness and volume measurements 
in DMO using Spectralis SD-OCT 
-  To investigate the effect of ranibizumab on choroidal thickness in DMO 
-  To investigate the correlation between retinal sensitivity and retinal thickness 
in DMO 
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2.2  Methods 
The  LUCIDATE  study  (LUCentis  In  Diabetic  macular  oedema  –  A  Treatment 
Evaluation)  was  a  randomised  clinical  trial  designed  to  compare  the  detailed 
structural  and  functional  effects  of  repeated  pan  anti-VEGF  inhibition  with 
ranibizumab with the effects of standard macular laser therapy after 48 weeks of 
treatment.  
2.2.1  Design, approval and participants 
This  trial  was  a  single  centre,  parallel  group,  phase  IIb  exploratory  trial  with 
imbalanced  randomisation  (2:1  ranibizumab:laser)  and  investigator  masking 
conducted at Moorfields Eye Hospital. 
 
The study conformed to the Declaration of Helsinki and prospective approval was 
obtained from the Central London Research Ethics Committee 4 of the UK National 
Research  Ethics  Service.    The  trial  was  registered  at  www.clinicaltrials.gov 
(NCT01223612). A clinical trial authorisation was obtained from the Medicines and 
Healthcare Products Regulatory Agency (MHRA) before recruitment commenced. 
 
Adults  aged  18  or  over  with  centre-involving  DMO  in  at  least  one  eye  were 
identified from Medical Retina clinics in the hospital. Informed consent was obtained 
from all participants before screening commenced but after a full explanation of the 
nature and possible risks of participation in the study. 
2.2.2  Patient eligibility 
The following criteria were used to guide patient enrolment: 
Inclusion criteria (ocular criteria apply to study eye) 
1.  Patients of either sex aged 18 years or over able to give informed consent 
throughout the study 
2.  Diagnosis of diabetes mellitus (type 1 or type 2) 
3.  Best corrected visual acuity between 55 and 79 ETDRS  letters at 1 meter 
(Snellen equivalent ≥ 6/24 and ≤ 6/9) 
4.  Clinically apparent centre-involving DMO with OCT central subfield thickness 
≥300 µm on Spectralis OCT 92 
 
5.  Sufficient pupillary dilation and media clarity for adequate fundus imaging 
6.  Intraocular pressure (IOP) <30 mmHg. 
7.  Visual acuity in fellow eye ≥ 2/60 
8.  Fellow eye has received no anti-VEGF treatment within the past 3 months and no 
expectation of such treatment during the study  
9.  Ability to return for study visits for 48 weeks of follow up 
 
Exclusion criteria (ocular criteria were applied to study eye only) 
1.  Macular ischaemia (foveal avascular zone (FAZ) greatest linear diameter > 1000 
µm or severe perifoveal capillary loss on fluorescein angiography). 
2.  Macular oedema from a cause other than diabetes e.g. post cataract surgery or 
related to vitreoretinal interface abnormalities. 
3.  Presence of an ocular condition such that visual acuity would not improve from 
resolution of macular oedema (e.g. permanent foveal pigmentary or atrophic 
changes, dense plaques of exudate or non-retinal conditions, such as amblyopia). 
4.  Presence of an ocular condition (other than diabetes) that might affect macular 
oedema or alter visual acuity during the course of the study (e.g. retinal vein 
occlusion, ocular inflammatory disease, neovascular glaucoma)  
5.  Substantial cataract likely to be responsible for at least three lines of visual loss 
(i.e. to 6/12 or worse in the absence of other pathology)  
6.  Any treatment for DMO in the past 3 months including macular laser treatment, 
injection of corticosteroid or anti-VEGF agents.  
7.  Panretinal photocoagulation (PRP) performed within 3 months prior to 
randomisation or anticipated in the next 6 months.  
8.  Active proliferative diabetic retinopathy in the study eye. 
9.  A condition that would prevent study participation, in the investigator’s opinion. 
10.  Haemoglobin A1c > 11.0 % 
11.  A past medical history of chronic renal failure that requires either dialysis or 
kidney transplant 
12.  Blood pressure >170/100 mmHg (i.e. systolic above 170 or diastolic above 100) 
13.  Arterio-thrombotic event within 6 months prior to randomisation including: 
myocardial infarction, acute congestive heart failure or other cardiac event, 
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14.  Major surgery planned during the trial period or within 28 days prior to 
randomisation. 
15.  Administration of another investigational drug within 30 days of randomisation. 
16.  Prior treatment with systemic anti-VEGF in 3 months prior to randomisation. 
17.  Pregnant or lactating women or women intending to become pregnant within the 
study period including 3 months after study cessation. 
18.  Intraocular surgery or major extraocular surgery within 3 months prior to 
randomisation or anticipated within next 6 months. 
19.  Aphakia. 
20.  Uncontrolled glaucoma. 
21.  Infective external ocular disease e.g. conjunctivitis, chalazion, or severe 
blepharitis 
22.  Allergy to fluorescein or ranibizumab. 
23.  Fertile male unwilling to use contraception for the duration of the study. 
2.2.3  Sample size 
The study was a planned exploratory analysis and hence no power calculation was 
performed; 36 subjects were deemed a suitable number by the trial statisticians to 
allow an assessment of normality of the exploratory outcome data and conduct a 
descriptive analysis. The number was also chosen based on the resources available to 
conduct the study. 
2.2.4  Randomisation 
One eye per participant was included in the study. If both eyes were eligible, the eye 
with  worse  visual  acuity  was  included.  Subjects  were  randomised  2:1  to  receive 
ranibizumab  or  laser,  using  random  permuted  blocks  of  varying  sizes,  with  the 
randomisation list generated by a computer. The allocation sequence was held by the 
trial  statistician  and  concealed  from  the  researcher  enrolling  and  assessing 
participants. The final two subjects were randomised simultaneously. 94 
 
2.2.5  Interventions in the trial 
Subjects  in  the  ranibizumab  arm  received  intravitreal  injections  of  ranibizumab 
(Lucentis®, 0.5 mg in 0.05 ml solution for injection, Novartis Pharmaceuticals UK 
Ltd) at baseline, 4 weeks and 8 weeks then four weekly as required according to pre-
defined  retreatment  criteria.  Retreatment  occurred  if  BCVA  was  reduced  by  ≥5 
letters from maximum acuity or if OCT central subfield thickness was > 300 µm. 
Subjects in the laser arm received modified ETDRS focal/grid laser at baseline and 
then  every  12  weeks  as  required  guided  by  fluorescein  angiography.  Laser  was 
performed using a green wavelength with 50-60 µm spot size, >500 µm from the 
edge of the  FAZ  with  the aim of causing mild blanching of the retinal  pigment 
epithelium. Focal laser was applied to untreated focal leaks and grid laser applied to 
areas of diffuse leakage and areas of non-perfusion that were not contiguous with the 
FAZ. 
 
2.2.6  Masking 
Visual  acuity  assessors,  OCT  technicians,  photographers  and  electrophysiology 
technicians  were  masked  to  treatment  allocation,  as  were  fluorescein  angiogram, 
fundus  photograph and  OCT graders, and reporting electrophysiologists.  Subjects 
were not masked to the treatment they were receiving; to do so would have entailed 
designing sham injection and sham laser procedures. 
2.2.7  Follow-up visits and investigations undertaken 
All  subjects  attended  at  baseline,  12,  24,  36  and  48  weeks.  Subjects  in  the 
ranibizumab group also attended at four-weekly intervals between these visits for 
assessment and retreatment if required. At baseline, 12, 24 and 48 weeks subjects 
underwent detailed functional and structural evaluation of the retina using a number 
of investigation modalities. 
 
2.2.7.1  Best-corrected ETDRS visual acuity 
This was measured using ETDRS charts in standard lighting conditions. Subjects 
underwent refraction at baseline, 12, 24 and 48 weeks and at intervening visits the 95 
 
most recent subjective refraction was used. Refraction was carried out by a certified 
trial optometrist using ETDRS chart “R” at 4m. Visual acuity was measured in the 
study eye, then the fellow eye. Standard instructions were given to subjects to read 
the letters on the chart one by one and to guess any letters they were unsure of until 
no further letters  could  be seen.  Visual  acuity scores  were calculated  for 1m  by 
adding 30 letters to the 4m score if more than 20 letters were read. If fewer than 20 
letters were read at 4m, +0.75DS was added to the trial frame and the first six lines 
of the chart were read at 1m, with this score added to the 4m score. ETDRS chart “1” 
was used for right eyes and chart “2” for left eyes. 
 
2.2.7.2  Colour contrast sensitivity 
Colour  contrast  sensitivity  (CCS)  was  evaluated  using  the  ChromaTest,  (City 
University, London), described in detail by Arden and more recently by Wong et al. 
[114, 116]. The test was regularly calibrated by technicians in the electrophysiology 
department.  The  subject  is  seated  1.5m  from  a  computer  monitor  on  which  is 
displayed  a coloured letter against an isoluminant  background. When the subject 
correctly identifies  a letter, the colour difference between the next  letter and the 
background is halved (doubled after an incorrect guess). In this way, a threshold 
value  for  CCS  is  reached.  The  “diabetes”  protocol  of  the  test  was  used  which 
measures CCS thresholds in the protan and tritan axes. 
 
2.2.7.3  Microperimetry 
Subjects  underwent  microperimetry  in  mesopic  conditions  in  the  study  eye  only 
using the Nidek MP1 device (Nidek technologies, Padua, Italy).  After pupil dilation 
and a ten minute period of partial dark adaptation, subjects were initially given brief 
training  on  the  operation  of  the  machine.  Standard  settings  were  used  with 
background  luminance  set  at  4  apostilbs.  The  microperimetry  protocol  used  a 
customised radial grid based consisting of 45 stimuli covering the central 12° of the 
macula; with  the inner  stimuli 1° apart and the outer stimuli  2° apart, shown in 
Figure 18. The stimulus size used was the Goldman III (26 min arc or 0.4 degrees) 
with a projection time of 200ms (white stimulus, white background). The starting 
light  attenuation  was  set  to  10dB  and  a  4-2-1  double  staircase  strategy,  as 96 
 
recommended by Vujosevic et al. to reduce testing time and possible fatigue was 
used [126].  
 
Figure 18 – Customised radial 45-point grid used for microperimetry; shown 
overlaid on a colour photograph of the fundus of one trial subject. 
 
Mean values for the central 4° and 12° of the macula were entered into the trial 
database. 
 
2.2.7.4  Electrophysiology 
Electrophysiological  testing  (rod  and  cone  specific  full-field  electroretinogram 
(ERG),  pattern  ERG  (PERG)  and  multifocal  ERG  (mfERG))  were  performed 
according  to  the  International  Society  for  Clinical  Electrophysiology  of  Vision 
(ISCEV) standards. Data were recorded from both study eye and fellow eye. The key 
elements of the investigation are detailed below. 
 
 The  PERG  was  obtained  before  pupil  dilation  in  photopic  conditions  with 
appropriate  refractive  correction  in  place.  The  subject  observed  an  alternating 
checkerboard on the display screen with check size 43’ of arc (0.72
o) and a reversal 
rate of 2.2 Hz. Full details are specified in the ISCEV standard [136]. Amplitudes of 
the P50 and N95 component, and the P50 peak time were recorded. Full-field ERGs 97 
 
were  obtained  using  a  Ganzfeld  bowl  stimulus  after  pupil  dilation  and  full  dark 
adaptation. Full details are specified in the ISCEV standard [144]; stimuli were used 
to record peak times and amplitudes of the dim flash rod response (b wave) and 
maximal  rod  response  (a  and  b  wave).  After  light  adaptation  the  30  Hz  flicker 
response  (amplitude  and  implicit  time)  and  maximal  photopic  response  (a  and  b 
wave amplitudes and peak times) were recorded. Multifocal ERGs were recorded 
using the Roland Consult system with a 61 hexagon pattern after the full field ERGs 
following the ISCEV standard [149]. Again, refractive correction was used where 
applicable and only data from the study eye was recorded. 
2.2.7.5  Optical coherence tomography scans 
Spectral domain optical coherence tomography (SD OCT) scanning was performed 
by  technicians  experienced  in  clinical  trials  work  using  the  Spectralis  OCT 
(Heidelberg Engineering, Heidelberg, Germany). Standard preset scan settings were 
used for all scans, with the following scan sets recorded: 
1.  “Fast” volume scan; 25 horizontal lines, 20ﾰ, 512x496, Automatic Real Time 
(ART) 9, “High Speed” mode. 
2.  “Dense” volume scan;  49 horizontal lines,  20ﾰ, 512x496, ART 16, “High 
Speed” mode. 
3.  Single horizontal line scan; 768 A-scans, ART 100, “High Speed” mode. 
4.  Single horizontal line scan; Enhanced Depth Imaging (EDI) mode, 768 A-
scans, ART 100, “High Speed” mode. 
All scans were centred on the fovea. Each baseline scan was used as a reference for 
follow-up scans, to make use of the “TruTrack” software of the Spectralis device, 
which uses a reference beam to image the eye and allows follow-up scans to be taken 
at the same location as previous scans.  
 
Additionally, three further “fast” volume scans were taken at baseline for evaluation 
of repeatability of retinal thickness and volume measurements, described below in 
section 2.2.10.2. Data for thickness and volume were obtained from the Heidelberg 
Eye Explorer (HEYEX) software (version 1.7.0.0, ©2011 Heidelberg Engineering 
GmbH,  Heidelberg,  Germany)  and  entered  into  an  Excel  spreadsheet  without 
formally correcting for retinal boundary detection error. The “fast” volume scans 
were used for retinal thickness and volume measurements. “Dense” volume scans 98 
 
were evaluated by the reading centre for grading of morphological features of DMO, 
with the high quality single line scan also used for evaluating foveal location and 
vitreomacular interface abnormalities. The scans were examined for the presence or 
absence of the following features in the inner or outer retina: 
-  Cysts 
-  Cystoid features 
-  Hyperreflective foci 
Additionally,  the  integrity  of  the  lines  thought  to  represent  the  external  limiting 
membrane  (ELM)  and  inner  segment-outer  segment  (IS-OS)  junction  (ellipsoid 
layer) was evaluated. Grading of all of these features was reported in the central 
subfield  and  in  the  inner  four  paracentral  subfields.  The  foveal  depression  was 
graded  as  normal  or  abnormal,  and  the  presence  of  vitreoretinal  interface 
abnormalities (vitreomacular traction (VMT), epiretinal membrane (ERM), macular 
hole) was noted. Figure 19 shows two typical scans to illustrate the appearance of the 
features graded. 99 
 
 
Figure 19 – Two representative OCT scans from subjects with DMO to illustrate the 
typical appearance of morphological features that were identified by graders in the 
reading centre. 
 
2.2.7.6  Colour photography 
At baseline and trial exit (48 weeks) four-field standard ETDRS colour photographs 
were taken for reading centre assessment of grade of diabetic retinopathy, shown in  
Figure 20. The four fields were each obtained using a 30° field of view and are 
defined as follows: 
Field 1 – Centred on disc, with the temporal border on the macula,  
Field 2 – Centred on the macula, the nasal border over the centre of the disc 100 
 
Field 3 – Superior to the macula, the inferior border level with the superior edge of 
the disc 
Field 4 – Inferior to the macula, the superior border level with the inferior edge of 
the disc 
 
Four-field retinal photography – shown for right eye 
 
 
 
 
 
 
 
 
Figure 20 – Diagram of fields used for standardised ETDRS retinal photography. 
 
Subjects were assigned a single numerical ETDRS grade at baseline and 48 weeks on 
the basis of the grading of the four images,  in  accordance with  the standardised 
ETDRS grading system [170]. 
2.2.7.7  Fundus Fluorescein Angiograms 
Fundus fluorescein angiography (FFA) was performed at the four main time points 
of the trial. After intravenous cannulation, subjects received a bolus injection of 5 ml 
20% sodium fluorescein. A series of frames centred on the macula were obtained 
during the transit phase. During the mid-phase of the angiogram, peripheral shots 
were obtained before returning to the macula to obtain late frames. Images were 
examined  by  masked  reading  centre  graders  to  record  area  and  greatest  linear 
dimension  (GLD)  of  the  foveal  avascular  zone  (FAZ)  and  grade  of  perifoveal 
capillary loss (PFCL) in four quadrants. Defining the FAZ was carried out manually 
on  the  Topcon  Imagenet  software  and  automatically  generated  measurements  for 
GLD and area were taken from this. Figure 21 shows an early phase frame from an 
angiogram to illustrate the FAZ and measurement of GLD. 
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Figure 21 – Frame from a typical fundus fluorescein angiogram to illustrate the 
outlining and measurement of the foveal avascular zone (FAZ). Note – measurement 
indicative of method only. 
 
Perifoveal capillary loss was graded in four quadrants around the macula (superior, 
inferior,  nasal,  temporal)  with  reference  to  ETDRS  standard  photographs  and  a 
numerical grade from 0 (absent) to 4 (severe) was assigned to each quadrant [173]. 
 
The masked grading of photographs both for retinopathy grade and foveal avascular 
zone  measurements  was  carried  out  by  a  trained  and  certified  senior  diabetic 
retinopathy grader from the Reading Centre with 100% adjudication by the clinician 
in charge of the centre. This was in accordance with the protocol for another recent 
clinical trial [74]. All eyes with change and 10% of eyes without change were also 
discussed with an independent masked clinician before grade agreement. Ten percent 
of eyes were re-graded independently of the adjudication and verification process by 
the  same  senior  grader  and  the  intra-grader  reliability  was  substantial  (kappa  of 
0.76). 
2.2.7.8  Other investigations 
At baseline and at 48 weeks, subjects underwent HbA1c testing to evaluate long-term 
diabetic control. Blood  pressure was recorded at  baseline, 12, 24  and  48 weeks. 102 
 
Cataract grade was evaluated at baseline and 48 weeks using an ordinal scale from 0 
to 3. Intraocular pressure was checked at every visit. 
2.2.8  Outcomes 
The  study  had  a  number  of  prospectively  defined  exploratory  structural  and 
functional  outcomes,  derived  from  the  comprehensive  investigation  set  described 
above and reported at baseline, 12, 24 and 48 weeks: 
Functional measures 
1.  Best-corrected ETDRS visual acuity 
2.  Colour contrast sensitivity: protan and tritan thresholds 
3.  Microperimetric retinal sensitivity: mean 4° and 12° sensitivity 
4.  Electrophysiological  parameters:  PERG  P50  amplitude  and  implicit  time, 
N95 amplitude; full field ERG rod and cone a and b wave amplitudes and 
implicit times, mfERG distribution of amplitudes 
Structural measures 
1.  OCT quantitative parameters: macular thickness and volume in nine ETDRS 
subfields 
2.  OCT qualitative changes: presence of features of DMO in inner and outer 
retina (cysts, cystoid oedema and hyperreflective foci); neurosensory retina 
changes  (ELM  interruptions,  photoreceptor  IS-OS  junction  abnormalities); 
vitreomacular  interface  abnormalities  (ERM,  VMT,  macular  or  lamellar 
hole). 
3.  Fluorescein angiography: greatest linear diameter (GLD) and area of foveal 
avascular zone (FAZ); degree of perifoveal capillary loss (PFCL) 
4.  Colour fundus photography: ETDRS grade of diabetic retinopathy 
 
2.2.9  Statistical plan 
Baseline characteristics of the patients were compared by treatment status to assess 
the adequacy of the randomisation by the trial statistician. Summary measures for the 
baseline  characteristics  were  mean  and  standard  deviation  for  continuous 
(approximate)  normally  distributed  variables;  median  and  interquartile  ranges  for 
non-normally distributed variables; and frequencies and percentages for categorical 103 
 
variables. Normality was assessed by the trial statistician by visual assessment of 
histograms  to  look  for  overt  kurtosis  or  skewness  of  data.  Since  this  was  an 
exploratory  trial,  no  intent-to-treat  analysis  was  conducted.  An  available  case 
analysis was conducted (as per a planned statistical analysis agreed upon prior to 
analysing the data). Adverse events were reported for the whole cohort. Summary 
statistics  were  computed  for  each  outcome  by  treatment  group.  Analysis  of 
covariance  was  used  to  compare  continuous  outcomes  between  treatment  groups 
with baseline values of the outcome as a covariate when differences between groups 
at baseline were present. Any statistical tests conducted used a 2-sided P-value of 
0.05; P-values were not formally adjusted for multiple testing. Data analysis was 
performed  using  STATA  statistical  software  (version  12,  StataCorp  LP)  and 
GraphPad Prism (version 6, GraphPad Software Inc., La Jolla, CA, USA). 
2.2.10 Post-hoc exploratory investigations 
Additional post-hoc exploratory investigations included the evaluation of choroidal 
thickness  by  OCT  enhanced  depth  imaging,  correlation  of  retinal  function  and 
structure by examining microperimetry and OCT results and a study to evaluate the 
repeatability of retinal thickness and volume measurements using Spectralis OCT. 
2.2.10.1  Longitudinal evaluation of choroidal thickness by enhanced depth imaging 
Horizontal  line  scans  taken  using  the  enhanced  depth  imaging  (EDI)  mode  to 
visualise the choroid were evaluated by a grader masked to treatment allocation. The 
automated Spectralis segmentation algorithm defines the inner retinal boundary at 
the location of the inner limiting membrane (ILM) and the outer retinal boundary at 
Bruch’s  membrane  (BM).  The  automated  segmentation  line  from  the  ILM  was 
manually aligned with the outer choroidal boundary, shown in Figure 22a, leaving 
the segmentation line for BM in place. The outer choroidal boundary was defined 
visually as the location where details of choroidal vasculature were no longer visible 
and a heterogeneous opacity, thought to represent the inner sclera boundary, was 
seen. This distance, from BM to outer choroidal boundary was taken to represent 
choroidal thickness. Thickness was measured at the fovea and at 500 µm intervals 
across the macula nasal and temporal to this, taking the automated measurement 
incorporated within the HEYEX software, shown in Figure 22b. Measurements were 104 
 
taken from scans at baseline, 48 weeks and additionally at 12 weeks to look for an 
early effect of treatment. Data was analysed using GraphPad Prism. 
 
Figure 22 – Method of obtaining choroidal thickness measurements from EDI scans. 
 
2.2.10.2  Structure-function correlation 
Data  were  explored  to  investigate  possible  correlation  between  visual  acuity  and 
retinal  thickness  and  then  between  retinal  sensitivity  and  retinal  thickness.  The 
method for correlating microperimetry results with OCT results is described below. 
 
Microperimetry results for each point tested were entered into an Excel spreadsheet 
and from this, mean sensitivity in an area of retina corresponding to each of the nine 
ETDRS subfields could be calculated. This was done by overlaying the ETDRS grid 
on the microperimetry grid and determining which test points were located in each 
subfield, shown in Figure 23. The microperimetry grid can be considered to consist 
of a central point plus four concentric circles at radii of 1°, 2°, 4° and 6°, while the 105 
 
ETDRS circular subfields are defined by circles of radii 500 µm, 1500 µm and 3000 
µm. The fovea has been reported to be located at approximately 15° from the disc 
[176] or alternatively at approximately 5mm from the disc [177], giving a conversion 
factor of approximately 1/3 mm per degree. Thus points forming the 2° circle lie at 
0.66  mm  radius  and  test  retinal  locations  lying  outside  the  central  subfield.  The 
points forming the 6° circle lie at a radius of approximately 2 mm and hence are 
outside the 1500 µm circle marking the inner subfields. 
 
Figure 23 – Diagram to show overlay of ETDRS grid (blue), with 1mm, 3mm and 
6mm diameter circles, on microperimetry test grid. Red circle shows microperimetry 
fixation target of 1° radius. 
 
The arithmetic mean of all points lying in a given subfield, including those lying on 
the radial lines forming the boundaries, was taken to represent the mean sensitivity in 
that subfield. For OCT results, the single retinal thickness reading from each subfield 
on the ETDRS map displayed on the HEYEX software was taken as mean retinal 
thickness in that subfield without correcting for retinal boundary detection error (see 
section 2.2.10.3). 
 
Scatter plots for each of the nine subfields using microperimetry and OCT results at 
baseline were created using GraphPad software to explore correlation between retinal 
thickness and sensitivity for all subjects at baseline. Further graphs were then created 
to show change in retinal sensitivity and change in retinal thickness. Correlation was 106 
 
checked using Pearson’s r statistic and if a significant correlation existed in the two 
groups, linear regression was then used to look for differences between groups to 
explore a possible treatment effect. 
2.2.10.3  Repeatability of macular thickness measurements in OCT study 
OCT images were used to evaluate the repeatability of retinal thickness and volume 
measurements. In addition to images from patients screened for this study, further 
images  from  patients  with  DMO  undergoing  screening  for  another  clinical  trial, 
which were obtained using the same OCT scanning protocol, were also included. For 
this  study,  subjects  underwent  four  consecutive  “fast”  volume  scans  using  the 
settings  described  above  at  a  single  sitting.  Subjects  sat  back  from  the  machine 
between each scan. The first scan was set as “reference” and the subsequent three 
scans were obtained in “follow-up” mode. 
 
Retinal  thickness  and  volume  measurements  for  the  nine  ETDRS  subfields  were 
obtained from the HEYEX software and  transferred to an Excel spreadsheet for 
calculation of coefficients of repeatability using methods described by Bland and 
Altman [178]. Specifically, in each subfield the variance of the four measurements 
for every patient was calculated initially in order to obtain Sw, the within subject 
standard deviation, from the square root of the average of the variances across all n 
subjects.  Coefficient  of  repeatability  (CR)  was  then  calculated  by  1.96  x  √(2x 
average  variance).  The  width  of  the  95%  confidence  interval  for  CR  was  then 
obtained by 1.96 x   where n=number of subjects and m=number of times the 
test was performed[179]. 
 
Scans were manually evaluated for the presence of inner or outer retinal boundary 
detection  error.  For  the  purposes  of  this  study,  significant  automated  boundary 
detection  error  was  defined  as  the  misplacement  of  either  of  the  ILM  or  BM 
boundaries continuously over a section of scanned retina of 1mm or greater. This 
was deemed to have occurred when the automated line clearly and unambiguously 
deviated  from  the  hyper-reflective  interface  representing  Bruch’s  membrane,  or 
deviated from the clearly visualised inner retinal boundary, e.g. by following hyper-
reflective interfaces anterior to the retina. Examples of this are shown in Figure 24. 107 
 
Scans with no significant boundary detection error were included in a sub-analysis to 
establish whether the CR improves when this type of error is absent. 
 
Figure 24 – Examples of boundary detection error. Top and bottom left: 
misplacement of ILM boundary. Top and bottom right – misplacement of BM 
boundary. 
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2.3  Results of the LUCIDATE study 
2.3.1  Recruitment 
Recruitment for the study commenced in November 2010 after full approval was 
gained from the Medicines and Healthcare products Regulatory Agency, the National 
Research Ethics Service and the Moorfields Research and Development department. 
Recruitment was completed in July 2011 and the final follow-up visit was in July 
2012. 
 
In total  87 potential patients  received the participant information  sheet  (PIS). Of 
these, 47 were invited for screening. Pre-screening was undertaken using existing 
clinical records to identify patients who would not meet the study criteria; patients 
were only invited for trial screening if they could potentially meet the study criteria.  
Table 4 summarises reasons for not screening 40 potential patients who had received 
the PIS. All these patients continued to receive standard NHS clinical care. 
 
Reason  Number 
Clearly would not meet 
inclusion/exclusion criteria 
  Macular ischaemia 
  Cataract/media opacity 
  Recent laser 
  Participating in another trial 
  Previous vitrectomy 
11 
 
  5 
  2 
  2 
  1 
  1 
Potentially  suitable  but  study  full  before 
could be contacted 
3 
Declined 
 
  Unwell 
  Unable to travel 
  Unable to have time off work 
  Concerned about risk of injection 
  Needed both eyes treating 
  No reason given 
15 
 
  1 
  3 
  2 
  3 
  1 
  4 
Unable to contact/failed to return calls  11 
 
Table 4 – LUCIDATE prescreening: reasons why potential participants who had 
received the participant information sheet were not invited for screening. 
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From the 47 potential participants screened, inclusion and exclusion criteria were 
met by 37 patients; reasons for screen failure are shown in  
Table 5. 
 
Reason  Number 
Macular ischaemia  2 
Active proliferative retinopathy  2 
Visual acuity too good  5 * 
HbA1C too high  1 
Fluorescein allergy  1 
Ocular infection  1 
 
Table 5 – Reasons for screen failure in LUCIDATE study. * - one patient failed 
screening twice, having been rescreened when vision had subjectively dropped. The 
total is greater than 10 because some patients had multiple reasons, e.g. proliferative 
retinopathy and poor visual acuity. 
2.3.2  Patient disposition and demographics 
The 37 subjects who met the inclusion and exclusion criteria were randomised in 
accordance with the study protocol; 25 were randomised to ranibizumab and 12 to 
laser, in accordance with the planned imbalanced randomisation described in the trial 
protocol.  Of  these,  36  received  treatment:  one  subject  in  the  ranibizumab  arm 
withdrew immediately after randomisation as he was not willing to comply with the 
contraceptive requirements of the study. The 48 week study period was completed by 
22 (88%) patients in the ranibizumab arm and 11 (92%) in the laser arm. Participant 
flow  through  the  study,  as  recommended  by  the  statement  of  the  Consolidated 
Standards of Reporting Trials (CONSORT) group, is shown in Figure 25. 110 
 
 
Figure 25 – CONSORT style diagram to show participant flow in the LUCIDATE 
study. 
 
There were therefore 33 participants who completed the study. This comprised the 
analysis set for exploratory outcome measures in accordance with the pre-defined 
statistical  analysis  plan.  Adverse  events  are  reported  for  all  36  participants  who 
received treatment. The baseline characteristics of study participants comprising the 
analysis  set,  including  demographic  information  and  details  of  their  systemic 
condition are shown in Table 6; details of their ocular condition are shown in Table 
7.  The  subjects  who  did  not  complete  the  study  were  comparable  in  terms  of 111 
 
demographic profile and systemic condition to those who completed the follow-up 
period. 
 
  Ranibizumab group  Laser group 
Number  22  11 
Sex (female)  7 (31.8%)  5 (45.5%) 
Age (years)  64.9 (58.4-71.0)*  67.4 (62.8-74.6)* 
Ethnicity: 
White 
Black 
Asian 
Other 
 
15 (68.2%) 
0 (0%) 
5 (22.7%) 
2 (9.1%) 
 
7 (63.6%) 
1 (9.1%) 
2 (18.2%) 
1 (9.1%) 
Type of diabetes 
1 
2 
 
4 (18.2%) 
18 (81.8%) 
 
0 (0%) 
11 (100%) 
Duration of diabetes (years)  18.5 (10-26)*  18 (14-25)* 
Systolic BP  130  135 
Diastolic BP  75  71 
HbA1C  7.93 (1.31)  7.25 (0.92) 
 
Table 6 – Baseline characteristics of participants who completed the LUCIDATE 
study. Data are shown as mean (SD) or number (%) except * - median (interquartile 
range). 
 
  Ranibizumab group  Laser group 
Study eye (left/right)  17/5  5/6 
Duration of DME (months)  21 (14, 27)*  32 (15, 60)* 
Mean  number  of  previous 
macular laser treatments 
3 (1, 4) *  4 (3, 5)* 
Cataract grade 
0 
1 
2 
3 
IOL 
 
6 (27.3%) 
12 (54.5%) 
0 (0%) 
0 (0%) 
4 (18.2%) 
 
1 (9.1%) 
5 (45.5%) 
1 (9.1%) 
0 (0%) 
4 (36.4%) 
 
Table 7 – Baseline ocular characteristics of participants who completed the study. 
Data are shown as mean (SD) or number (%) except * - Median (Interquartile range). 
2.3.3  Treatments given 
All subjects in the ranibizumab arm received injections of ranibizumab at baseline, 4 
and 8 weeks. All subjects in the laser arm received macular laser therapy at baseline. 
A summary of the total number of treatments given at each time point and the mean 
cumulative number of treatments given is provided in Table 8. Ranibizumab treated 112 
 
subjects received a mean of 9 injections and laser treated subjects had a mean of 2.6 
sessions of macular laser over the course of the trial. 
 
  Ranibizumab group  Laser group 
  Number of 
treatments given 
at each time 
point 
Mean 
cumulative 
number of 
treatments 
Number of 
treatments given 
at each time 
point 
Mean 
cumulative 
number of 
treatments 
Baseline  22  1  11  1 
4 weeks  22  2     
8  22  3     
12  16  3.7  9  1.8 
16  17  4.5     
20  16  5.2     
24  13  5.8  4  2.2 
28  14  6.5     
32  15  7.1     
36  15  7.8  5  2.6 
40  12  8.3     
44  13  9.0     
48  N/A  9.0  N/A  2.6 
 
Table 8 – Total number of treatments at each time point and mean cumulative 
number of treatments in the two groups. 
 
One subject in each arm underwent cataract surgery in the study eye during the trial. 
At exit from the trial, there was no significant change in either group in systemic 
diabetes control or blood pressure. 
 
2.3.4  Functional outcome data 
Results of macular function tests to demonstrate efficacy of ranibizumab and laser 
treatment are presented at baseline, 12, 24 and 48 weeks for the 33 subjects who 
completed the study. The data are summarised in Table 9. 
2.3.4.1  Visual acuity 
Mean (SD) BCVA at baseline in the ranibizumab group was 70.4 (4.9) letters and 
63.8  (5.7)  letters  in  the  laser  group.  This  improved  to  76.4  (8.5)  letters  in  the 
ranibizumab group at 48 weeks but decreased to 62.9 (10.6) letters in the laser group 
(p=0.083 ANCOVA). This represented a 6 letter gain for ranibizumab versus a loss 
of 0.9 letters for laser. Box plots to show this data are displayed in Figure 26. 113 
 
 
Figure 26 – Box plots of visual acuity data from the LUCIDATE study to show 
change in BCVA from baseline at four follow-ups. 
2.3.4.2  Microperimetry 
Retinal sensitivity in the central 4° improved from 10.8 (3.7) to 14.0 (4.2) dB in the 
ranibizumab group and from 10.2 (3.8) to 12.1 (3.4) dB in the laser group (p=0.19). 
Sensitivity  in  the  central  12°  improved  from  13.3  (2.7)  to  15.7  (2.8)  dB  in  the 
ranibizumab treated subjects and for laser treated subjects the improvement was from 
13.4 (2.5) to 14.5 (2.0) dB (p=0.12), shown in Figure 27.  114 
 
 
Figure 27 – Retinal sensitivity results from MP1 microperimetry for the two groups 
in the LUCIDATE study. Results shown as mean ± SD. 
2.3.4.3  Colour contrast sensitivity 
Colour  contrast  sensitivity  in  the  protan  axis  improved  for  ranibizumab  treated 
subjects from 21.4 (22.5) % to 18.0 (16.9) % but worsened in the group receiving 
laser  from  22.9  (22.8)  %  to  31.0  (35.0)  %.  Tritan  sensitivity  also  improved  for 
ranibizumab  treated  subjects  from  80.7  (29.6)  %  to  69.9  (34.5)  %.  There  was 
improvement, to a lesser degree, in laser treated subjects from 88.9 (20.7) % to 85.8 
(25.0) %. Results are shown in Figure 28; it can be seen that there is little evidence 
of a difference between the two groups at 48 weeks. 
 
Figure 28 – Colour contrast sensitivity results for the two treatment groups. Bars 
show mean + SD. P values shown for two-tailed unpaired t test.  
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  Ranibizumab 
group (n=22 all 
time points) 
Laser group 
(n=11 all time 
points) 
BCVA letter score     
0 weeks  70.4±4.9  63.8±5.7 
12 weeks  73.1±6.2  60.8±5.6 
24 weeks  75.7±7.7  64.4±7.5 
36 weeks  75.3±8.9  61.3±9.0 
48 weeks  76.4±8.5  62.9±10.6 
Protan threshold  
sensitivity / % 
   
0 weeks  21.4±22.5  22.9±22.8 
12 weeks  18.2±15.7  32.5±35.4 
24 weeks  16.4±15.9  18.0±22.6 
48 weeks  18.0±16.9  31.0±35.0 
Tritan threshold 
sensitivity / % 
   
0 weeks  80.7±29.6  88.9±20.7 
12 weeks  71.0±33.5  92.4±13.6 
24 weeks  71.8±34.8  84.7±24.2 
48 weeks  69.9±34.5  85.8+25.0 
Microperimetry 4° 
sensitivity / dB 
   
0 weeks  10.8 ±3.7  10.2 ±3.8 
12 weeks  11.9 ±3.9  11.2 ±3.4 
24 weeks  12.7 ±4.1  10.1 ±3.7 
48 weeks  14.0 ±4.2  12.1 ±3.4 
Microperimetry 12° 
sensitivity / dB 
   
0 weeks  13.3 ±2.7  13.4 ±2.5 
12 weeks  14.3 ±3.0  13.8 ±2.5 
24 weeks  15.0 ±2.6  13.1 ±2.3 
48 weeks  15.7 ±2.8  14.5 ±2.0 
 
Table 9 – Summary of the results of functional investigations for subjects in the 
LUCIDATE study. 116 
 
2.3.4.4  Pattern electroretinogram 
The amplitudes of the major waveforms of the PERG, the P50 and N95, are shown in 
Table  10,  together  with  the  peak  time  for  the  P50  component.  Where  technical 
difficulties such as eye closure or excessive blinking during the test occurred, the 
results for that subject at that visit are not included. In cases where the PERG was 
undetectable  despite  a  technically  satisfactory  examination,  indicating  severe 
macular dysfunction, the data are not included in group means as the amplitude and 
peak time of an undetectable wave should not be considered as zero. Laser treated 
subjects  experienced  a  decline  of  0.13  µv  (10.5%)  in  the  P50  component  from 
baseline  to  48  weeks,  while  ranibizumab  treated  subjects  showed  minor 
improvement (0.04 µv; 2.9%). These results are shown in Figure 29. There were only 
minor variations in the P50 peak time from visit to visit and there was no discernible 
difference between the two groups. Results for the amplitude of the N95 component 
mirrored those for the P50, with a decline of 0.21 µv (10.5%) for laser and a decline 
of 0.04 µv (1.8%) for ranibizumab. 
 
 
 
Figure 29 – Results of PERG in two treatment groups showing change in amplitude 
of P50 and N95 waveforms; data shown as mean ± SD. 
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  Ranibizumab  Laser 
No. 
analysed 
P50 
amplitude/µv 
P50 
peak 
time/ms 
N95 
amplitude/ 
µv 
No. 
analysed 
P50 
amplitude/µv 
P50 
peak 
time/ms 
N95 
amplitude/ 
µv 
0 
weeks 
17  1.37 ±0.40  54.6 
±5.6 
2.17 ±0.70  8  1.21 ±0.41  55.8 
±3.8 
2.00 ±0.51 
12 
weeks 
14  1.21 ±0.35  54.2 
±3.9 
2.16 ±0.60  9  1.08 ±0.32  53.7 
±5.2 
1.50 ±0.38 
24 
weeks 
17  1.23 ±0.56  53.9 
±4.2 
2.16 ±0.83  10  1.10 ±0.41  51.9 
±4.3 
1.62 ±0.56 
48 
weeks 
18  1.41 ±0.45  54.8 
±3.7 
2.13 ±0.71  9  1.08 ±0.36  53.5 
±3.7 
1.79 ±0.72 
 
Table 10 – Amplitudes and peak times of the major waves of the PERG for ranibizumab and laser treated subjects. Data are presented as 
mean ± SD in µv and ms as appropriate. 118 
 
2.3.4.5  Multifocal electroretinogram 
Descriptive results of the mfERG are presented, as there were several technically 
poor  recordings  and  mfERG  has  a  high  signal-to-noise  ratio  making  quantitative 
analysis unreliable.  Furthermore,  as  the waveform for each hexagon  represents  a 
computer-generated extraction of data from a larger ERG signal, it does not truly 
represent the actual ERG amplitude from that section of the retina. The results were 
evaluated  in  terms  of  the  presence  or  absence  of  central  and  peripheral  macular 
dysfunction,  with  reference  to  laboratory  normal  data,  by  an  electrophysiologist 
experienced in the interpretation of mfERG.  
 
All subjects at baseline had moderate to severely reduced central responses, defined 
as an amplitude reduction of 70% or greater, indicating evidence of moderate to 
severe central macular dysfunction. Mild to moderate peripheral macular dysfunction 
(25-70% reduction in  amplitude) was  present  in  7 (64%) subjects  from  the laser 
group at baseline compared with 8 (36%) in the ranibizumab group.  
 
By 48 weeks in the ranibizumab treated group, 7 (36%) had a mild to moderate 
increase in central function, 3 (14%) had worsened function and 12 (55%) remained 
the  same.  In  the  laser  treated  group,  2  (18%)  had  improved  function,  3  (27%) 
worsened  and  6  (55%)  had  no  noticeable  change.  The  degree  of  peripheral 
dysfunction remained similar in both groups. 
 
An  example  of  a  multifocal  ERG  result  demonstrating  improvement  in  a 
ranibizumab treated subject is shown overleaf in Figure 30. 
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Figure 30 – Example of multifocal ERG from a ranibizumab treated patient. By 48 weeks, the amplitude of the central hexagon has 
increased. Paramacular and peripheral responses remain relatively unaltered. 120 
 
2.3.5  Structural imaging studies 
Details of the effects on retinal structure of the two treatments were obtained from 
OCT scans, colour photographs and fluorescein angiograms. 
2.3.5.1  Optical coherence tomography 
Retinal thickness and volume measurements were derived from the “fast” volume 
scan protocol comprising 25 individual line scans. Grading of morphological features 
was performed on the “dense” volume scans. 
 
Retinal thickness and volume 
Retinal thickness in the central subfield decreased in both groups over the course of 
the study. Ranibizumab treated subjects showed a decrease in thickness from 455 
(79) µm at baseline to 324 (78) µm at 48 weeks. Laser treated subjects decreased 
from 488 (96) µm to 385 (98) µm. The graph in Figure 31 shows this reduction of 
132 µm for ranibizumab compared to the 103 µm reduction for laser (p=0.06 at 48 
weeks), but also illustrates the rapid reduction in retinal thickness for ranibizumab 
treated subjects which is evident at 12 weeks, compared to the slower reduction in 
thickness with laser.   
Results from the other eight ETDRS subfields were similar, with reductions evident 
throughout the macula in both groups. The thickness data for all subfields are shown 
in Table 11 together with total macular volume. 
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Figure 31 – Reduction in OCT central subfield thickness for two groups in the study; 
results shown as mean ± SD. 121 
 
    Ranibizumab  Laser  P-value 48 
weeks 
    0 weeks  48 weeks  Change  0 weeks  48 weeks  Change   
Centre  455.4 
±78.7 
323.9 
±78.1 
-131.5 
±98.0 
488.2 
±96.3 
385.3 
±98.2 
-102.9 
±88.4 
0.06 
Inner 
Superior  458.7 
±84.2 
369.7 
±61.0 
-89.0 
±63.6 
448.8 
±96.6 
390.0 
±58.0 
-58.8 
±67.3 
0.37 
Nasal  424.7 
±56.6 
356.4 
±31.9 
-68.3 
±53.1 
440.1 
±105.2 
400.0 
±78.0 
-40.1 
±46.5 
0.03 
Inferior  413.9 
±64.1 
339.3 
±26.5 
-74.6 
±55.3 
426.6 
±49.8 
385.8 
±39.6 
-40.8 
±37.2 
0.0003 
Temporal  455.5 
±75.8 
349.0 
±49.3 
-106.5 
±68.6 
450.2 
±70.3 
384.9 
±40.6 
-65.3 
±65.1 
0.05 
Outer 
Superior  366.3 
±86.0 
319.8 
±45.6 
-46.5 
±48.0 
360.5 
±73.4 
336.7 
±51.3 
-23.8 
±31.1 
0.34 
Nasal  365.1 
±62.9 
322.7 
±27.3 
-42.5 
±46.4 
370.0 
±59.5 
358.5 
±53.5 
-11.5 
±29.9 
0.02 
Inferior  334.7 
±70.5 
290.9 
±26.6 
-43.8 
±49.5 
331.5 
±42.2 
319.9 
±37.5 
-12.4 
±17.5 
0.02 
Temporal  363.3 
±76.8 
303.5 
±37.0 
-59.8 
±46.3 
369.3 
±104.4 
340.3 
±74.4 
-29.0 
±48.5 
0.06 
Total macular 
volume 
10.53 
±1.62 
8.96 
±0.81 
-1.57 
±0.98 
10.47 
±1.69 
9.77 
±1.15 
-0.69 
±0.82 
0.03 
 
Table 11 – Thickness (µm) in the nine ETDRS subfields and total macular volume (mm
3) from OCT scans for the two treatment groups. 
Data shown as mean ±SD. P-values for two-tailed t-test (unpaired), without correcting for multiple comparisons.122 
 
Morphology 
The results of the grading to show the prevalence of the morphological features of 
DMO identified by masked reading centre graders is shown for the two groups in 
Table  12.  Trends  towards  decreased  prevalence  of  some  of  these  features  were 
identified in both groups, but clear differences between the groups were not apparent. 
 
Feature  0 weeks  48 weeks  Fisher's 
exact 
test P 
Ranibizumab  Laser  Ranibizumab  Laser 
Central 
subfield 
Subretinal fluid  22.7  18.2  4.5  18.2  0.25 
Inner 
retina 
Cysts  22.7  18.2  27.3  27.3  1.00 
Cystoid  81.8  90.9  45.5  72.7  0.27 
HRF  81.8  90.9  77.3  63.6  0.68 
Outer 
retina 
Cysts  27.2  9.1  27.3  9.1  0.39 
Cystoid  90.9  81.8  59.1  54.5  1.00 
HRF  77.3  81.8  63.6  45.5  0.70 
Inner 
subfields 
Inner 
retina 
Cysts  54.5  54.5  68.2  45.5  0.44 
Cystoid  81.8  90.9  54.5  72.7  0.25 
HRF  95.5  100  100  100  1.00 
Outer 
retina 
Cysts  40.9  45.5  50  54.5  0.71 
Cystoid  90.9  100  77.3  72.7  1.00 
HRF  95.5  100  95.5  100  1.00 
Abnormal foveal depression  100  100  59.1  90.9  0.11 
Interrupted ELM  68.2  63.6  54.5  100  0.01 
Interrupted IS-OS junction  86.4  72.7  77.3  100  0.14 
 
Table 12 – Prevalence (%) of morphological features of DMO in the two groups; 
n=22 for ranibizumab and n=11 for laser. 
.  
The  prevalence  of  subretinal  fluid  in  the  central  subfield  decreased  in  the 
ranibizumab arm but not the laser arm by 48 weeks. There was no clear evidence of a 
treatment effect in either group on retinal cysts in the inner or outer retina either in 
the  central  subfield  or  the  four  surrounding  (inner)  subfields.  The  prevalence  of 
cystoid oedema did appear to decrease with both treatments. All subjects had an 
abnormal foveal depression at baseline. In the laser group, 9% of subjects (1/11) had 
a normal foveal depression by 48 weeks but in the ranibizumab group this was 40% 
(9/22  subjects).  The  two  groups  were  comparable  at  baseline  in  terms  of  the 
prevalence of interruptions in the lines representing the external limiting membrane 
or inner segment-outer segment (IS/OS) junction (ellipsoid layer), but at 48 weeks 
the ranibizumab group showed a significantly lower prevalence of interrupted ELM 
compared  with  laser  (P=0.01,  Fisher’s  exact  test).  The  prevalence  of  interrupted 123 
 
IS/OS junction in the laser group increased while the ranibizumab group decreased 
(P=0.14).  
 
Evaluation of vitreomacular interface abnormalities revealed very little change in 
either  group  over  the  course  of  the  study.  In  the  ranibizumab  group,  5  subjects 
(22.7%) had an epiretinal membrane at baseline compared to 4 subjects in the laser 
group (36.4%). At 48 weeks there was no significant difference in these figures. One 
subject  in  the  ranibizumab  group  had  an  incomplete  PVD  identified  at  baseline, 
which  persisted  until  48  weeks.  No  subjects  had  lamellar  hole,  macular  hole  or 
vitreomacular traction at any time point. 
 
2.3.5.2  Colour fundus photography 
Four-field color photographs were graded at baseline and 48 weeks to obtain the 
numerical  ETDRS  grade  of  diabetic  retinopathy.  One  subject  in  the  laser  group 
worsened by one grade, 6 remained the same and 4 improved by one grade. Two of 
the ranibizumab group worsened by one grade; 1 by three grades and 10 remained 
the same. Seven improved by one grade and 2 by 2 grades (Table 4Table 13). 
 
    Early Treatment Diabetic Retinopathy Study grade 
    35  43  47  53  61  65 
Ranibizumab  0 weeks  1 (4.5)  9 (41.0)  5 (22.7)  6 (27.3)  1 (4.5)  0 (0) 
48 
weeks 
2 (9.1)  12 
(54.5) 
5 (22.7)  1 (4.5)  1 (4.5)  1 (4.5) 
Laser  0 weeks  0 (0)  7 (63.6)  2 (18.2)  2 (18.2)  0 (0)  0 (0) 
48 
weeks 
2 (18.2)  5 (45.5)  3 (27.3)  1 (9.1)  0 (0)  0 (0) 
 
Table 13 – Grade of diabetic retinopathy in the two groups at baseline and 48 weeks 
from masked reading center grading of colour fundus photographs.  
 
Representative examples of colour fundus photographs from subjects in the study, 
presented together with OCT images and microperimetry data from baseline and 48 
weeks, are shown in Figure 32 (ranibizumab) and Figure 33 (laser). 124 
 
 
Figure 32 – Colour fundus photographs, OCT image, retinal thickness maps and 
microperimetry results from ranibizumab treated subject in the LUCIDATE study at 
baseline and 48 weeks. 125 
 
 
Figure 33 – Colour fundus photographs, OCT image, retinal thickness maps and 
microperimetry results from laser treated subject in the LUCIDATE study at baseline 
and 48 weeks. 126 
 
2.3.5.3  Fluorescein angiography 
All subjects had a baseline foveal avascular zone (FAZ) greatest linear dimension 
(GLD)  less  than  1000  µm  on  fluorescein  angiography.  One  subject  in  the 
ranibizumab group had an angiogram that was deemed ungradable at baseline and 
was excluded from analysis. In both groups there was a small increase in FAZ area 
from baseline to 48 weeks (ranibizumab: 0.255 (0.102) mm
2 to 0.321 (0.111) mm
2; 
laser: 0.346 (0.163) mm
2 to 0.432 (0.192) mm
2). Although this suggests that macular 
ischaemia has progressed during the study, there was no evidence of a difference 
between  the  two  groups  to  suggest  a  treatment  effect  (P=0.476,  analysis  of 
covariance). 
  
Perifoveal capillary loss (PFCL) was graded by the reading centre in four quadrants 
from 0 (none present) to 4 (severe loss). A total score from 0-16 was obtained by 
adding  the  scores  in  the  four  quadrants.  The  ungradable  angiogram  in  the 
ranibizumab  group  was  similarly  excluded  from  this  analysis  as  was  a  further 
angiogram in the laser group where capillary loss could not be accurately graded. At 
baseline in the laser group, median (IQR) PFCL score was 9.5 (8.25-10.75) and in 
the ranibizumab group was 10 (9-11). By 48 weeks, this had worsened by at least 
one grade in 15/40 (37.5%) of quadrants graded in the laser group and in 24/84 
(28.6%) of quadrants in the ranibizumab group. However, this represented a change 
in score to 11 (10-12) for laser and 10 (9-12) for ranibizumab. The changes in grade 
for each quadrant were added to give a single score per subject and there was no 
difference in score between the two groups (P=0.65, Rank-sum test). 
2.3.6  Safety data 
2.3.6.1  Full field electroretinography 
The comprehensive data set from the full field ERGs to evaluate rod and cone system 
function  is  shown  in  Table  14.  Technically  unsatisfactory  recordings,  e.g.  those 
compromised by blink artifact, were excluded from this analysis.  
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      Ranibizumab  Laser 
    Time 
point 
Amplitude  Peak time  Amplitude  Peak time 
Rod 
(DA 
0.01) 
b-wave 
0 weeks  140.5 ±69.5  105.5 ±9.5  120.9 ±41.2  109.3 ±10.6 
12 weeks  124.2 ±68.1  103.4 ±12.5  124.1 ±41.9  110.1 ±11.5 
24 weeks  135.8 ±81.1  103.9 ±11.0  132.7 ±48.8  112.0 ±11.3 
48 weeks  144.7 ±81.7  104.3 ±10.7  121.4 ±44.6  109.5 ±9.1 
             
Bright 
flash 
(DA 
11.0) 
a-wave 
0 weeks  248.6 ±76.5  14.4 ± 1.0  257.0 ±64.3  17.0 ±3.2 
12 weeks  235.8 ±88.8  14.5 ±1.3  245.0 ±71.5  17.6 ±3.2 
24 weeks  233.8 ±83.6  14.3 ±1.2  233.6 ±55.9  17.0 ±4.5 
48 weeks  227.5 ±76.5  14.3 ±1.3  249.5 ±68.1  16.2 ±2.6 
           
b-wave 
0 weeks  386.6 ±125.1  53.0 ±5.4  365.0 ±53.5  56.5 ±6.2 
12 weeks  354.5 ±127.6  53.3 ±5.0  354.5 ±62.3  56.1 ±4.8 
24 weeks  354.5 ±122.7  52.3 ±4.5  364.5 ±87.5  56.2 ±4.9 
48 weeks  367.8 ±113.2  53.4 ±5.5  365.9 ±61.0  53.8 ±3.6 
             
Cone 
flicker 
(LA 
30Hz) 
30 Hz 
0 weeks  86.0 ±32.2  30.9 ±3.5  69.1 ±24.5  33.5 ±5.0 
12 weeks  76.1 ±23.4  30.4 ±3.1  62.7 ±19.9  33.5 ±4.9 
24 weeks  77.9 ±33.0  30.4 ±3.1  65.4 ±21.2  33.0 ±4.3 
48 weeks  79.2 ±28.1  31.6 ±3.4  62.3 ±20.2  33.0 ±4.2 
             
Photopic 
single 
flah 
(LA 2.0) 
a-wave 
0 weeks  32.3 ±10.4  15.0 ±1.1  31.8 ±8.7  16.2 ±1.6 
12 weeks  28.3 ±7.8  15.5 ±3.0  26.4 ±8.7  16.2 ±1.9 
24 weeks  27.9 ±11.0  15.1 ±1.2  30.0 ±8.4  16.8 ±4.1 
48 weeks  29.3 ±9.9  15.4 ±1.2  29.5 ±7.6  16.3 ±1.5 
           
b-wave 
0 weeks  114.8 ±42.5  32.4 ±2.2  88.2 ±27.9  35.0 ±4.1 
12 weeks  100.8 ±32.7  32.8 ±4.3  81.8 ±27.8  35.2 ±4.5 
24 weeks  98.5 ±43.3  32.4 ±2.3  89.1 ±26.1  35.3 ±7.0 
48 weeks  105.5 ±37.3  33.0 ±2.5  91.0 ± 19.7  34.6 ±3.8 
 
Table 14 – Amplitudes and implicit times of the major ERG waveforms, shown in µv 
or ms respectively, presented as mean ± SD. 
 
Rod system function was evaluated by the dark-adapted ERGs, comprising the dim 
flash ERG (DA 0.01) and the bright flash scotopic ERG (DA 11). There was no 
change identified in the dim flash ERG b-wave in either group over 48 weeks. For 
the  brighter  flash  ERG  (DA  11),  the  mean  a-wave  amplitude  decreased  in  the 
ranibizumab group from 249 µv to 228 µv with no change in peak time, while the b-
wave amplitude decreased from 387 µv to 368 µv, again with no change in peak 
time. There was no similar change in the laser group; shown in Figure 34. None of 
the changes were clinically significant in any patient. 128 
 
 
 
Figure 34 – Amplitudes of a- and b-waves from bright flash scotopic (DA 11) 
electroretinogram for ranibizumab and laser treated subjects in the LUCIDATE 
study. 
 
Evaluation of the cone system by the light-adapted ERGs revealed no significant 
changes. Minor variability occurred in the amplitude of the 30 Hz flicker ERG (LA 
30 Hz), but there was no change in peak time exceeding 1 ms in the group overall. 
Similarly, the photopic flash ERG (LA 2.0) did not reveal any significant change in 
function in either group. There was no clinically significant change in implicit time 
for any of the waveforms measured. 
 
2.3.6.2  Adverse events and withdrawals 
Ocular and non-ocular adverse events  occurred in  both treatment  groups  and are 
reported in Table 15. There were no cases of endophthalmitis in either treatment arm.  
Ocular adverse events occurred more frequently in the ranibizumab arm (19 vs. 1) 
and  were  related  to  the  injection  procedure  itself.    There  were  more  non-ocular 
adverse events in the ranibizumab arm (44 vs. 17), although the frequencies of the 
most common of these were similar in the two arms. No serious adverse events were 
related to the study drug or injection procedure. There were 2 deaths reported during 129 
 
the study (1 per treatment arm), neither of which related to the study drug. One 
subject in the ranibizumab arm died from advanced hepatocellular carcinoma which 
likely predated his entry into the trial as he was at that point under investigation for 
unexplained thrombocytopaenia. One subject in the laser arm died from acute renal 
failure precipitated by gastroenteritis while on an overseas trip. One patient in the 
ranibizumab arm withdrew after 20 weeks as he was moving overseas. There were 
no suspected unexpected serious adverse reactions (SUSARs). 
 
N (%)  Ranibizumab (n=24)  Laser (n=12) 
Ocular:     
Blepharitis    1 (8) 
Conjunctivitis  1  (4)   
Corneal abrasion  3 (13)   
Eye pain/discomfort  4 (17)   
Posterior vitreous detachment  1 (4)   
Raised intraocular pressure  1 (4)   
Rash (periocular)  1 (4)   
Subconjunctival haemorrhage  6 (25)   
Visual disturbance  2 (8)   
Non-ocular:     
Abdominal pain/diarrhoea  1 (4)   
Acute renal failure  1 (4)  1 (8) 
Anaemia  1 (4)   
Exertional dyspnoea  1 (4)   
Fall/collapse  1 (4)  1 (8) 
Headache  4 (17)  1 (8) 
Hepatocellular carcinoma  1 (4)   
Intermittent claudication  1 (4)   
Musculoskeletal pain/injury  7 (29)  3 (25) 
Retinal detachment non-study 
eye 
1 (4)   
Skin infection/swelling/rash  7 (29)  2 (17) 
Toothache  1 (4)   
Upper respiratory tract 
infection 
12 (50)  5 (42) 
Urinary tract infection  2 (8)  2 (17) 
Viral illness  3 (13)  1 (8) 
Vitamin B deficiency    1 (8) 
Death  1 (4)  1  (8) 
 
Table 15 – Adverse events in the study, reported as number (%) of participants 
experiencing event. 
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2.3.7  Longitudinal evaluation of choroidal thickness by enhanced depth 
imaging 
The 33 subjects who completed 48 weeks follow-up also comprised the analysis set 
for the choroidal thickness study. At baseline, before treatment, mean (SD) choroidal 
thickness at the fovea was greater than for any other location measured across the 
macular at 285 (68) µm. The choroid was thicker in the temporal region than in the 
nasal region: the mean of five measurements from 0.5 to 2.5 mm temporally was 263 
µm compared to 236 µm for the equivalent five measurements nasally. The profile of 
choroidal thickness for all subjects at baseline is shown in Figure 35. 
 
There was no significant change in choroidal thickness in either treatment group over 
the  course  of  the  study  at  any  location  in  the  macula.  Table  16  shows  the 
measurements  for  choroidal  thickness  at  the  subfoveal  location,  and  for  mean 
choroidal thickness, obtained by taking a mean of the 12 measurements across the 
macula from 2.5 mm nasally to 3.0 mm temporally at 500 µm intervals and including 
the  subfoveal  measurement.  Retinal  thickness  measurements  from  the  central 
subfield  are shown for  comparison.  The results for the two treatment  groups for 
every location measured across the macula are shown in Figure 36A and B.  
 131 
 
3.0m m  N asal
2.5m m  N asal
2.0m m  N asal
1.5m m  N asal
1.0m m  N asal
0.5m m  N asal
F o vea
0.5m m  T em p o ral
1.0m m  T em p o ral
1.5m m  T em p o ral
2.0m m  T em p o ral
2.5m m  T em p o ral
3.0m m  T em p o ral
0
100
200
300
400
500
A ll subjects at baselin e
Location
C
h
o
r
o
i
d
a
l
 
t
h
i
c
k
n
e
s
s
/

m
 
Figure 35 – Choroidal thickness across the macula (shown for a left eye) for all 
subjects at baseline. Inverted y-axis to demonstrate choroidal thickness profile in 
usual OCT orientation. 
 
  Ranbizumab  Laser 
  Baseline  48 weeks  Baseline  48 weeks 
Subfoveal Choroidal 
Thickness   278.5 ±62.7   278.7 ±81.8  297.0 ±70.7   308.2 ±75.2  
Mean Choroidal 
Thickness   243.5 ±58.8   245.5 ±58.3  264.6 ±51.8   255.7 ±52.9 
OCT central subfield 
thickness (retina)  455.4 ±78.7  323.9 ±78.1  488.2 ±96.3  385.3 ±98.2 
 
Table 16 – Choroidal thickness measurements in µm for two treatment groups at 
baseline and 48 weeks. Retinal thickness measurements from OCT scans are shown 
for comparison. 
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Figure 36A and B – Graphs to show choroidal thickness at baseline and 48 weeks in 
two treatment groups – laser (A) or ranibizumab (B). Graphs orientated to show 
choroidal profile for left eye in usual OCT view. 
 
To investigate whether there was an early effect on choroidal thickness of either 
treatment, the scans taken at 12 weeks were analysed in the same way. All subjects at 133 
 
this  time  point  had  either  received  three  consecutive  ranibizumab  injections  or 
macular  laser.  These  results  are  shown  in  Figure  37A  and  B.  There  was  no 
significant  difference in either the laser or ranibizumab group between choroidal 
thickness at baseline and 12 weeks (multiple t-tests). 
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Figure 37A and B – Graphs to show choroidal thickness at baseline and 12 weeks in 
two treatment groups – laser (A) or ranibizumab (B). Graphs orientated to show 
choroidal profile for left eye in usual OCT view. 134 
 
 
Data were further examined to explore the possible correlation of choroidal thickness 
with retinal thickness and with visual acuity. At baseline, there was no correlation 
between choroidal thickness at the fovea and either retinal centre point thickness or 
central subfield thickness. Figure 38 shows results for retinal thickness in the central 
subfield and subfoveal choroidal thickness.  
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Figure 38 – Subfoveal choroidal thickness vs. retinal central subfield thickness 
(Pearson r = -0.03, P=0.86). 
 
However, there was a weak positive correlation between choroidal thickness and 
visual acuity that did not reach statistical significance (Pearson r = 0.31, P=0.08), 
shown in Figure 39. 
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Figure 39 – Subfoveal choroidal thickness vs. ETDRS visual acuity for all subjects at 
baseline. 
 
2.3.8  Structure-function correlation studies 
Data were analysed for the 33 patients who completed 48 weeks of follow up in the 
main study. Visual acuity at baseline showed a trend towards a significant negative 
correlation with retinal thickness (Pearson r = -0.3017, P = 0.088), shown in Figure 
40. Applying linear regression to these results, the slope of the line gives a decrease 
of 2.1 ETDRS letters for every 100 µm gain in central subfield thickness. 
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Figure 40 – Scatter plot to show ETDRS visual acuity vs. central subfield thickness 
for all subjects at baseline. 136 
 
At 48 weeks, change in retinal thickness was plotted against change in visual acuity 
for two treatment groups. There was a significant correlation present for ranibizumab 
treated subjects (r = -0.65, P = 0.001) but not for laser (r = 0.025, P = 0.9). Linear 
regression for ranibizumab treated subjects only showed that a change of 4.1 letters 
was associated with a retinal thickness change of 100 µm, shown in Figure 41. 
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Figure 41 – Scatter plot to show correlation between change in retinal thickness and 
change in visual acuity for two treatment groups at 48 weeks. Linear regression 
shown for ranibizumab. 
 
To explore whether there was better correlation between retinal thickness and an 
objective  measure  of  retinal  sensitivity,  results  for  retinal  thickness  in  the  nine 
ETDRS  subfields  were  correlated  with  microperimetry  results  in  the  same  nine 
subfields.  At  baseline,  a  negative  correlation  was  present:  as  retinal  thickness 
increased, sensitivity decreased. Results for the nine ETDRS subfields are shown in 
Figure 42. 
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Figure 42 – Scatter plots to show correlation between retinal sensitivity and retinal thickness for all subjects at baseline, grouped by 
treatment allocation.138 
 
Because all nine subfields showed similar results and no difference between subjects 
allocated to laser or ranibizumab was evident, all points were combined to estimate 
the  overall  effect  of  thickness  on  sensitivity,  shown  in  Figure  43.  There  was  a 
statistically significant correlation between retinal thickness and retinal sensitivity 
overall (r = -0.5216, P<0.0001). The results of linear regression gave a slope of -
0.02233 ± 0.002127, i.e. each micron increase in retinal thickness is associated with 
a loss of approximately 0.02 dB sensitivity. Alternatively, 1 dB change in retinal 
sensitivity is associated with a change in thickness of approximately 45 µm. 
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Figure 43 – Graph to show correlation of retinal thickness with retinal sensitivity for 
all subjects at baseline (n=33) in all ETDRS subfields. 
 
Confirmatory evidence of this finding is shown by longitudinal evaluation of retinal 
sensitivity change and retinal thickness change, shown by scatter plots in Figure 44. 
Each of the nine subfields appears to show a similar negative correlation, so values 
for all nine subfields were combined to estimate the effect of thickness change on 
sensitivity, shown in Figure 45. 
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Figure 44 – Scatter plots to show change in retinal thickness from baseline to week 48 versus change in retinal sensitivity over the same 
period, plotted for nine ETDRS subfields 140 
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Figure 45 – Graph to show correlation between retinal thickness change and retinal 
sensitivity change for nine ETDRS subfields for laser and ranibizumab treated 
subjects. 
 
For  both  treatment  groups  there  was  a  significant  correlation  between  change  in 
retinal  thickness  and  change  in  sensitivity  (laser:  r  =  -0.1990,  P=0.0483; 
ranibizumab: r = -0.3074, P<0.0001). Linear regression showed that a 1 dB change in 
sensitivity was associated with a change in thickness of 118 µm for laser and 74 µm 
for ranibizumab, but there was no significant difference between the slopes for the 
two groups (P=0.35). Calculating a combined slope for all data points gives a change 
of retinal thickness of 82 µm for 1 dB change in sensitivity. 
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2.3.9  Repeatability of OCT measures of macular thickness and volume 
In addition to the 37 patients recruited to the LUCIDATE study, 13 patients who had 
been screened for  LUCIDATE or another clinical  trial investigating treatment  of 
DMO with very similar inclusion/exclusion criteria were included in this sub-study 
to give a total of 50 subjects, of which 18 were female. The mean age was 61.7 years 
(range 30-82). 31 subjects were Caucasian, 12 Asian-Indian, 3 Afro-Caribbean and 4 
from other ethnic groups. Mean ETDRS best-corrected visual acuity was 67 letters 
(range 47-82). 
2.3.9.1  Automated measures of macular thickness and volume 
The  mean  thickness  and  volume  values  for  each  macular  subfield  with  repeated 
measurements are summarised in Table 17 and Table 18.  
 
Measurement  1  2  3  4 
  Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Centre  476.7  102.4  476.5  459.5  476.8  102.7  476.6  103.2 
Inner 
Superior  456.9  94.4  455.2  90.8  455.3  90.7  455.1  90.9 
Temporal  455.7  87.3  454.6  85.6  454.6  86.2  454.9  85.7 
Inferior  435.2  419.5  434.5  416.5  434.0  71.6  434.5  71.8 
Nasal  441.5  84.0  440.7  82.8  441.1  83.2  440.8  83.6 
Outer 
Superior  371.2  83.7  372.2  84.2  371.8  83.9  372.6  85.1 
Temporal  368.6  83.8  368.1  81.9  368.2  82.3  368.6  82.4 
Inferior  348.8  66.9  349.5  66.4  348.8  67.3  349.4  66.9 
Nasal  374.3  61.0  373.7  59.4  372.9  60.1  373.8  59.9 
Centre point 
thickness 
473.6  125.2  475.0  469.5  475.2  125.8  473.9  126.1 
 
Table 17 – Repeated measurements from nine OCT subfields and centre point 
thickness, in µm. 
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Measurement  1  2  3  4 
  Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Centre  0.37  0.08  0.37  0.08  0.37  0.08  0.37  0.08 
Inner 
Superior  0.72  0.15  0.71  0.14  0.72  0.14  0.72  0.14 
Temporal  0.72  0.14  0.71  0.13  0.71  0.13  0.71  0.13 
Inferior  0.68  0.11  0.68  0.11  0.68  0.11  0.68  0.11 
Nasal  0.69  0.13  0.69  0.13  0.69  0.13  0.69  0.13 
Outer 
Superior  1.93  0.45  1.93  0.45  1.94  0.45  1.94  0.46 
Temporal  1.88  0.43  1.88  0.42  1.88  0.42  1.88  0.42 
Inferior  1.81  0.36  1.81  0.36  1.81  0.36  1.81  0.36 
Nasal  1.92  0.34  1.92  0.33  1.92  0.33  1.92  0.34 
Total macular 
volume 
10.73  1.73  10.72  1.69  10.72  1.69  10.73  1.70 
 
Table 18 – Repeated macular volume measurements from nine OCT subfields and 
overall total macular volume, in mm
3. 
 
For retinal thickness and volume in each subfield, for centre point thickness and for 
total macular volume, mean values for each patient were plotted against standard 
deviation to demonstrate no correlation between variability and the magnitude of the 
measurement. Results for central subfield thickness are shown in Figure 46; plots for 
other subfields similarly demonstrated no relationship. 
 
Figure 46 – Plot of central subfield thickness against standard deviation to 
demonstrate lack of correlation between size of measurement and degree of 
variability. 
 
The coefficient of repeatability (CR) for retinal thickness in the central subfield was 
8.03 µm (95% confidence interval 7.70 – 8.35 µm). CR in the other subfields ranged 143 
 
from 6.54 µm to 18.25 µm; results shown in Table 19. CR for macular volume was 
0.08 mm
3 or lower for all subfields and 0.21 mm
3 for total macular volume. 
 
Subfield  Thickness / µm  Volume / mm
3 
  CR  Confidence 
interval 
CR  Confidence 
interval 
Centre  8.03  7.70 – 8.35  0.01  0.01 – 0.01 
Inner 
Superior  18.25  17.51 – 19.00  0.03  0.03 – 0.03 
Temporal  7.67  7.36 – 7.98  0.01  0.01 – 0.01 
Inferior  14.77  14.16 – 15.37  0.02  0.02 – 0.02 
Nasal  9.75  9.35 – 10.15  0.02  0.02 – 0.02 
Outer 
Superior  14.14  13.56 – 14.71  0.08  0.08 – 0.09 
Temporal  6.54  6.27 – 6.81  0.04  0.04 – 0.05 
Inferior  10.16  9.75 – 10.58  0.05  0.05 – 0.05 
Nasal  11.67  11.19 – 12.14  0.07  0.06 – 0.07 
Centre point  21.62  20.74 – 22.51     
Total macular volume      0.21  0.20 – 0.22 
 
Table 19 – Coefficients of repeatability for macular thickness and volume in the nine 
ETDRS subfields, for centre point thickness and total macular volume. 
 
2.3.9.2  Scans with retinal boundary detection error 
Significant  automated  retinal  boundary  detection  error  as  described  above  was 
present  in  13  (26%)  subjects.  For  the  remaining  37  subjects  without  significant 
segmentation error, the CR was now 7.44 µm (95% confidence interval 7.09 – 7.79 
µm) in the central subfield. Estimates for CR in the remaining eight subfields ranged 
from  3.97  µm  (outer  nasal)  to  7.23  µm  (inner  inferior),  demonstrating  that  the 
exclusion of scans with significant segmentation error reduced the CR and hence 
improved the repeatability of retinal thickness  measures. Results for all subfields 
before and after the exclusion of scans with boundary detection error are shown in 
Figure 47A and B. 144 
 
 
A 
 
B 
Figure 47A and B – Repeatability of retinal thickness measures before (A) and after 
(B) scans with significant boundary detection error were excluded. 
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2.3.9.3  Prevalence of media opacity and vitreomacular interface abnormality 
Mild to moderate cataract was present in 7/13 (53.8%) of subjects with significant 
boundary detection error and in 21/37 (56.8%) of those without (p=1.00, Fisher’s 
exact test). Similar numbers in both groups were pseudophakic (3/13, (23.1%) vs. 
8/37, (21.6%), p=1.00). More subjects who had boundary detection error were found 
to have vitreomacular interface abnormalities (epiretinal membrane, vitreomacular 
traction, or thickened posterior hyaloid membranes) than those without boundary 
detection error (8/13 (61.5%) vs. 14/37 (37.8%), p=0.197). 
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2.4  Discussion 
The LUCIDATE study was an exploratory single-masked randomised clinical trial, 
designed to compare the effect of ranibizumab with laser on a number of parameters 
evaluating retinal function and structure. 
 
The study provided some evidence, but not statistically significant differences, for a 
marginal benefit of ranibizumab on visual acuity, retinal sensitivity, colour contrast 
sensitivity and retinal thickness. No new safety concerns have been reported, and in 
particular  there  was  no  evidence  of  an  increase  in  macular  ischaemia  with 
ranibizumab and no worsening of global retinal dysfunction. 
 
Post-hoc analyses showed no difference in choroidal thickness with either treatment 
for DMO, and a modest correlation between microperimetric retinal sensitivity and 
retinal  thickness.  The  repeatability  of  OCT  measures  of  macular  thickness  and 
volume using Spectralis SD-OCT have been reported. 
2.4.1  Functional outcome data 
Across different modalities, there is evidence that ranibizumab may lead to improved 
function compared with laser, but statistical significance was not reached. 
2.4.1.1  Visual acuity 
The visual acuity improvement of 6 ETDRS letters in the ranibizumab group is in the 
same  order  of  magnitude  as  the  improvement  seen  in  larger  trials  such  as  the 
RESTORE study, or the DRCR.net protocol I trial. In RESTORE, the group treated 
with ranibizumab alone gained a mean ± SD of 6.8 ± 8.3 letters at one year and in the 
DRCR.net study the visual acuity gain was 9 ± 12 letters [79, 81]. This suggests that 
in terms of visual acuity response, the cohort in this study is comparable with the 
wider population of patients with DMO. In this study the lower limit to visual acuity 
for inclusion was 55 letters (approximately 6/24), compared to 39 (6/48) and 24 
(6/96) letters respectively in the two larger trials. There is some evidence from the 
DRCR.net that participants with a lower visual acuity at baseline gain more letters 
with ranibizumab treatment although end up with a worse final acuity [180]. This 
may in part be due to a “ceiling effect” where patients with better acuity at baseline 147 
 
have less potential for improvement. Given the better mean visual acuity at baseline 
in this study (70 letters compared with 63 in the DRCR.net study), it is perhaps 
unsurprising that a gain of only 6 letters was seen on average. The decline of 0.9 
letters in the laser arm is comparable to the decline of 0.5 letters reported in the 
BOLT study carried out at the same institution on a similar cohort of patients [73]. 
 
The greatest limitation to interpretation of data from the study is that despite a valid 
randomisation  method,  subjects  in  the  ranibizumab  group  had  a  mean  BCVA  7 
letters  greater  than  the  laser  group  at  entry  to  the  trial  (70.4  vs  63.8).  Stratified 
randomisation could have prevented this difference at baseline. This may have meant 
that the subjects in the two groups were not comparable in terms of disease status. 
Comparison of the baseline characteristics shows that there were no subjects with 
type 1 diabetes in the laser group and the duration of macular oedema was longer. 
The difference in baseline characteristics, including visual acuity, is a limitation to 
the  study  as  the  two  groups  may  have  had  different  severity  of  disease  and 
subsequently different responses to the investigations undertaken. 
 
Subjects with good visual acuity who did not meet the criteria for retreatment at the 
penultimate study visit (44 weeks) may have experienced a drop in visual acuity 
prior to the exit assessments. One subject who was treated at 40 weeks experienced a 
drop in visual acuity from 74 letters at 44 weeks to 59 letters at exit, and met the 
criteria for further ranibizumab treatment were the trial to have continued. Subjects 
treated with ranibizumab gained on average 8.9 letters from baseline if maximum 
acuity at any time point after baseline is considered.  
 
2.4.1.2   Microperimetry 
As discussed in the introduction to this chapter, microperimetry has been used to 
characterise  decreased  retinal  sensitivity  in  DMO  and  to  evaluate  the  effects  of 
treatment, but no previous study has reported the effects of ranibizumab on retinal 
sensitivity in this condition. 
 
The mean retinal sensitivity in the present study improved in the central 4° of the 
macula by 3.2 dB with ranibizumab and 1.9 dB with laser. Some improvement may 148 
 
be  attributable  to  a  learning  effect,  but  a  trend  towards  greater  functional 
improvement with ranibizumab compared to laser treatment appears to exist. Smaller 
improvements  in  retinal  function  are  seen  in  the  central  12°  of  the  macula;  this 
measure includes a greater amount of retina unaffected by central oedema. 
 
A randomised trial comparing standard ETDRS laser with micropulsed diode laser 
carried out microperimetry at a number of time points over one year and showed a 
decline in sensitivity of 0.72 and 1.69 dB in the central 4° and 12° respectively 
following ETDRS laser and a small improvement with diode laser (0.74 and 0.87 dB 
at one year) [131]. Although the baseline characteristics of subjects in the two studies 
appear comparable, subjects treated with ETDRS laser in this study actually had 
improved sensitivity, to a  greater degree than for micropulsed diode laser in  the 
Italian study. Ranibizumab treated subjects had an even greater improvement. This 
finding  suggests  that  ETDRS  laser  is  safe  and  is  not  leading  to  loss  of  retinal 
function by this modality, although it remains fairly ineffective in terms of visual 
acuity change. 
 
2.4.1.3  Colour contrast sensitivity 
The presence of colour vision defects in diabetic retinopathy and their association 
with macular disease has been well documented. In this study as expected, subjects 
at  baseline  had  raised  colour  discrimination  thresholds  in  protan  and  tritan  axes. 
Following treatment with ranibizumab, an improvement in the thresholds is apparent 
in both axes. After laser treatment, protan axis thresholds have increased. Defects in 
this  axis  have  been  reported  to  be  associated  with  ischaemia  [117].  Tritan  axis 
thresholds have improved, but to a lesser degree than with ranibizumab. It is possible 
that a learning  effect  is present  with  this  test,  but  the 12 week interval  between 
testing makes this unlikely. The evidence from this study suggests that this type of 
functional defect in DMO may have an element of reversibility. 
 
2.4.1.4  Pattern and multifocal electroretinograms 
In keeping with the improved visual acuity, retinal sensitivity and colour contrast 
sensitivity  for  ranibizumab  compared  with  laser,  PERG  P50  amplitude  remains 149 
 
preserved in the ranibizumab group while there is an approximate 10% decline for 
laser.  At  intermediate  time  points,  the  P50  amplitude  in  the  ranibizumab  group 
declined slightly, but this did not correlate with visual acuity or retinal sensitivity 
changes.  PERG  amplitudes  have  previously  been  reported  to  decrease  following 
laser  treatment  in  diabetic  macular  oedema  [141],  and  although  there  are  other 
reports  of  the  amplitude  increasing  after  injection  of  either  triamcinolone  or 
bevacizumab [142, 143], in this longer study with repeated ranibizumab injections 
and  a  control  group  for  comparison,  no  evidence  of  a  significant  increase  in 
amplitude has been demonstrated.  
The central amplitudes of the mfERG improve in a greater proportion of ranibizumab 
treated subjects than laser, and fewer treated with ranibizumab show deterioration in 
central function. These changes in the central hexagon may represent alterations in 
macular or foveal function that are not large enough to drive an increase in the PERG 
amplitude which is recorded over a larger area of retina. The high signal to noise 
ratio of the mfERG coupled with high test-retest variability owing to patient fatigue 
and fixation instability makes the results from this test difficult to interpret reliably 
and hence quantitative analysis of mfERG results has not been carried out. 
2.4.2  Structural imaging studies 
Both groups in the study showed evidence of resolution of structural abnormalities of 
DMO on OCT, but there was also evidence of progression of ischaemia in both arms 
of the study. Ranibizumab treated subjects had better improvements in OCT retinal 
thickness and decreased prevalence of certain morphological features. 
2.4.2.1  OCT 
OCT imaging enables rapid non-invasive interrogation of macular morphology and 
thickness and is well established as an essential imaging modality in the assessment 
of the patient with macular disease. The quantitative OCT findings in this study of a 
rapid (i.e. present by 12 weeks) and sustained decrease in central subfield thickness 
following ranibizumab treatment  are in  keeping with  other trials of this  agent  in 
DMO. Additionally, laser treated subjects exhibited decreased retinal thickness, but 
to a lesser extent, and this difference approached statistical significance. Our OCT 
findings are in keeping with decreased retinal thickness shown in other studies. In 150 
 
other subfields, thickness had also deteriorated in both groups, but always more in 
the ranibizumab group, and correspondingly, total macular volume was also reduced 
to a greater extent with ranibizumab. It is possible that the presence of boundary 
detection error on OCT may have had an impact on the results (see section 2.4.5). 
Thickness  reductions  in  the  inner  subfields  were  always  greater  than  in  the 
corresponding outer subfield and greatest of all in the central subfield itself. This 
likely reflects the centre-involving nature of the macular oedema and the greater 
retinal thickness in these inner five subfields at baseline. 
 
Evaluation  of  morphology  by  masked  Reading  Centre  graders  revealed  that  all 
subjects  had  an  abnormal  foveal  contour  at  baseline  and  that  there  was  a  high 
prevalence (80-90%) of cystoid changes in the inner and outer retina in both groups, 
present  in  the  central  subfield  and  surrounding  four  subfields.  Cysts  are  less 
common; their lower prevalence in inner retina in the central subfield reflects the 
retinal  anatomy  in  this  location  which  is  dominated  by  outer  retinal  structures. 
Hyperreflective foci are very common, occurring in approximately 80-100% of scans 
graded. By 48 weeks, the prevalence of most of these features has decreased and just 
under half of the ranibizumab group have a normal foveal contour, while 90% of 
those  treated  with  laser  remain  abnormal  in  this  respect.  However,  there  is  no 
discernible benefit seen from ranibizumab in terms of a reduction in the prevalence 
of the features such as cysts, cystoid changes or hyperreflective foci when compared 
with laser.  
 
The  improved  resolution  of  SD  OCT  has  allowed  the  visualisation  of  high 
reflectivity lines in the outer retina. These lines are in the region of the photoreceptor 
inner segment-outer segment junction (termed the ellipsoid layer) and the external 
limiting membrane (ELM). However, it is likely that the axial resolution of SD-OCT 
is still insufficient to visualise these extremely thin features. These are shown in 
Figure  48,  from  Heidelberg,  which  illustrates  the  relationship  believed  to  exist 
between OCT images and the layers of the retina defined histologically (see Figure 3, 
section 1.2).  151 
 
 
Figure 48 – Diagram to show the relationship between the recognised histological 
layers of the retina and the appearance of hypo- and hyper-reflective bands on a 
cross-sectional OCT scan (courtesy of Heidelberg Engineering, downloaded from 
http://eyewiki.aao.org/Optical_Coherence_Tomography). 
 
In this trial, grading examined the integrity of the IS-OS junction and the ELM on 
OCT  scans.  Approximately  two-thirds  of  subjects  at  baseline  had  visible 
discontinuity (interruptions) of the line thought to coincide with the ELM and more 
had interruptions of the IS-OS junction. By 48 weeks, all of the laser subjects now 
had  interruptions  present  in  both  lines  but  the  percentage  with  interruptions 
following ranibizumab treatment had decreased. This may be evidence of a treatment 
effect,  but  it  is  also  possible  that  decreased  retinal  thickness  overall  in  the 
ranibizumab group compared with laser has led to increased visibility of these lines 
and that in situations where extensive amounts of fluid remain, masking of deeper 
retinal structures occurs.  
 
Since this trial was designed, a number of reports have linked integrity of the lines 
with altered visual acuity or retinal sensitivity. Maheshwary et al. showed that in 
DMO an increasing area of disruption of the IS-OS layer was associated with poorer 
visual  acuity  [181].  Correlating  IS-OS  disruption  with  retinal  sensitivity  from 
microperimetry, Landa et al. showed in wet and dry AMD that disruption correlated 
inversely with sensitivity and to a lesser extent with visual acuity [182]. The ELM 
has also been investigated in this setting, and Ito et al. found that integrity of this line 
correlated  with  visual  acuity  in  addition  to  the  IS-OS  junction  line  [183].  These 152 
 
findings merit further exploration and a further exploratory analysis of this data set 
could  involve  correlating  interruptions  in  these  outer  retinal  layers  with  retinal 
sensitivity from microperimetry results and examining the change longitudinally. 
 
2.4.2.2  Colour fundus photography 
In  this  small  exploratory  study,  numbers  do  not  allow  a  clear  assessment  of  a 
treatment effect from ranibizumab or laser on the progression of diabetic retinopathy. 
In both groups, the trend was for grade of retinopathy to remain the same or improve 
slightly.  Evaluation  of  the  results  from  larger  trials  has  shown  that  ranibizumab 
treatment is more likely than sham to result in an improvement of 2 or 3 grades or 
greater in diabetic retinopathy over two years [184]. Interestingly though, even with 
mandatory monthly dosing of ranibizumab for two years in this study, there were still 
approximately 11% of participants experiencing a progression in retinopathy. This 
suggests that while VEGF inhibition may be important for retinopathy progression 
overall, other factors may also be contributing.  
2.4.2.3  Fluorescein angiography 
Evidence from masked grading of fluorescein angiograms in this study suggests that 
in  both  groups  there  was  a  slight  progression  of  macular  ischaemia,  based  on 
enlargement of the foveal avascular zone area and a small increase in the overall 
grade of perifoveal capillary loss. A verification protocol between graders in the 
Reading Centre helped ensure that gradings were reproducible; only one angiogram 
was excluded from FAZ area grading at both time points. The finding of progression 
of ischaemia over one year is in contrast to the findings in the BOLT study where 
there was no increase in FAZ size following 12 months of laser or bevacizumab 
treatment [73]. There was no difference in enlargement between the two groups at 48 
weeks so this is unlikely to represent a treatment effect of ranibizumab, rather it is 
more likely that this group of patients were different from the group enrolled in the 
BOLT study in terms of severity of disease and rate of progression. Further study of 
macular ischaemia following ranibizumab therapy may be warranted. 153 
 
2.4.3  Safety data and adverse events 
Safety outcomes in this small exploratory study included the data from full field 
electroretinograms representing global retinal function, the fluorescein angiography 
data discussed above and the reporting of adverse events. 
2.4.3.1  Full field electroretinograms 
Electroretinography data assessed global function of the rod and cone systems in the 
retina, and was reported by an experienced electrophysiologist who was masked to 
treatment allocation. 
 
The  electroretinography  data  do  not  suggest  that  deterioration  in  global  retinal 
function  has  occurred  in  either  group.  The  only  index  seen  to  change  was  the 
scotopic bright flash ERG in the ranibizumab group, which exhibited decreased a 
and  b  wave  amplitude  but  no  change  in  peak  time.  Therefore  it  is  possible  that 
localised  loss  of  function  has  occurred,  but  there  is  no  evidence  of  generalised 
dysfunction.  The  absence  of  any  change  in  the  cone  system  is  reassuring  and 
suggests that this may be a chance finding. A paired t-test for bright flash a-wave 
amplitudes in the ranibizumab group (n=20 for reliable recordings at baseline and 48 
weeks) gives P=0.02, but for the b-wave amplitudes P=0.2, suggesting this may be 
statistical  noise.  A  statistically  significant  deterioration  in  both  wave  amplitudes 
would  be  needed  for  evidence  of  a  genuine  effect.  Other  factors  such  as  pupil 
dilation can affect electrophysiological results. Further investigation would require 
serial electroretinography on a similar number of patients undergoing ranibizumab 
treatment over a period of time. 
2.4.3.2  Adverse events 
The pattern of adverse events seen during the trial reflects those reported in larger 
trials of ranibizumab for both DMO and age-related macular degeneration. Ocular 
adverse events occurred more commonly in the ranibizumab arm and were related to 
the injection procedure. Non-ocular adverse events also occurred more frequently 
with ranibizumab treatment, with upper respiratory tract and urinary tract infections 
occurring  commonly.  This  may  in  part  be  due  to  reporting  bias;  as  ranibizumab 
subjects were seen every four weeks compared to 12 weekly for laser, there were 
more opportunities for them to report adverse events. 154 
 
A  recent  consecutive  case  series  to  establish  the  incidence  of  endophthalmitis 
following  intravitreal  injection  found  a  rate  of  0.035%  following  injection  in  an 
office setting (i.e. not in the operating theatre) comparable to that used in this study 
[185]. It is therefore reassuring that in this study of approximately 200 intravitreal 
injections there were no cases of endophthalmitis. One death occurred in the laser 
arm, and the other serious adverse events that did occur were not felt to be due to the 
investigational medicinal product (ranibizumab). The death in the ranibizumab arm 
was due to advanced hepatocellular carcinoma. This subject was under investigation 
for thrombocytopaenia at trial entry; this is a feature of the condition and has been 
proposed  in  conjunction  with  α-foetoprotein  levels  as  a  screening  test  for  this 
carcinoma. It is therefore highly likely that the tumour was present in its early stages 
at recruitment. Another subject in the ranibizumab arm had a number of hospital 
admissions meeting the definition for serious adverse events arising from an initial 
incident:  a  fall  leading  to  a  pelvic  fracture.  This  was  treated  conservatively,  but 
during  recovery  from  this  she  developed  recurrent  urinary  tract  infections  and 
anaemia which necessitated hospital admission. She developed nephrotic syndrome 
which  was  investigated  by  renal  biopsy;  this  showed  characteristic  features  of 
diabetic  nephropathy  rather  than  nephropathy  as  a  result  of  anti-VEGF  toxicity 
which has different pathological features (personal communication from Dr Yakoub, 
Consultant Nephrologist, Royal London Hospital). 
 
All serious adverse events were reported to the trial sponsor in accordance with trial 
regulations  and  to  Novartis  following  a  contract  agreed  with  them  prior  to 
commencing the trial. 
 
2.4.4  Choroidal thickness 
The possible role of the choroid in the pathophysiology of diabetic retinopathy and 
the development of readily available imaging techniques to investigate its structure 
have led to several studies reporting changes in choroidal thickness in the presence 
of diabetic retinopathy. Different investigators have reported choroidal thinning in 
the presence of diabetic retinopathy, with some finding that more severe forms of 
retinopathy and the presence of macular oedema are associated with more thinning 155 
 
[101-103,  163,  164].  Recently,  a  cross-sectional  study  has  reported  a  further 
reduction  in  choroidal  thickness  following  anti-VEGF  therapy  with  bevacizumab 
[104]. This study retrospectively analysed patients who had received bevacizumab in 
one eye and laser in another. Although the authors state that patients were included if 
the two eyes had the same level of retinopathy, this raises the question of why the 
treating physician selected one eye for bevacizumab treatment. It is not possible to 
exclude the possibility that eyes treated with bevacizumab were different from those 
receiving laser. 
 
Results from this exploratory, post-hoc analysis of a randomised clinical trial do not 
show evidence of a change in choroidal thickness over 48 weeks with either laser or 
ranibizumab treatment. As discussed above, unstratified randomisation meant that 
subjects in the laser group had on average worse visual acuity and slightly longer 
duration of DMO at baseline. Despite this, choroidal thickness in both groups was 
highly comparable at baseline and at 48 weeks. Both groups did, however, show 
some  evidence  of  an  early  reduction  in  choroidal  thickness  at  12  weeks.  The 
significance of this finding is unclear and it warrants further study. 
 
While retinal thickness correlates with visual acuity and also with retinal sensitivity, 
(see section 2.4.5), there was no evidence of correlation between choroidal thickness 
and retinal thickness and only weak evidence of a correlation with visual acuity. This 
correlation with visual acuity may be a chance association, rather than causative: if 
choroidal thickness is linked to increased diabetic retinopathy severity this in itself 
may be associated with worse visual acuity. Further studies of the role of the choroid 
in diabetic retinopathy and effects of treatments for DMO on choroidal thickness are 
needed. 
2.4.5  Structure function correlation 
In  this  study,  there  was  not  a  statistically  significant  correlation  between  retinal 
thickness in the central subfield at baseline and visual acuity, as the P value was 
0.08. Larger studies have shown that centre-point thickness measured on TD OCT 
correlates with visual acuity, with an effect size reported of 4.4 letters for every 100 
µm change in thickness [174]. Examining visual acuity and retinal thickness change 156 
 
did  reveal  a  statistically  significant  correlation  at  48  weeks,  but  only  in  the 
ranibizumab  group,  with  a  similar  effect  size  (4.1  letters)  found  to  that  reported 
previously. The Bonferroni correction for multiple comparisons has not been applied 
to this exploratory data and further investigation of the strength of correlation is 
needed.  In  the  laser  group,  the  results  were  variable,  with  a  number  of  subjects 
having decreased visual acuity despite reduced central subfield thickness. This result 
could be indicative of retinal atrophy occurring.  
 
Results  from  correlating  microperimetry  with  OCT  show  that  a  statistically 
significant correlation is present between retinal sensitivity and retinal thickness. In 
this trial, ranibizumab treatment resulted in decreased retinal thickness at 48 weeks 
in all subfields on OCT scanning. Identifying this correlation suggests that across the 
whole  macula  reducing  retinal  thickness  improves  sensitivity.  This  may  have 
beneficial functional effects for patients; it would be interesting to examine reading 
speed, contrast sensitivity and functional measures other than the fovea-dominated 
measure of high contrast sensitivity. A previous report investigating the relationship 
between retinal sensitivity and thickness in 11 subjects found a change of 0.05 dB for 
every 1 µm increase in thickness over 280 µm, but with a wide confidence interval 
[186]. This relationship is in the same order of magnitude as that found in the current 
study. 
 
Although statistical analysis shows a significant correlation is present, inspection of 
the scatter plot shows that there is still a wide range of retinal sensitivity associated 
with  a  particular  thickness,  so  results  should  be  interpreted  with  caution.  While 
correlation between thickness and sensitivity may be important, other morphological 
changes present on OCT, such as interruptions in the ELM and IS-OS junction lines 
may have measurable effects on point sensitivity. Further study to identify those 
structures present on OCT that are indicative of functional loss should be undertaken. 
This may in turn have predictive value in terms of response to ranibizumab or other 
treatments. 157 
 
2.4.6  Repeatability study 
Change in OCT based macular thickness measurement is used as one of the criteria 
for retreatment in eyes with DMO both in clinical practice and in clinical trials [73, 
81, 84, 85]. While laser treatment is typically performed based on the detection of 
clinically  significant  macular  oedema  on  slit-lamp  examination,  the  advent  of 
pharmacological  treatments  for  DMO  means  that  quantitative  measures  are  now 
employed to guide enrolment and retreatment decisions; an approach followed in this 
trial. It is therefore important to establish the repeatability of OCT-derived macular 
thickness  measurements,  as  a  knowledge  of  repeatability  would  better  allow 
physicians to identify true clinical change from measurement variability.  
 
Spectral domain (SD) OCT technology has resulted in faster image acquisition time 
and higher resolution images compared to older time domain (TD) technology. The 
Spectralis  OCT  combines  SD  OCT  technology  with  eye  tracking  and  line  scan 
averaging to improve the signal-to-noise ratio, potentially enhancing the ability of 
segmentation algorithms to detect the true inner and outer retinal boundaries. Data 
presented  from  this  exploratory  study  represents  the  first  report  evaluating  the 
repeatability of retinal thickness and volume measurements from the Spectralis OCT 
in eyes with DMO. Previous studies of repeatability in macular disease have yielded 
poorer repeatability estimates (higher CR values) than the current study (see Table 
20).  Evaluation  of  repeatability  in  neovascular  age-related  macular  degeneration 
using Zeiss Stratus TD OCT has estimated CR for the central macular subfield at 
67µm,  representing  23%  of  the  total  macular  thickness  [100].  The  Diabetic 
Retinopathy Clinical Research Network (DRCR.net) study examining subjects with 
DME using the Zeiss OCT-3 machine reported the half-width of the 95% confidence 
interval for change (equivalent to the Bland Altman CR) to be 38μm[166]. 
 
Evaluation of SD OCT devices has yielded similar results. The Cirrus SD OCT was 
found to have a coefficient of repeatability of 42.4 µm in the central subfield for 
subjects with neovascular AMD [187], which improved to 26.1 µm once scans with 
segmentation error had been removed. In DME, no significant difference was found 
between TD and SD devices in two separate studies [167, 168]. Although this study 
was not designed to compare the SPECTRALIS™ OCT directly with a TD device, 158 
 
the estimates obtained for CR are an order of magnitude better than those previously 
reported in TD devices and in the SD devices that have been used in comparative 
studies.  
 
Study  Disease  Sample 
Size 
(eyes) 
Device  Central  (A1) 
Subfield 
Coefficient  of 
Repeatability 
Massin  et  al. 
(2001) [165] 
DME  10  TD (Humphrey OCT)  <21 µm* 
Krzystolik et al. for 
the  DRCR.net 
[166] 
DME  212†  TD (Zeiss OCT3)  38 µm 
Patel et al. [100]  nvAMD  51   TD (Stratus OCT)  67 µm  
 
Forooghian  et  al. 
[167] 
 
DME 
 
33 
TD (Stratus OCT) 
 
SD (Cirrus HD-OCT) 
17.9 µm 
 
19.0 µm  
 
Domalpally  et  al. 
[168] 
 
DME 
 
63 
TD (Stratus OCT) 
 
SD  (Topcon  3D  OCT 
1000) 
27.4 µm 
 
20.1 µm  
Parravano  et  al. 
[187] 
nvAMD  49  SD (Cirrus HD-OCT)  42.4 µm  
 
Table 20 – Summary of previous studies reporting coefficients of repeatability in 
macular disease using both TD and SD OCT devices.  All TD studies used the 6 
radial line scan protocol (6mm length) (termed “Fast Macular Thickness Map” by 
Zeiss) and SD studies used the 128 horizontal line protocol (512 A scans per line; 
6mm x 6mm). *exact figure not reported. †107 patients. 
 
Retinal  boundary  segmentation  error  has  been  shown  to  have  an  impact  on  the 
repeatability of retinal thickness measurements in neovascular AMD [100]. In this 
sub-study, coefficients of repeatability improved when scans affected by significant 
retinal boundary detection error were excluded. This suggests that when interpreting 
OCT scans, caution should be exercised in using automated retinal thickness values 
if segmentation error has occurred. Although a 1 mm length of scan was chosen to 
identify  misplacement  of  retinal  boundaries,  there  is  no  accepted  definition  for 
segmentation error and defining this differently could have led to different results. It 
was more common to find vitreomacular interface abnormalities in subjects whose 
scans were affected by segmentation error, and this may be an important cause for 
failure of the OCT algorithm to correctly place retinal boundaries. 
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Strengths of this repeatability study include the sample size and number of repeated 
measurements which ensure that the study is powered to estimate Sw to within 11% 
of  the  true  population  value  [179].  Choosing  to  run  this  study  in  parallel  to 
recruitment for a clinical trial is a potential weakness, however, as subjects may be 
more  carefully  selected  and  less  indicative  of  the  range  of  pathology  present  in 
general clinics. 
 
Diurnal variation has been proposed as a cause for variability in macular thickness 
measurements.  Studies  utilising  TD  OCT  devices  have  demonstrated  diurnal 
variation  in  macular  thickness  in  subjects  with  DMO,  with  retinal  thickness 
decreasing throughout the day. Estimates for this change range from 13 µm [188] to 
49 µm [189] in the central subfield. This has previously been of limited clinical 
relevance  as  the  magnitude  of  this  change  is  similar  to  the  inherent  test-retest 
variability of TD OCT devices reported in Table 20. This study with the Spectralis 
OCT found a smaller CR than the estimated diurnal variation previously reported. 
This suggests that this phenomenon may be clinically important given the greater 
precision of measurements taken with this device. 
 
In summary, this study shows that using the Spectralis OCT, it is possible to obtain 
retinal scans with excellent intra-session repeatability in eyes with DMO. The results 
suggest that a retinal thickness change of greater than 8 microns in the central 1mm 
subfield is more indicative of clinical change rather than measurement variability. 
The results of this study may be used to design retreatment criteria in clinical trials. 
In clinical practice, the results can be used to distinguish true clinical change from 
measurement variability. 
 
 
2.5  Conclusions 
The  aim  of  the  LUCIDATE  study  was  to  evaluate  the  effect  of  ranibizumab  on 
parameters of retinal function in order to establish whether there was evidence of 
worsening  macular  ischaemia  or  global  retinal  dysfunction,  compared  with  laser 
treatment. Secondary objectives were to investigate the effect of ranibizumab and 
laser  treatment  on  choroidal  thickness  in  DMO,  to  investigate  the  correlation  of 160 
 
microperimetric  retinal  sensitivity  with  retinal  thickness,  and  to  study  the 
repeatability of retinal thickness and volume measurements with Spectralis OCT in 
this condition. 
 
The  study  has  demonstrated  in  the  modalities  of  visual  acuity,  colour  contrast 
sensitivity,  microperimetric  retinal  sensitivity  and  pattern  electroretinogram  that 
there is some evidence of benefit from ranibizumab compared to laser, but results did 
not reach statistical significance. 
 
For grading of macular ischaemia from fluorescein angiography and evaluation of 
global retinal dysfunction from full-field electroretinograms, there is no evidence 
that ranibizumab treatment leads to a worsening of these parameters. 
 
Exploratory  post-hoc  analyses  report  no  change  in  choroidal  thickness  following 
ranibizumab or laser treatment in this condition, in contrast to some recent reports 
suggesting an effect of anti-VEGF agents on this parameter.  
 
The Spectralis OCT device has been shown to yield highly repeatable measures of 
retinal  thickness  and  volume  in  DMO,  which  improve  when  scans  with  retinal 
boundary detection error are excluded. 
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3 The RaDiVit
* Study 
This chapter reports a randomised controlled trial designed to investigate the impact 
of ranibizumab pre-treatment on diabetic vitrectomy surgery. 
 
*RaDiVit – Ranibizumab in Diabetic Vitrectomy 
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3.1  Background 
 
Treatment  for  proliferative  retinopathy  is  directed  at  reducing  or  removing  the 
molecular signals that lead to the growth of new vessels: neovascularisation. This is 
typically achieved by panretinal laser photocoagulation but uncontrolled proliferative 
disease may require surgery to clear fibrovascular tissue and prevent the sequelae of 
vitreous haemorrhage and tractional retinal detachment. When the typical results of 
surgery for retinopathy are examined it is seen that significant numbers of patients 
have  poor  outcomes  and  complications.  As  discussed  in  Chapter  1,  vascular 
endothelial  growth  factor  (VEGF)  is  strongly  implicated  in  the  pathogenesis  of 
proliferative retinopathy: injecting VEGF into primate eyes causes retinopathy [28], 
levels of VEGF correlate with severity of retinopathy [25] and blocking VEGF leads 
to  regression  of  iris  neovascularisation  in  the  primate  eye  [27].  VEGF  blockade 
might therefore have a role as a treatment modality to improve the results of surgery 
for proliferative diabetic retinopathy. 
 
3.1.1  Outcomes of surgery for proliferative diabetic retinopathy 
The  Diabetic  Retinopathy  Vitrectomy  Study  established  the  benefit  of  early 
vitrectomy for vitreous haemorrhage that had persisted for at least one month. In the 
early surgery group, 25% had visual acuity of 10/20 (equivalent to 6/12) or better at 
2 year follow-up, compared to 15% in the group where surgery was deferred for a 
year [92]. A further investigation by the same study group showed that surgery was 
beneficial for patients with severe active fibrovascular proliferation, with 6/12 visual 
acuity achieved by 44% of the group receiving early vitrectomy compared to 28% 
managed  by  observation  and  laser,  with  vitrectomy  only  performed  for  severe 
complications [190]. These findings in the 1980s continue to drive surgical decision 
making for advanced proliferative diabetic retinopathy, as shown by a prospective 
study of 174 vitrectomy procedures in diabetic patients at a single institution [93]. 
This study showed that the most common indication for surgery (43% of eyes) was 
non-clearing vitreous haemorrhage, with the next most common (32.8%) tractional 
retinal detachment (TRD) involving the macula. Results were good in terms of visual 163 
 
acuity, with approximately 29% of eyes achieving 6/15 or better visual acuity, which 
is comparable with the results of the DRVS. The proportion of patients with very 
poor  visual  outcomes  also  appears  to  have  reduced:  only  1.8%  of  eyes  in  the 
Moorfields study had no light perception at final follow-up while in the DRVS this 
could be as high as 25% (although differences in laser management at the time of the 
earlier  study  make  direct  comparison  difficult).  Visual  improvement  following 
diabetic vitrectomy can be expected in approximately 75% of eyes treated with only 
9% worsening significantly. 
 
One of the most common complications that can occur following diabetic vitrectomy 
is post-operative vitreous cavity haemorrhage (POVCH), with the Moorfields study 
reporting an incidence of 22%, although other studies have reported a range of 5-
80%  (see  [191]).  This  can  occur  in  the  early  post-operative  period  or  late  (2-6 
months) and if persistent can result in the need for further surgery. By impairing the 
view of the retina, it also makes further treatment of diabetic retinopathy difficult and 
can lead to raised intraocular pressure as the haemorrhage is reabsorbed. It occurs 
through  a  variety  of  mechanisms  including  clot  breakdown  and  entry  site 
neovascularisation. The additional visual disability and necessity for further surgical 
procedures are inconvenient for patients and physicians. Any intervention that could 
reduce the incidence of this complication would therefore be welcomed. 
 
3.1.2  Anti-vascular  endothelial  growth  factor  agents  as  adjuncts  to 
diabetic vitrectomy surgery 
Post-operative  vitreous  cavity  haemorrhage  may  occur  because  of  persistent 
neovascularisation, e.g. at surgical entry sites, but also on the retina; and advanced 
fibrovascular proliferation makes surgery difficult and is a recognised predictor of 
poor visual outcome [94]. An intervention to inhibit neovascularisation and reduce 
vascularity  of  fibrovascular  membranes  could  therefore  reduce  post-operative 
complications and make surgery technically easier. Pre-operative therapy with anti-
VEGF  agents  potentially  would  have  this  beneficial  effect  on  new  vessel 
proliferation  through  anti-angiogenic  action  and  so  warrants  investigation  to 164 
 
establish whether it is a useful therapeutic strategy both to facilitate safe surgery and 
reduce the incidence of POVCH.  
 
Numerous  case  reports  and  retrospective  series  have  reported  the  effects  of 
bevacizumab pre-treatment on diabetic vitrectomy surgery leading to the exploration 
of its impact in clinical trials. Because there has been no clear consensus on the 
clinical  question  requiring  an  answer,  the  trials  have  significant  methodological 
differences  and  heterogeneous  outcome  measures,  making  direct  comparison 
between them difficult. Ranibizumab has been little used apart from a single report in 
a randomised study investigating its impact on intra-operative haemorrhage. 
3.1.2.1  Bevacizumab 
Case reports and small series investigating bevacizumab use illustrate the potential 
benefit of the drug but also highlight a safety concern. Chen and Park reported the 
first use of pre-operative bevacizumab in a patient undergoing diabetic vitrectomy, 
noticing a regression of vascular tissue anterior to the retina with an apparent switch 
to fibrosis facilitating surgery after a single injection [192]. In 18 eyes with PDR 
undergoing diabetic vitrectomy pre-operative bevacizumab “improved the ease of 
surgery” as dissection of fibrovascular membranes with regressed neovascularisation 
was technically easier; but no effect on visual acuity was found [193]. 
 
The  rapid  induction  of  fibrosis  by  regression  of  new  vessels  in  fibrovascular 
membranes  as  a  result  of  bevacizumab  therapy  could  potentially  exacerbate  pre-
existing TRD and may worsen the clinical situation. Ishikawa et al. reported that in 
eyes that had received bevacizumab with a longer interval between injection and 
surgery, strong fibrosis and adhesions could be present that did not occur in cases 
where the interval between injection and surgery had been shorter [108]. In 11/211 
eyes that had received bevacizumab prior to diabetic vitrectomy in another study, 
tractional retinal detachment (TRD) developed or existing TRD progressed [107]. 
However,  conclusions  from  these  uncontrolled,  retrospective  studies  should  be 
interpreted with caution and do not provide definitive evidence that pre-treatment 
with bevacizumab worsens outcomes. 
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A  number  of  randomised  controlled  trials  have  reported  the  outcomes  of  pre-
operative  bevacizumab,  but  differences  in  methodology  make  direct  comparison 
between  them  difficult.  Two  early  trials  report  a  potentially  beneficial  effect  on 
duration and difficulty of surgery: 
Rizzo et al. randomised 22 patients with either tractional or combined tractional-
rhegmatogenous retinal detachments to bevacizumab one week before surgery or no 
intervention [194]. Their main outcome measure was “feasibility of surgery” with 
visual  acuity  and  anatomical  outcomes  at  6  months  secondary  outcomes.  They 
showed that in patients who had received bevacizumab, surgery was typically shorter 
at 57 vs. 83 minutes, with fewer tool exchanges (27 vs. 53) and a tendency to carry 
out blunt membrane dissection more frequently than sharp dissection. There were no 
differences in visual acuity or retinal reattachment rate. This study was unmasked, 
does not describe the generation of the random number sequence used, and does not 
report methods of allocation concealment so it is not possible to exclude bias. These 
investigators  did,  however,  recognise  the  potential  impact  of  case  complexity  on 
their  results,  so  they  compared  surgical  outcome  between  the  groups  using  a 
previously reported complexity score [195]. 
 
Modarres  et  al.  report  a  randomised  controlled  trial  of  40  patients  receiving 
intravitreal bevacizumab 3-5 days prior to surgery, again with surgical metrics and 
visual acuity as outcome measures [196]. In this study, surgeons were masked to 
treatment  allocation  but  the  method  of  randomisation  is  not  reported  by  the 
investigators. A total of 22 patients received bevacizumab and 18 formed the control 
group. There was no difference in visual acuity between the groups at 3 months, but 
all seven post-operative vitreous cavity haemorrhages occurred in the group that had 
not received bevacizumab. The investigators also report a shorter duration of surgery 
(62 vs. 95.5 minutes) and fewer uses of endodiathermy or the backflush cannula as 
surrogate measures of reduced intraoperative bleeding. 
 
A further study by di Lauro et al. of 72 eyes randomised to sham or bevacizumab 
either  7  or  20  days  before  surgery  adds  to  the  evidence  that  surgery  may  be 
technically  easier  with  pre-operative  bevacizumab:  surgical  time,  endodiathermy, 
intraoperative bleeding and iatrogenic breaks were all reduced in the bevacizumab 
group [105]. The investigators also report a reduced incidence of POVCH in the 166 
 
bevacizumab  groups,  but  lack  of  surgeon  masking  to  treatment  allocation  again 
introduces the possibility of bias. 
 
The randomised controlled trial least at risk of bias investigating bevacizumab for 
this  indication  was  carried  out  by  Ahmadieh  et  al.  who  randomised  68  eyes 
undergoing diabetic vitrectomy surgery to either intravitreal bevacizumab or sham 
[197]. This study includes both patient and investigator masking, uses a valid method 
of randomisation (random permuted block method) and reports on the outcomes of 
all  participants.  Some  subjects  experienced  clearing  of  vitreous  haemorrhage 
between injection and planned date of surgery, obviating the need for vitrectomy; but 
in  the  group  that  did  undergo  surgery,  the  investigators  report  a  statistically 
significant improvement in visual acuity and reduction in POVCH for those that had 
received bevacizumab. 
 
A  systematic  review  by  Zhao  et  al.  of  intravitreal  bevacizumab  in  diabetic 
vitrectomy has attempted to bring together the disparate outcome measures used in 
the trials described above and carry out a meta-analysis [198]. Based on the results of 
six randomised trials and one non-randomised study, the meta-analysis showed a 
modest  beneficial  effect  for  bevacizumab  on  surgical  parameters:  intraoperative 
bleeding, frequency of endodiathermy, number of iatrogenic retinal tears and mean 
surgical  time  all  favoured  bevacizumab  administration.  Post-operatively,  blood 
resorption time and recurrent vitreous haemorrhage were reduced and visual acuity 
was slightly better with bevacizumab. However, these results need to be interpreted 
with caution as not all studies were included in every comparison due to differences 
in reporting outcomes, and numbers involved in some comparisons were small.  
 
A Cochrane review has analysed the impact of bevacizumab pre-treatment on post-
operative vitreous cavity haemorrhage [191]. This review only included four trials 
[105, 194, 196, 197] and found a number of methodological flaws leading to risk of 
bias in all but Ahmadieh’s trial report, and did not conduct a meta-analysis due to 
these methodological issues. The review does comment however, that three trials 
report reduced incidence of POVCH.  167 
 
3.1.2.2  Ranibizumab 
Ranibizumab has not so far been evaluated for use in diabetic vitrectomy, except for 
one small randomised study that investigated intra-operative bleeding following an 
injection of the drug one week previously [199]. The study included 19 patients and 
collected  a  fluid  sample  from  the  vitrectomy  surgical  cassette  which  was  then 
subjected to haemocytometry. The overall cell counts ranged in number over several 
orders  of  magnitude  but  a  small  reduction  in  intraoperative  haemorrhage  was 
reported with prior ranibizumab. The methodology used in this study was previously 
described  by  the  same  investigators  in  an  investigation  into  the  effect  of 
bevacizumab on this outcome, which also showed a small reduction in erythrocyte 
count in the surgical fluid of patients in the treatment group [106]. The studies did 
not evaluate any clinical outcomes such as visual acuity or POVCH. 
 
3.1.3  Cytokines in the vitreous of patients with  advanced proliferative 
diabetic retinopathy 
Chapter  1  described  the  importance  of  VEGF  in  the  pathogenesis  of  diabetic 
retinopathy, including how hypoxia sensing leads to the transcription of a number of 
genes and a cascade of cytokine production including VEGF and pro-inflammatory 
cytokines.  Levels  of  VEGF  are  elevated  in  diabetic  vitreous,  but  with  complex 
pathways implicated in  the pathophysiology of retinopathy, it is likely  that other 
cytokines  will  have  altered  levels  and  be  involved  in  the  generation  of 
neovascularisation  and  increase  in  vascular  permeability.  The  cytokine  profile  in 
diabetic vitreous might then be altered by anti-VEGF therapy in ways not limited to a 
reduction in VEGF itself. 
3.1.3.1  Cytokine changes in proliferative diabetic retinopathy 
The  cytokines  interleukin  (IL)  6  and  IL-8  are  associated  with  macrophage  and 
neutrophil  activation,  form  part  of  the  inflammatory  cascade  and  have  been 
repeatedly shown to be elevated in diabetic retinopathy. Yuuki et al. showed that 
elevated levels of both cytokines were found in the vitreous from diabetic subjects 
with proliferative retinopathy  compared with non-diabetic controls [200] and other 168 
 
investigators have corroborated this finding. Nakamura showed elevated levels of IL-
6 in conjunction with increased levels of advanced glycation end products (AGEs) 
[201] and Petrovic et al. showed elevated levels of IL-8 in the vitreous from 71 eyes 
with proliferative retinopathy [202]. Arjamaa et al. hypothesised that as IL-6 is able 
to  induce VEGF expression, its levels  may be  related to  upregulation  of HIF-1α 
following hypoxia sensing. They found that IL-6 levels correlated with degree of 
neovascular activity and also with IL-8 levels, but did not find an alteration in HIF-
1α expression [203].  
 
The  chemokines  monocyte  chemoattractant  protein-1  (MCP-1)  and  interferon-γ 
inducible protein of 10 KDa (IP-10) are involved in attracting monocytes and T-cells 
respectively to sites of inflammation. Abu El-Asrar et al. found that vitreous levels 
of these two signalling molecules were elevated in proliferative diabetic retinopathy 
[204]. These mediators have been shown to play a role in angiogenesis and fibrosis 
and results from the investigations described above suggest that local production is 
responsible for elevated levels as a corresponding rise in serum levels of cytokines 
has not been demonstrated. 
 
Cytometric bead analysis allows the evaluation of concentrations of a number of 
cytokines  simultaneously.  Lange  et  al.  investigated cytokine concentrations  using 
this technique in diabetic vitreous in conjunction with measuring vitreous oxygen 
tension, and found elevated levels of IL-6 and IL-8 in addition to IP-10 and VEGF, 
confirming  some  of  the  findings  described  above  [205].  They  also  found  raised 
levels of the cellular proliferation cytokine Flt-3 ligand and the anti-inflammatory T 
helper cell 2 cytokine IL-9, suggesting that a delicate balance between pro- and anti-
inflammatory messengers exists in this condition.  
 
In summary, more than one group of investigators have shown elevated levels of IL-
6, IL-8, IP-10 and MCP-1 in proliferative diabetic retinopathy. These cytokines are 
linked  to  angiogenesis  and  fibrosis  but  how  they  are  regulated  with  respect  to 
hypoxia sensing and the signals leading from ischaemia to their up-regulation have 
not been fully defined. 
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3.1.3.2  Effects of anti-VEGF treatment on the cytokine profile in proliferative diabetic 
retinopathy 
Bevacizumab has been preferred to ranibizumab in investigations to date that have 
investigated the cytokine profile in diabetic retinopathy after VEGF inhibition, but a 
number of studies  have shown that it reduces  the concentration of VEGF in  the 
vitreous  at  different  time  intervals  following  injection.  For  example,  Ma  et  al. 
showed  that  VEGF  was  elevated  in  diabetic  vitreous  but  the  concentration  was 
significantly  reduced  after  bevacizumab  injection  [206].  This  reduction  in 
concentration was apparent even in subjects who had received bevacizumab a mean 
of 34 days before sampling, but VEGF levels were not as low following treatment as 
in  subjects  without  neovascular  pathology.  Additionally,  plasma  levels  of  VEGF 
were significantly reduced following bevacizumab administration. 
 
While reduced VEGF levels following bevacizumab injection have been confirmed 
by the findings  of other investigators, there is  limited and sometimes conflicting 
information  regarding  changes  to  other  vitreous  cytokines  following  VEGF 
inhibition. Arimura et al. found reduced VEGF and SDF(stromal cell derived factor)-
1α after bevacizumab injection but no change in other cytokines, particular IL-6 and 
8 [207]. Jeon and colleagues did find significantly elevated  levels of IL-6 and 8 one 
day after bevacizumab therapy [208], but it is possible that the injection procedure 
itself could raise the levels of these pro-inflammatory cytokines in the short term as 
part of a wound healing response. Connective tissue growth factor (CTGF) levels 
increased after bevacizumab injection and correlated with increased retinal fibrosis 
detected clinically in one investigation [209], but although Sohn et al. also observed 
a clinical increase in fibrosis, they did not find a significant change in CTGF levels 
[210].  
 
Evidence  therefore  validates  the  expected  action  of  bevacizumab  in  substantially 
reducing levels of VEGF in the vitreous of subjects with diabetic retinopathy, but no 
convincing  picture  emerges  of  its  effects  on  other  pro-  and  anti-angiogenic  or 
inflammatory cytokines. Ranibizumab has not been investigated in this setting, so 
new  data  may  add  to  the  understanding  of  the  pathophysiology  of  diabetic 
retinopathy and the wider effects of VEGF inhibition in this condition. 170 
 
3.1.4  Aims and objectives of the study 
Trials that have evaluated anti-VEGF agents have been of variable quality and many 
suffer from methodological flaws in the method of randomisation or masking. Most 
have  investigated  bevacizumab  owing  to  its  reduced  price  compared  with 
ranibizumab or pegaptanib, but one study of intraoperative haemorrhage investigated 
ranibizumab. Different outcome measures have been chosen; typically either surgical 
metrics  such  as  duration  or  ease  of  surgery,  or  incidence  of  post-operative 
haemorrhage. Reviews of the trials carried out have suggested that there may be a 
benefit  for pre-operative bevacizumab on these outcomes.  However, amongst  the 
vitreoretinal surgical community there is still lack of agreement over whether anti-
VEGF agents are beneficial in this condition. 
 
The aims of the trial reported in Chapter 3 are: 
-  To investigate the effect  of ranibizumab pre-treatment  on visual  acuity at 
three  months  following  vitrectomy  surgery  for  advanced  proliferative 
retinopathy 
-  To investigate the effect of ranibizumab on intra-operative and post-operative 
vitreous haemorrhage 
-  To  investigate  the  degree  to  which  ranibizumab  facilitates  vitreoretinal 
surgery in this condition 
-  To investigate the safety of giving ranibizumab prior to surgery in terms of its 
effect on pre-existing tractional retinal detachment 
-  To investigate changes in the vitreous cytokine profile following ranibizumab 
treatment. 
 
A  trial  to  provide  answers  to  these  clinical  questions  is  likely  to  require  large 
numbers of patients, so a pilot study to determine the feasibility of such a trial and 
carry  out  a  power  calculation  to  estimate  the  numbers  required  is  therefore  an 
appropriate first step. 
 
Previous trials conducted in this area have sometimes reported the results from a 
single surgeon and in other cases multiple surgeons have been used. While surgical 
skill remains a parameter that is difficult to quantify, the disadvantage of a single-171 
 
surgeon  trial  is  that  results  may  not  be  generalisable  to  the  wider  surgical 
community.  Therefore  this  trial  will  feature  multiple  surgeons,  but  through 
randomisation and masking will attempt to address this potential confounding factor. 
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3.2  Methods 
The  RaDiVit  study  (Ranibizumab  in  Diabetic  Vitrectomy)  was  a  pilot  study  to 
investigate the impact of ranibizumab pre-treatment on vitrectomy surgery for the 
complications of proliferative diabetic retinopathy. 
 
As a pilot study, there was no formal hypothesis to be tested, but the null hypothesis 
for a definitive study would be that ranibizumab pre-treatment has no effect on visual 
acuity when given prior to vitreoretinal surgery for advanced proliferative diabetic 
retinopathy. 
3.2.1  Design, approval and participants 
This  trial  was  a  single  centre,  parallel  group;  phase  II  pilot  study  with  1:1 
randomisation, featuring masking of patients, surgeons and investigators, conducted 
at Moorfields Eye Hospital, a tertiary referral centre for vitreoretinal surgery. 
 
The study conformed to the Declaration of Helsinki and prospective approval was 
sought from the Central London Research Ethics Committee 1 of the UK National 
Research Ethics Service prior to commencing recruitment.  The trial was registered 
at  www.clinicaltrials.gov  (NCT01306981).  A  clinical  trial  authorisation  was 
obtained from the MHRA before recruitment commenced. 
 
Adults  aged  18  or  over  with  complications  of  proliferative  diabetic  retinopathy 
requiring  vitrectomy  surgery  with  anticipated  delamination  of  fibrovascular 
complexes were identified from vitreoretinal clinics at Moorfields Eye Hospital at 
the time they were listed for surgery. Subjects were required to have fibrovascular 
tissue proliferating from the retina in more than one location, as it is in this subset of 
patients  that  troublesome  intra-operative  and  post-operative  bleeding  can  occur. 
Subjects  with  a  vitreous  haemorrhage  arising  from  a  presumed  single  point  of 
traction are likely to have excellent outcomes from surgery and do not represent a 
group of patients where anti-VEGF use would typically be considered.  
3.2.2  Patient eligibility 
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Inclusion criteria 
1.  Patients  of  either  sex  aged  18  years  or  over  able  to  give  informed  consent 
throughout  the  study  and  return  for  study  visits  up  to  12  weeks  following 
surgery 
2.  Diagnosis of diabetes mellitus (type 1 or type 2) 
3.  Proliferative diabetic retinopathy in the study eye, with complications of this 
requiring  vitrectomy  surgery  with  anticipated  delamination  of  pre-retinal 
fibrovascular complexes 
 
Exclusion criteria (ocular criteria applied to study eye only) 
1.  Vitreous haemorrhage presumed to be caused by vitreous traction on a single, 
focal point of vitreoretinal attachment 
2.  Cataract that, in the opinion of the investigators, would be significant enough to 
impair the view during surgery; or planned combined cataract and vitrectomy  
3.  Previous vitrectomy on study eye 
4.  Uncontrolled glaucoma  
5.  Active or suspected ocular or periocular infections. 
6.  Active severe intraocular inflammation 
7.  Vision in fellow eye 3/60 or worse  
8.  Hypersensitivity to the active substance or to any of the excipients. 
9.  History of stroke, peripheral vascular disease, angina or myocardial infarction 
within six months prior to randomisation 
10.  Systemic  anti-VEGF  or  pro-VEGF  treatment  within  3  months  prior  to 
randomisation 
11.  Pregnancy or lactation 
12.  Fertile male or female unwilling to use contraception 
3.2.3  Sample size 
A sample size of 30 was deemed adequate to determine the feasibility and enable 
calculation of sample size for a subsequent definitive trial. Descriptive statistics only 
are presented for this pilot randomised clinical trial. 174 
 
3.2.4  Randomisation 
One eye per participant was included in the study to guard against the impact of 
adverse events from exposure of both eyes to the investigational medicinal product. 
If both eyes were eligible, the eye with the clinical priority for surgery was included. 
Randomisation was stratified according to anticipated surgical complexity score as 
described  by  Castellarin  et  al.  [195].  One  point  is  scored  for  each  quadrant  of 
fibrovascular proliferation (FVP), one point for FVP both anterior and posterior to 
the  equator,  one  point  for  tractional  retinal  detachment,  one  point  for 
rhegmatogenous  detachment  and  a  final  point  for  absence  of  posterior  vitreous 
detachment.  The  score  was  determined  pre-operatively  based  on  the  ultrasound 
findings. Scores of 5 and below were deemed low complexity; 6 and above high 
complexity, based on the finding of a mean complexity score of 5.5 by Rizzo et al. 
[194]. Subjects  were randomised 1:1  to  the ranibizumab group or control  group, 
using random permuted blocks of varying sizes, with two separate randomisation 
lists  generated  by  a  statistician.  The  allocation  sequence  was  held  by  the  trial 
statistician and concealed from the researcher enrolling and assessing participants. 
3.2.5  Masking 
The  patients,  investigators  and  operating  surgeons  were  all  masked  to  treatment 
allocation.  Trial  injections  were  administered  by  an  unmasked  investigator 
experienced in the delivery of intravitreal injections who had no further contact with 
the trial subject. 
3.2.6  Intervention 
Subjects  received  their  allocated  intervention  at  7  days  ±1  day  prior  to  surgery. 
Subjects in the ranibizumab arm received an intravitreal injection of ranibizumab 
(Lucentis®, 0.5 mg in 0.05 ml solution for injection, Novartis Pharmaceuticals UK 
Ltd),  while  subjects  in  the  control  arm  received  a  subconjunctival  injection  of 
sodium chloride, 0.05ml of 0.9% solution for injection. Subjects in both groups were 
prepared  identically  with  topical  anaesthetic  and  povidone  iodine;  they  received 
topical levofloxacin immediately before and after the injection and four times daily 
for four days after. Injections were administered using a 1ml syringe and 30-gauge 175 
 
needle by the unmasked investigator.  
3.2.7  Surgery  
Pars  plana  vitrectomy  was  carried  out  by  a  number  of  consultant  vitreoretinal 
surgeons experienced in diabetic vitrectomy surgery, using 20-gauge instruments. A 
sample of venous blood and up to 1 ml of undiluted vitreous was obtained at the 
beginning  of  surgery.  All  surgeons  used  a  similar  technique  of  core  vitrectomy 
followed by en-bloc delamination of fibrovascular membranes, control of bleeding 
by infusion pressure and endodiathermy. Retinal breaks were treated with endolaser 
and a suitable tamponnade agent was selected by the surgeon. All patients received 
additional endolaser panretinal photocoagulation. Vitrectomy duration was recorded 
from  initial  light  pipe  insertion  to  final  removal  after  completion  of  laser. 
Additionally  recorded  were  the  number  of  backflush  cannula  applications, 
endodiathermy usage, anterior and posterior iatrogenic retinal breaks, intraoperative 
bleeding score (0-none;  1-mild,  stopped by bottle elevation;  2-moderate, forming 
clots or persistent; 3-severe, covering half of posterior pole) and surgeon-derived 
complexity score as described above (from Castellarin et al.) to allow validation of 
the ultrasound derived complexity score. 
3.2.8  Follow-up visits and investigations 
All subjects attended at baseline, 1 week later for surgery, then 6 and 12 weeks post-
operatively. 
 
At all visits subjects underwent refracted best-corrected Early Treatment Diabetic 
Retinopathy  Study  (ETDRS)  visual  acuity  and  a  full  ophthalmic  examination 
including relative afferent pupillary defect (RAPD) check and intraocular pressure 
(IOP)  measurement.  At  baseline  and  on  the  day  of  surgery  subjects  underwent 
standardised ophthalmic ultrasound by one of two operators masked to treatment 
allocation. Scans were obtained using an Acuson Sequoia 512 scanner with a 14 
MHz linear probe (Siemens Medical Solutions USA; Mountain View, CA, USA). 
Ultrasound  was  used  to  determine  the  extent  and  location  of  fibrovascular 
proliferation, the presence of tractional or rhegmatogenous retinal detachment with 
measurement of height and base dimensions where appropriate. At baseline and 12 176 
 
weeks  post-operatively,  blood  pressure  and  HbA1c  were  recorded  and  subjects 
underwent colour fundus photography and fluorescein angiography when this was 
not precluded by vitreous haemorrhage. ETDRS visual acuity, fundus photography 
and fluorescein angiography were carried according to the standardised protocols 
described in Chapter 2. 
3.2.9  Treatment of vitreous and plasma samples  
Vitreous  samples  collected  at  the  commencement  of  vitrectomy  surgery  were 
immediately  placed  into  EDTA-coated  Eppendorf  tubes  and  kept  on  ice.  At  the 
earliest opportunity, the vitreous sample was centrifuged at 400g (2200 RPM) for 5 
minutes at 4°C and divided into 110 µl aliquots in further EDTA-coated Eppendorf 
tubes and frozen at -80°C. Venous blood samples were collected using a standard 
EDTA-coated Vacutainer tube and immediately placed on ice. Blood was spun at 
1500g (5000 RPM) for 10 minutes at 4°C and divided into 200 µl aliquots in plain 
Eppendorf tubes before being frozen at -80°C. 
 
In addition to the 30 pairs of samples obtained during the trial a further 7 pairs of 
vitreous and plasma samples from non-diabetic control subjects were available for 
analysis.  These  had  been  obtained  previously  when  the  subjects  had  undergone 
vitrectomy for other indications (e.g. macular hole, epiretinal membrane). Samples 
had been treated in a similar way to the present samples. 
3.2.10 Multiplex cytokine analysis 
Vitreous and plasma samples were subjected to multiplex bead analysis for detection 
of  cytokines  as  described  by  Groer  et  al.  [211].  Samples  were  analysed  using  a 
Milliplex 39 cytokine kit (catalogue number MPXHCYTO60-(KPMX39), Millipore 
UK Ltd, Oxford, UK) testing for the following cytokines: endothelial growth factor 
(EGF), eotaxin, fibroblast growth factor 2 (FGF-2), Flt-3 ligand (Flt-3L), fractalkine, 
granulocyte  colony-stimulating  factor  (G-CSF),  granulocyte-macrophage  colony 
stimulating factor (GM-CSF), growth-related oncogene (GRO), interferon (IFN)-α2, 
IFN-γ, interleukin (IL)-1α, IL-1β, IL-1Rα, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, 
IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IFN-inducible protein-10 
(IP-10), monocyte chemoattractant protein (MCP)-1, MCP-3, macrophage-derived 177 
 
cytokine  (MDC),  macrophage  inflammatory  protein  (MIP)-1α,  MIP-1β,  sCD40L, 
sIL-2Rα,  transforming  growth  factor  (TGF)-α,  tumour  necrosis  factor  (TNF)-α, 
TNF-β, and VEGF. 
 
Samples were tested at the laboratories of Millipore U.K. (Oxford, U.K.) using a 
Luminex analyser as described by Lange et al. [205]. Cytokine concentrations in this 
method were determined by comparing to standard curves prepared on the same plate 
and run in parallel to quality control samples. Cytokines not meeting the calibration 
standard  were  excluded  from  the  analysis  and  samples  where  the  coefficient  of 
variation (CV) between samples exceeded 30% were also excluded. 
3.2.11 Investigation of intraoperative bleeding 
Quantification  of  intraoperative  haemorrhage  was  undertaken  by  recording  a 
subjective score from the operating surgeon in addition to microscopic evaluation of 
surgical irrigation fluid. The contents of the vitrectomy surgical cassette at the end of 
surgery  were  collected  and  subjected  to  haemocytometry.  This  cassette  collects 
aspirated fluid during surgery and contains irrigation fluid with blood cells released 
from intraoperative haemorrhage. Additionally it contains the vitreous contents with 
any pre-existing haemorrhage removed during the initial vitrectomy. 
 
The total volume of fluid was calculated by mass, assuming 1g=1ml. After thorough 
agitation, a sample of fluid was placed on the Neubauer improved counting chamber 
(Figure 49) and examined under a microscope. Cell counts were obtained using a 
standard technique, where the mean of four counts of 0.1 µl was used, unless the cell 
density was very high, when four counts from the 0.004 µl grid were used. 
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Figure 49- Neubauer improved counting chamber (from: Wikimedia commons). 
3.2.12 Outcomes 
The following outcomes were defined prospectively: 
Primary outcome measure:  
ETDRS best-corrected visual acuity at 12 weeks following surgery 
Secondary outcome measures:  
1.  Ease of performing vitrectomy surgery (subjective score by surgeon)  
2.  Intra-operative bleeding (subjective score by surgeon and objective analysis of 
collected surgical fluid by haemocytometry) 
3.  Incidence of post-operative vitreous haemorrhage 
4.  Extent of retinal neovascularisation (from masked grading of colour fundus 
photographs) 
5.  Height, transverse and longitudinal dimensions of tractional retinal detachment, 
measured by ultrasound 
6.  Extent of macular perfusion (from masked grading of fluorescein angiograms) 
7.  Vitreous and plasma levels of VEGF and related cytokines 
3.2.13 Statistical methods 
This was a pilot randomised controlled trial, so no formal sample size calculation 
was  conducted.  Thirty  patients  were  deemed  sufficient  by  the  group  of  trial 
investigators to explore feasibility and gather information needed to determine the 
size of a subsequent definitive trial.  
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Baseline characteristics of the patients were compared by treatment groups by the 
trial statisticians to assess the adequacy of the randomisation. Summary measures for 
the  baseline  characteristics  were  means  and  standard  deviations  (or  median  and 
interquartile  range  (IQR))  for  continuous  (or  non-normally  distributed 
continuous/ordinal  variables);  and  frequencies  and  percentages  for  categorical 
variables. The trial statisticians assessed for normality by inspection of histograms.  
Summary statistics were computed for each outcome by treatment group. STATA 
statistical software (version 12, StataCorp LP) was used for data analysis. Although 
randomisation  was  stratified  by  complexity  there  was  a  single  high  complexity 
patient and so results are presented for the group in total. 
 
Laboratory findings were analysed using GraphPad Prism (version 6.02, GraphPad 
Software, Inc.). The Kruskal Wallis test with adjustment of P values for multiple 
comparisons  (three  groups)  was  used  to  compare  average  cytokine  values  by 
treatment group in an exploratory analysis of laboratory findings. 
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3.3  Results 
3.3.1  Recruitment 
A clinical trial authorisation confirming approval for the study was obtained from the 
MHRA on 11/03/2011; a favourable ethical approval was received from the Central 
London Research Ethics Committee (REC) 1 on 22/03/11 and local research and 
development approval was given on 30/03/11. 
 
Fifty-nine potential patients were approached and given the patient information sheet 
(PIS);  21  of  these  declined  to  attend  screening  and  6  became  ineligible  due  to 
changes in their condition. Thirty-two patients attended screening, two of whom did 
not meet the inclusion criteria (one pregnant, one no longer required surgery). 
  
Thirty eyes  of 30 subjects  were  enrolled in  the study between August  2011 and 
December 2012, with follow-up completed in March 2013. Fifteen subjects were 
randomised to ranibizumab, 15 to control. All patients had been previously managed 
for  proliferative  retinopathy  by  panretinal  photocoagulation  prior  to  listing  for 
surgery. 
3.3.2  Patient disposition and demographics 
All  subjects  received  their  allocated  intervention.  Demographic  and  non-ocular 
characteristics  of  the  trial  participants  were  comparable  between  groups  and  are 
shown in Table 21. 
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  Control group 
 
Ranibizumab group 
Number  15  15 
Female sex  9 (60%)  3 (20%) 
Age (years)  48.7 ±18  57.1 ±14 
Ethnicity: 
White or white British 
Black or black British 
Asian or Asian British 
Other 
Not recorded 
 
8 (53.3%) 
2 (13.3%) 
2 (13.3%) 
3 (20.0%) 
0 
 
8 (53.3%) 
2 (13.3%) 
3 (20.0%) 
1 (6.7%) 
1 (6.7%) 
Type of diabetes 
1 
2 
 
6 (40%) 
9 (60%) 
 
4 (26.7%) 
11 (73.3%) 
Duration of diabetes 
(years) 
21 (15, 28)  19 (10, 23) 
Systolic BP  132 ±22  128 ±22 
Diastolic BP  75 ±9  78 ±11 
HbA1c  9.3 ±1.8 (n=13)  8.2 ±1.1 (n=14) 
 
Table 21 – Patient demographics and non-ocular baseline characteristics. Results are 
shown as mean ± standard deviation for normally distributed data; median (IQR) if 
non-normally distributed continuous data; number (%) for categorical data. BP – 
blood pressure; HbA1c – glycosylated haemoglobin. 
 
The ocular characteristics of study participants are shown in Table 22; again the two 
groups are comparable in terms of degree of visual loss, vitreous haemorrhage grade 
and cataract. 
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  Control (n=15) 
 
Ranibizumab (n=15) 
ETDRS letter score  32.3  ±19  (0-62;  CF=1, 
HM=1) 
28.5  ±26  (0-72;  HM=2, 
PL=1) 
RAPD present  3 (20%)  4 (27%) 
Rubeosis present  0  0 
Anterior chamber 
inflammation grade (0-4) 
0  0 
Intraocular pressure 
(mmHg) 
16.5 ±4  16.8 ±3 
Lens status 
Pseudophakic 
Cataract grade 0 
1 
2 
3 
4 
 
3 (20.0%) 
4 (26.7%) 
6 (40.0%) 
1 (6.7%) 
1 (6.7%) 
0 (0%) 
 
5 (33.3%) 
4 (26.7%) 
5 (33.3%) 
1 (6.7%) 
0 (0%) 
0 (0%) 
Vitreous haemorrhage 
score  
0 (no haemorrhage) 
1 (minor haemorrhage) 
2 (disc and large vessels 
visible) 
3 (no fundus view) 
 
 
3 (20.0%) 
8 (53.3%) 
2 (13.3%) 
2 (13.3%) 
 
 
6 (40.0%) 
5 (33.3%) 
1 (6.7%) 
3 (20.0%) 
 
Table 22 – Ocular baseline characteristics of the two groups. Results are shown as 
mean ± standard deviation for normally distributed data; number (%) for categorical 
data. ETDRS – Early Treatment Diabetic Retinopathy Study; RAPD – relative 
afferent pupillary defect. 
 
All subjects attended as planned one week after screening for surgery. The median 
interval between trial intervention and surgery was 7 days (range 6-8 days). 
3.3.3  Losses to follow up and withdrawals 
No subject withdrew from the trial prior to the primary endpoint at 12 weeks. One 
subject was temporarily lost to follow-up and attended the final trial visit 50 weeks 
after  surgery.  His  data  were  included  in  the  final  analysis.  All  other  trial  exit 
assessments were conducted within 4 weeks of the 12 week time point. 
3.3.4  Primary outcome 
Mean (SD) visual acuity at 12 weeks post-operatively in the ranibizumab treated 
group was 52.6 (21) letters compared with 46.7 (25) letters in the control group. This 183 
 
represents an improvement of 24 (27) letters for ranibizumab and 14 (31) letters for 
control. Visual acuity results are summarised in Table 23. No clinically significant 
visual acuity change occurred between trial intervention and surgery. 
 
  Baseline  Day of 
surgery 
6 weeks  12 weeks 
Control  32.3±19.3  30.3±17.6  46.4±23.2  46.7±25.4 
Ranibizumab  28.5±26.5  29.1±27.8  51.5±22.1  52.6±21.0 
 
Table 23 – ETDRS visual acuity at different time points throughout the trial shown 
as mean ±SD. 
 
3.3.5  Secondary outcomes 
3.3.5.1  Ease of performing vitrectomy surgery 
The majority of cases in both groups were performed under local anaesthetic (sub-
Tenon’s block). The median (IQR) duration of vitrectomy was 51 (38, 82) minutes in 
the control group and 63 (42, 87) minutes in the ranibizumab group. Further surgical 
metrics  are  listed  in  Table  24.  Similar  numbers  of  endodiathermy  and  backflush 
cannula  applications  occurred  in  both  groups  and  there  were  similar  numbers  of 
iatrogenic breaks in the two groups. The overall surgical difficulty score was rated as 
2 for more patients in the ranibizumab group and 3 for more patients in the control 
group. Twelve patients in each group required tamponnade agents to treat retinal 
breaks and/or proliferative vitreoretinopathy (PVR). In most cases, this was sulfur 
hexafluoride gas, although one subject in each group required perfluorocarbon and 
two subjects in the ranibizumab group required silicone oil. 
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  Control  Ranibizumab 
Anaesthetic 
LA (number): 
GA (number: 
 
10 
5 
 
12 
3 
Duration  of  vitrectomy  in 
minutes (median (IQR)): 
51 (38, 82)  63 (42, 87) 
Intraoperative bleeding 
score: 
0 
1 
2 
3 
 
 
2 
8 
5 
0 
 
 
3 
10 
2 
0 
Mean number of 
endodiathermy 
applications: 
 
 
1.5 
 
 
1.1 
Mean number of backflush 
cannula applications: 
 
2.8 
 
2.5 
Total number of iatrogenic 
breaks (all patients) 
Anterior: 
Posterior: 
 
 
6 
9 
 
 
3 
9 
Overall surgical difficulty 
score: 
0 (very easy) 
1 (routine) 
2 (moderate) 
3 (complex, challenging) 
4 (extremely difficult) 
 
 
1 
2 
3 
9 
0 
 
 
1 
1 
6 
6 
1 
 Surgeon-determined pre-
op complexity score (0-8): 
 
Median 4 
 
Median 5 
Tamponnade agent used: 
SF6 (number): 
C3F8: 
Silicone oil: 
 
11 
1 
0 
 
9 
1 
2 
 
Table 24 – Surgical parameters for two groups. LA – local anesthetic; GA – general 
anesthetic; SF6 – sulfur hexafluoride; C3F8 – perfluorocarbon.  
 
3.3.5.2  Intraoperative haemorrhage 
More patients in the ranibizumab group had mild intraoperative bleeding (10 vs. 8) 
and fewer had moderate bleeding (2 vs. 5). Fluid was successfully collected from the 
vitrectomy  cassette  in  29/30  cases.  In  one  case  in  the  control  group,  a  loose 
connection in the surgical tubing prevented the collection of fluid. Volumes of fluid 
collected varied considerably, as did concentration of red blood cells. The estimated 
total red blood cell counts obtained by multiplying the number of cells counted on 185 
 
the haemocytometer by the total fluid volume are shown in Table 25. Data were not 
assumed to be normally distributed.  
  Control 
n=14 
Ranibizumab 
n=15 
Lowest  1.15 x 10
6  2.72 x 10
6 
Highest  3.65 x 10
8  5.20 x 10
8 
Median  6.55 x 10
7  2.91 x 10
7 
Interquartile range  8.44 x 10
7  8.31 x 10
7 
 
Table 25 – Red blood cell counts from surgical fluid, shown as total number of red 
blood cells in the collected fluid. 
 
There was no significant difference in red blood cell count in the operative fluid 
between the two groups (Mann Whitney U test p=0.37). 
3.3.5.3  Incidence of post-operative vitreous haemorrhage 
In  both  groups,  there  were  minor  variations  in  degree  of  vitreous  haemorrhage 
between baseline and surgery. At 6 weeks post-op, there were two subjects in each 
arm with  vitreous  haemorrhage but  these  were  both  severe in  the  control  group, 
compared to mild and moderate in the ranibizumab group. By 12 weeks no subject in 
the  ranibizumab  group  had  any  vitreous  haemorrhage  while  two  persisted  in  the 
control group, summarised in Table 26.  
 
  Baseline  Surgery visit  6 weeks post-
op 
12 weeks 
post-op 
Control 
Grade: 0 
1 
2 
3 
 
3 
8 
2 
2 
 
4 
7 
4 
0 
 
13 
0 
0 
2 
 
13 
1 
1 
0 
Ranibizumab 
Grade: 0 
1 
2 
3 
 
6 
5 
1 
3 
 
5 
6 
1 
3 
 
13 
1 
1 
0 
 
15 
0 
0 
0 
 
Table 26 – Numbers of subjects with different grades of vitreous haemorrhage at 
different trial time points. For explanation of grading, see Table 22. 186 
 
3.3.5.4  Extent of retinal neovascularisation 
At baseline, colour photographs where grading was possible showed proliferative 
diabetic retinopathy in all subjects. By 12 weeks, four subjects in the ranibizumab 
group and one in the control group were graded as non-proliferative retinopathy. The 
remainder still had evidence of proliferative retinopathy but the modal ETDRS grade 
for both groups was 61 (mild PDR), indicating that surgery achieved the intended 
aim of treating advanced proliferative disease. Results are shown in Table 27 
 
ETDRS Grade  Baseline  12 weeks 
Ranibizumab  Control  Ranibizumab  Control 
NPDR  20         
35         
43         
47      2   
53      2  1 
PDR  61  5  1  7  11 
65      3  1 
71  2  2  1   
75    1     
81  2  2     
85  2  6     
90  3  2     
 
Table 27 – Numbers of subjects with different grades of diabetic retinopathy at 
baseline and 12 weeks. At baseline, 14 sets of photos were gradable in each group. 
At 12 weeks, 15 sets in the ranibizumab group and 13 in the control group were 
gradable. 
 
Example images of the extent of retinal neovascularisation and presence of advanced 
proliferative retinopathy before and after surgery are shown in Figure 50.  
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Figure 50 – Colour fundus photographs to show pre- and post-operative appearances 
of a subject with advanced proliferative diabetic retinopathy in the RaDiVit pilot 
trial. This subject was in the ranibizumab arm. 
 
Area of retinal neovascularisation was graded in a step-wise fashion from 0 disc 
diameters (DD) to >30 DD when image quality allowed. In the ranibizumab group, 
11/12 subjects graded at baseline had greater than 10 DD of proliferation; by 12 
weeks 12/15 had fewer than 10 DD and of these, four had no visible proliferation. 
Similarly in the control group 11/13 at baseline had greater than 10 DD proliferation 
and at 12 weeks 13/13 had fewer than 10 DD; one had no visible proliferation. 
3.3.5.5  Extent of tractional retinal detachment 
The  ultrasound  appearance  of  a  tractional  retinal  detachment  in  a  patient  with 
advanced proliferative retinopathy is shown in Figure 51. The results of ultrasound 
evaluation at baseline and on the day of surgery are shown in Table 28.  
 
 
Figure 51 – B-scan ultrasound to show fibrovascular proliferation and tractional 
retinal detachment (circled) in advanced proliferative diabetic retinopathy. Image 
courtesy of Mr Paul Sullivan. 
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  Control  Ranibizumab 
  Baseline  1 week post 
injection 
Baseline   1 week post 
injection 
Quadrants of FVP:  
1 
2 
3 
4 
 
0 
2 
1 
12 
 
0 
2 
0 
13 
 
0 
1 
2 
12 
 
0 
2 
2 
11 
FVP location 
Anterior: 
Posterior: 
Both: 
 
 
14 
1 
 
 
15 
0 
 
 
15 
0 
 
 
13 
2 
Number  with  TRD 
present: 
 
 
6 (40%) 
 
7 (47%) 
 
10 (67%) 
 
11 (73%) 
Number  of  TRDs 
involving macula: 
 
 
5 (33%) 
 
5 (33%) 
 
5 (33%) 
 
5 (33%) 
Number with RRD:  1 (7%)  1 (7%)  1 (7%)  0 (0%) 
Dimensions  of 
TRD* 
Height (mm): 
 
Base (mm): 
 
 
2.2±0.5 
 
11.9±5.0  x 
13.2±4.6  
 
2.5±0.6 
 
12.6±5.3 x 
13.5±4.4 
 
2.4±0.9 
 
11.9±4.7 x 
11.5±5.3 
 
2.4±1.0 
 
12.1±5.0 x 
12.5 ±6.2 
Dimensions of TRD 
Height (mm): 
 
Base (mm): 
 
 
2.58±1.04 
 
11.9±5.00  x 
13.2±4.60 * 
 
2.96±1.19 
 
13.4±5.53 x 
14.5±5.02 
 
2.33±0.86 
 
11.8±4.44 x 
10.8±5.48 
 
2.14±1.15 
 
10.6±5.89 x 
10.8 ±6.76 
Extent of PVD: 
-  None 
-  Partial 
-  Complete 
 
 
15 
 
 
15 
 
 
15 
 
 
15 
Ultrasound  derived 
complexity  score 
(0-8) 
 
Median 4 
 
Median 4 
 
Median 5 
 
Median 5 
 
Table 28 – Ultrasound findings for two groups at baseline and one week after study 
injection. FVP – fibrovascular proliferation; TRD – tractional retinal detachment; 
RRD – rhegmatogenous retinal detachment; PVD – posterior vitreous detachment. 
*Includes only those subjects with TRD present at baseline and 1 week where 
measurements could be obtained: n=5 control; n=9 ranibizumab. 
 
No  clear  evidence  of  an  increase  in  the  number  of  quadrants  of  fibrovascular 
proliferation (FVP) was seen. Two subjects in the ranibizumab group had anterior 
FVP detected one week after injection. One subject in each group had a tractional 189 
 
retinal  detachment  (TRD)  identified  on  the  day  of  surgery  that  had  not  been 
identified at baseline; in a further subject in the ranibizumab group ultrasound did 
not detect a retinal break (rhegmatogenous detachment) on the day of surgery that 
had been detected at baseline. The axial resolution of the ultrasound was limited by 
the calipers to ±0.2 mm. There was a small increase in height of TRD in the control 
group of 0.38 mm and in the ranibizumab group the decrease in TRD height was 
smaller  than  the  limit  of  axial  resolution.  The  accuracy  of  the  transverse  and 
longitudinal measurements of the base dimensions of the retinal detachment were 
limited by the resolution of the scanner to ±1.6 mm. No change in base dimensions 
exceeded this limit of resolution in either group. In all subjects the vitreous gel was 
attached to areas of TRD and vitreoretinal adhesions and detached elsewhere (partial 
PVD). 
 
The median complexity score derived retrospectively by the operating surgeon in the 
two groups was the same as that obtained by ultrasound (see Table 24 and Table 28). 
However, scoring by the surgeon identified more TRDs and combined tractional-
rhegmatogenous retinal detachments (TRRDs) than by ultrasound (control: 11 TRD 
of which 2 were TRRD; ranibizumab 13 TRD of which 6 were TRRD). This is likely 
due  to  the  inability  of  ultrasound  to  detect  small  breaks  in  TRDs  that  are  only 
visualised surgically. 
 
3.3.5.6  Extent of macular perfusion 
Fluorescein angiograms were only gradable at baseline in 3/15 subjects in the control 
group and 5/15 in the ranibizumab group. All showed moderate to severe perifoveal 
capillary loss. At 12 weeks, the mean (SD) FAZ greatest linear dimension (GLD) 
was 637 (236) µm in the control group (9 angiograms graded) and 765 (576) µm in 
the ranibizumab group (10 graded). FAZ area was 0.315 (0.147) mm
2 for control and 
0.403 (0.562) mm
2 for ranibizumab. Median total score for perifoveal capillary loss 
was 14 in both groups, indicating scores of 3-4 (moderate to severe) in each of the 
four  quadrants.  Thus  in  both  groups  there  was  evidence  of  significant  macular 
ischaemia but no evidence of a treatment effect. 190 
 
3.3.5.7  Vitreous and plasma levels of VEGF and related cytokines 
Vitreous samples were analysed on one 96-well plate and plasma samples analysed 
on  a  second  96-well  plate  between  2  replicates  of  quality  control  samples  and 
following a calibration curve. Calibration data was fitted using a weighted (1/y
2) 5-
parameter logistic curve fit of the mean Median Fluorescent Intensity (MFI) values. 
One vitreous sample was too viscous to pipette and so was unable to be analysed. 
The quality control data for one cytokine (sCD40L) on the plate containing vitreous 
samples did not meet the required standard of accuracy and so this was excluded 
from the analysis of vitreous. The lower limit of quantification for the assay was 
reported as 3.2 pg/ml and the upper limit 10000 pg/ml except for sIL-2Rα where the 
lower limit was 16 pg/ml. For the purposes of statistical analysis where the cytokine 
concentration was below the limit of detection for the assay the concentration was 
taken as 1.6 pg/ml and where above the limit of detection was rounded down to 
10000 pg/ml (following the method of Lange et al.). For sIL-2Rα the concentration 
was taken as 8 pg/ml when the result was below the detection limit of the assay. 
 
Vitreous results 
Twelve cytokines were not detected in the vitreous from any subject (IFN-γ, IL-1β, 
IL-2, IL-7, IL-9, IL-12(p40), IL-12(p70), IL-13, IL-17, sIL-2Rα, TNFα and TNFβ). 
Nine cytokines had significantly altered levels in the control group from this trial 
(representing diabetic subjects not treated with ranibizumab) compared with non-
diabetic  historical  control  samples.  These  are  shown  in  Table  29.  Seven  showed 
increased levels in diabetes and of these, two: IL-1α and VEGF, were significantly 
reduced in the vitreous of subjects treated with ranibizumab compared to the diabetic 
subjects in the trial who received saline. Two further cytokines appeared to show 
decreased levels in diabetes, but Fractalkine was only detected in one sample from 
the current batch and IFN- α2 in three, compared to all of the non-diabetic samples 
so it is possible that differences in handling of the more recent batch of samples 
could have prevented detection of these cytokines. 
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Cytokine  Non-diabetic 
control (n=7) 
RaDiVit saline 
control (n=14) 
RaDiVit 
ranibizumab 
(n=15) 
Kruskal-
Wallis P-
value 
IL-1α  1.60 (0)  4.01 (8.64)   
1.60 (0) 
0.01 
0.03* 
IL-4  1.60 (0)  43.54 (27.77)   
62.08 (56.79) 
0.02 
NS 
IL-6  1.60 (0)  32.51 (74.42)   
25.06 (12.45) 
0.0007 
NS 
IL-8  3.82 (3.40)  43.68 (108.61)   
46.15 (99.82) 
0.0006 
NS 
IP-10  218.15 (102.90)  980.90 (808.69)   
586.24 (653.32) 
0.0001 
NS 
MCP-1  1446.60 
(1988.81) 
5318.61 
(1759.68) 
 
4625.98 
(2801.65) 
0.003 
NS 
VEGF  1.60 (0)  65.88 (505.66)   
1.60 (0) 
0.002 
0.0001* 
Fractalkine  58.99 (38.69)  1.60 (0)   
1.60 (0) 
<0.0001 
NS 
IFN-α2  20.95 (24.66)  1.60 (0)   
1.60 (0) 
0.0002 
NS 
 
Table 29 – Vitreous concentrations of cytokines (pg/ml) with levels significantly 
altered in subjects with diabetes. Two cytokines, IL-1α and VEGF, were reduced 
following ranibizumab treatment compared to levels in the control group. Data 
shown as median (interquartile range). P-values corrected for multiple comparisons. 
* - P-value for control vs. ranibizumab. See text for cytokine legend. 
 
Further analysis showed a trend towards increased levels of EGF in diabetic subjects 
(P=0.08).  MDC,  although  not  significantly  elevated  in  control  diabetic  samples 
compared to non-diabetics, was significantly reduced in ranibizumab treated samples 
(P=0.015)  and  Flt-3  ligand  similarly  showed  a  trend  towards  reduction  by 
ranibizumab  (P=0.06)  despite  no  evidence  of  elevation  in  the  control  diabetic 
samples.  The  remaining  cytokines  did  not  have  significantly  different  levels 
compared to non-diabetic controls. 
 
Plasma results 
In plasma, all 39 cytokines were detected in at least three samples. Six cytokines had 
altered  levels  in  the  diabetic  control  group  compared  with  non-diabetic  controls, 192 
 
shown in Table 30. Only one of these, G-CSF, had increased levels in diabetes; the 
other five had reduced levels.  
 
No cytokine had significantly altered levels in subjects in the ranibizumab group. 
VEGF levels were reduced in the ranibizumab treated group (29.04 (51.07) pg/ml vs. 
65.41 (80.94) pg/ml) but this did not reach statistical significance, so an effect on 
systemic VEGF levels cannot be demonstrated or excluded. 
 
Cytokine  Non-diabetic 
control (n=7) 
Control (n=15)  Ranibizumab 
(n=15) 
Kruskal-
Wallis P-
value 
G-CSF  20.01 (16.97)  44.25 (23.10)   
27.82 (22.25) 
0.0087 
NS 
Eotaxin  1174.32 (120.08)  93.25 (77.08)   
80.21 (53.62) 
0.002 
NS 
Flt-3 
ligand 
62.99 (34.03)  1.60 (0)   
1.60 (0) 
0.0003 
NS 
GRO  1114.15 (544.69)  163.73 (319.82)   
95.84 (55.47) 
0.0194 
NS 
IL-13  4.78 (9.62)  1.60 (0)   
1.60 (0) 
0.04 
NS 
MCP-3  7.89 (17.30)  1.60 (0)   
1.60 (0) 
0.03 
NS 
sCD40L  5370.26 
(1659.96) 
473.32 (218.00)   
366.44 (202.91) 
0.003 
NS 
 
Table 30 – Plasma levels of cytokines with reduced concentration in the vitreous 
from subjects with diabetes. Values shown as median (IQR). 
3.3.6  Safety 
There was one adverse event meeting the pre-defined criteria for an SAE in each 
group: in the control group, one subject was admitted to hospital with hypoglycaemia 
10  weeks  after  surgery.  In  the  ranibizumab  group,  one  subject  was  admitted  to 
hospital with raised intraocular pressure later on the day of surgery. Neither was 
believed to be related to study drug administration. Ocular and non-ocular adverse 
events are summarised in Table 31. There were more vitreous cavity haemorrhages 
in the control group than in the ranibizumab group, and more vitreous haemorrhages 193 
 
in the non-study eye in the control group. More subjects in the control group had an 
upper respiratory tract infection. 
 
  Control  Ranibizumab 
Ocular adverse events 
Cataract 
Eye pain 
Eye redness 
Raised intraocular pressure 
Vitreous cavity haemorrhage 
Vitreous haemorrhage in 
non-study eye 
 
0 
1 
0 
0 
3 (6 episodes)  
 
4 (5 episodes) 
 
1 
0 
2 
1 (SAE) 
3 (4 episodes) 
 
0 
Non-ocular adverse events 
Hypoglycemia 
Upper respiratory tract 
infection 
 
1 (SAE) 
5 (8 episodes) 
 
0 
1 
 
Table 31 – Summary of ocular and non-ocular adverse events in the two groups 
during the RaDiVit study, shown as number of subjects experiencing adverse event. 
Where an adverse event occurred more than once in the same subject this is 
indicated. SAE – serious adverse event. 
 
During surgery, there were fewer total iatrogenic breaks in the ranibizumab group 
than in  the control  group (12 vs.  15;  see  Table  24), and 10 vs.  12 required  gas 
tamponnade. Two subjects in the ranibizumab group required silicone oil, however. 
No subject in either group developed recurrent rhegmatogenous retinal detachment 
during the study period. 194 
 
3.4  Discussion 
Ranibizumab pre-treatment in the RaDiVit study resulted in an additional gain of 10 
letters compared with the control group at the three month primary endpoint. The 
results of this pilot randomised controlled trial suggest that using ranibizumab in this 
way prior to diabetic vitrectomy may be beneficial and warrants further exploration 
in a larger, powered study. 
3.4.1  Design of the trial 
While previous randomised trials have used bevacizumab in this setting, this trial is 
the  first  to  explore  in  detail  the  impact  of  ranibizumab  in  diabetic  vitrectomy. 
Ranibizumab  is  the  agent  licensed  for  intraocular  use  in  age-related  macular 
degeneration and DMO, and has increased binding efficacy together with a shorter 
half  life  in  the  vitreous  combined  with  bevacizumab.  This  means  it  may  have  a 
different  safety  profile  and  merits  investigation.  Reports  of  worsening  tractional 
retinal detachment with bevacizumab therapy [107, 108] mean that safety concerns 
remain with the use of bevacizumab for this indication. 
3.4.1.1  Endpoint selection 
Previous trials investigating bevacizumab have used a variety of primary endpoints 
that makes direct comparison between them difficult. Rizzo et al. chose “feasibility 
of  surgery”  [194],  as  did  Modarres  et  al.  [196]  (“facilitation  of  the  surgery  and 
decrease of complications” sic). The primary outcome measure for Ahmadieh et al. 
was early post-operative vitreous haemorrhage [197]. In designing this pilot study, 
best  corrected  visual  acuity  was  chosen  as  the  single  primary  endpoint  as  it 
represents  the  outcome  that  is  likely  to  be  of  most  importance  to  patients;  this 
outcome was reported at 3 months (12 weeks) post-operatively as this represents a 
time point when post-operative complications are likely to have settled, but post-
vitrectomy cataract limiting vision should not have yet developed. If there was a 
difference in rates of post-operative vitreous haemorrhage at 3 months, this may be 
captured by a difference in visual acuity. 
 
Duration  of  surgery  and  technical  difficulty  of  operating  are  important  surrogate 
endpoints  that  may  have  an  impact  on  service  delivery  or  post-operative 195 
 
complication  rate.  Shorter  operations  may  be  safer  for  the  patient  in  terms  of 
anaesthetic  risk,  and  are  beneficial  to  hospitals  needing  to  make  the  best  use  of 
limited operating theatre resources. However, as they may not affect the final visual 
outcome, they are appropriately included as secondary endpoints.  
 
The  first  secondary  outcome  was  prospectively  defined  as  “Ease  of  performing 
vitrectomy  surgery”.  This  was  assessed  by  vitrectomy  duration  and  a  surgical 
difficulty  score  reported  by  the  operating  surgeon,  which  is  an  unvalidated, 
subjective measure. The second of the secondary outcomes evaluated intra-operative 
haemorrhage  by  using  a  subjective  score  defined  in  a  previous  randomised  trial 
[212],  quantification  of  the  use  of  instruments  designed  to  control  haemorrhage 
(backflush  cannula  and  endodiathermy),  and  by  laboratory  evaluation  of  waste 
surgical  fluid  containing  red  blood  cells  as  previously  described  by  other 
investigators  [106,  199].  There  are  two  major  limitations  to  this  last  technique: 
firstly, the surgical cassette will contain pre-existing haemorrhage aspirated at the 
start of the operation; and secondly, haemorrhage aspirated via the backflush cannula 
is not collected in the cassette but rather ends up in the collecting bag of the surgical 
drape. However, this fluid from the drape bag is likely to be further contaminated by 
conjunctival  bleeding  so  does  not  represent  a  good  measure  of  intraoperative 
haemorrhage arising solely from the vitreous cavity. 
 
To our knowledge, no investigators have previously studied objectively the effect of 
anti-VEGF injection on the progression of tractional retinal detachment, although 
anecdotal reports where there had been a long interval between injection and surgery 
reported a progression of TRD in some cases (e.g. [108]). By using ocular ultrasound 
to measure the size of the TRD by a masked investigator, we were able to provide an 
objective  determination  of  any  change  in  TRD  occurring  following  ranibizumab 
injection. 
3.4.1.2  Control group 
Given  the  clinical  equipoise  already  stated,  it  was  deemed  unethical  to  give  the 
investigational medicinal product to all subjects. Using the fellow eye as an internal 
control for subjects receiving ranibizumab would not provide useful comparison data 
as diabetic retinopathy is frequently of differing severity in the two eyes and it would 196 
 
be unusual to find subjects who required this type of surgery in both eyes at the same 
time. It was therefore clear that a parallel-group, randomised design would provide 
the best methodology to assess the impact of ranibizumab administration. 
 
Intravitreal  injections  carry  a  risk  of  intraocular  infection  (endophthalmitis), 
haemorrhage  and  retinal detachment,  so  injecting  a placebo substance  would not 
represent an ethical choice as a comparator. Furthermore, it is not believed that anti-
VEGF injection for this condition exerts its effect by a physical mechanism on the 
fibrovascular  tissues;  another  reason  why  placebo  intravitreal  injection  is  not 
required.  Some  trials  of  intravitreal  injections  have  used  sham  injections  in  the 
control group, where the barrel of the syringe with no needle attached is pressed 
against the conjunctiva to simulate an injection. This is entirely safe, and unlikely to 
cause any side effects. However, the propensity of a genuine intravitreal injection to 
cause  subconjunctival  haemorrhage  means  that  any  patient  with  this  finding  one 
week  later  would  by  inference  have  received  the  active  injection,  leading  to 
inadvertent  investigator  unmasking.  Given  the  subjective  nature  of  some  of  the 
assessments of surgical difficulty, it is important that both the operating surgeon and 
the  investigator  collecting  the  data  remain  masked  to  treatment  allocation.  We 
therefore  chose  to  use  subconjunctival  injection  of  saline  as  the  comparator 
procedure. This carries virtually zero risk of significant ocular adverse events, but 
because it carries a small chance of causing a subconjunctival haemorrhage, like 
intravitreal injection, it avoids the accidental unmasking of subjects that could occur 
with  a  sham  injection.  Another  trial  investigating  ranibizumab  for  non-clearing 
vitreous haemorrhage in proliferative diabetic retinopathy received ethical approval 
to  use  this  technique  in  their  comparator  arm  (NCT01030770, 
www.clinicaltrials.gov).  
3.4.1.3  Stratified randomisation 
Trials of small numbers of patients have an inherent risk of imbalance between the 
two  groups  being  studied.  This  can  occur  despite  the  use  of  appropriate 
randomisation methods. It was felt that in this study there was a significant chance of 
imbalance between the two groups with respect to the complexity of cases, with the 
possibility of a misleading result arising if cases that were technically less difficult 
were clustered in one of the groups. The trial was therefore designed to use stratified 197 
 
randomisation, with cases being classified as either low or high complexity based on 
the complexity score described by Grigorian et al. In their similar trial, Rizzo et al. 
found a mean complexity score of 5.5, so cases were deemed low complexity if they 
scored  1-5  (a  score  of  0  would  make  them  ineligible  for  the  trial)  and  high 
complexity  for  scores  of  6-8.  Because  vitreous  haemorrhage  could  impair  the 
assessment of the fundus and hence make difficult the observation of features needed 
to  derive  a  complexity  score,  we  chose  to  use  ultrasound  findings  for  its 
determination. The final complexity score was also obtained retrospectively from the 
operating surgeon who had full knowledge of the status of the retina to validate the 
use of ultrasound in this setting.  
 
3.4.2  Primary outcome results 
Subjects treated with ranibizumab one week prior to vitrectomy surgery in this study 
had better visual acuity at 12 weeks post-operatively than subjects receiving a control 
injection  of  subconjunctival  saline.  Vitrectomy  surgery  resulted  in  a  substantial 
improvement  in  visual  acuity  in  both  groups,  but  to  a  greater  extent  in  the 
ranibizumab treated group (approximately 5 ETDRS lines vs. 3 lines). This improved 
acuity  is  in  keeping  with  visual  acuity  gains  reported  in  a  prospective  study  of 
diabetic vitrectomy surgery [93], but an additional beneficial effect of ranibizumab 
pre-treatment needs validating in a larger, powered, randomised controlled trial. It is 
highly unlikely that these results represent a negative effect from subconjunctival 
saline,  as  it is  biologically  implausible  that  a  tiny  injection  outside  the  eye  of  a 
pharmacologically  inactive  substance  could  have  any  effect  on  visual  acuity  12 
weeks later. 
 
At baseline, the two study groups were comparable and the lower visual acuity was 
in the ranibizumab group. There was no evidence of confounding factors that could 
influence the visual  acuity outcome:  similar numbers  had type 1 and 2 diabetes; 
systemic control of diabetes and hypertension was similar; furthermore there were 
only small differences in numbers of pseudophakic patients and in cataract grade 
between the two groups. 198 
 
3.4.3  Secondary outcome results 
If the difference in visual acuity between the two groups detected by the primary 
outcome  measure  represents  a  genuine  difference,  it  is  not  possible  to  establish 
whether this is by a direct effect of ranibizumab treatment or because of a secondary 
effect,  for  example  by  reducing  the  rate  of  post-operative  vitreous  cavity 
haemorrhage  or  other  complications.  Exploration  of  the  pre-defined  secondary 
outcome measures may yield further information in this regard.  
3.4.3.1  Ease of performing vitrectomy surgery and intraoperative haemorrhage 
In contrast to previous studies that have shown shorter surgical duration or fewer 
instrument exchanges when an anti-VEGF agent has been used as an adjunct prior to 
vitrectomy-delamination  surgery,  we  found  no  evidence  of  a  difference  in  the 
duration of vitrectomy between the two groups. The intraoperative bleeding score 
was skewed towards “mild” in both groups, but fewer in the ranibizumab group were 
scored as “moderate”. This suggests that intraoperative haemorrhage in this trial did 
not  present  a  major  surgical  problem.  The  difference  is  probably  not  clinically 
significant  given  that  the  number  of  uses  of  the  backflush  cannula  and 
endodiathermy was very similar between groups. More surgeons rated the operation 
as  “complex,  challenging”  in  the  control  group  but  one  case  in  the  ranibizumab 
group was rated as “extremely difficult”. This was due to the formation of strong 
vitreoretinal adhesions in a case of combined TRRD, where effective delamination is 
already very difficult. Most cases were rated as moderate to complex in difficulty 
and  limited  conclusions  can  be  drawn  from  this  previously  unvalidated  scale, 
especially given the inclusion of multiple surgeons in this study. 
 
In contrast to the single previous report quantifying intraoperative haemorrhage in 
diabetic patients receiving ranibizumab pre-treatment [199], no difference was found 
in red blood cell count from operative fluid between the two groups. The technique 
of red blood cell counting using the haemocytometer is prone to error from a number 
of  factors.  The  surgical  cassette  may  not  contain  all  of  the  intraoperative 
haemorrhage, red cell clumping or lysis could occur and errors in counting may also 
contribute to inaccuracy. A reliable and reproducible technique for quantification of 
intraoperative  haemorrhage  is  still  awaited;  flow  cytometry  may  be  worthy  of 
investigation. 199 
 
3.4.3.2  Incidence of post-operative vitreous haemorrhage 
Vitreous cavity haemorrhage occurred in three subjects in each group, although more 
frequently in the control group (6 vs. 4) and at the 12 week primary endpoint two 
subjects in the control group still had severe vitreous cavity haemorrhage obscuring 
fundus details whereas all ranibizumab treated subjects were free from haemorrhage. 
It still cannot be concluded whether anti-VEGF agents reduce the incidence of post-
operative haemorrhage in this situation. The Cochrane review examining the effect 
of pre-operative bevacizumab on POVCH concluded that the results  of only one 
study supported its use while methodological problems in the other studies prevented 
firm conclusions being drawn [191]. Because this study uses a different agent, it is 
unlikely that it could be included in an update to the review unless the terms of 
reference were changed. 
3.4.3.3  Extent of retinal neovascularisation and macular ischaemia 
Evidence from reading centre grading of colour photographs showed that following 
surgery,  grade  of  diabetic  retinopathy  improved  in  both  groups  as  fibrovascular 
tissue was removed and areas of proliferation were treated. By the trial exit, four 
subjects in the ranibizumab group and one in the control group were graded as non-
proliferative  retinopathy.  Additionally,  the  area  of  retinal  neovascularisation 
decreased substantially from enrolment to the primary endpoint in both groups, with 
the majority of subjects initially having greater than a 10 DD area of proliferation at 
the outset but less than 10 DD at exit. More subjects treated with ranibizumab had no 
evidence of neovascularisation at trial exit (4 vs. 1), consistent with the improved 
ETDRS retinopathy grade. The absence of neovascularisation in more subjects may 
be linked to the reduced incidence of haemorrhage in the ranibizumab group. 
 
Very advanced diabetic eye disease meant that fluorescein angiograms were only 
graded in small numbers of patients at baseline. All subjects where angiograms were 
graded showed evidence of severe macular ischaemia: perifoveal capillary loss was 
graded as moderate to severe. Where angiograms were graded at exit, substantial 
variability of FAZ GLD and area was present in both groups, with no firm evidence 
of a difference. Again, all subjects had grades of perifoveal capillary loss suggestive 
of moderate to severe ischaemia. No conclusions can therefore be drawn about the 200 
 
safety of ranibizumab in the setting of macular ischaemia from this small study with 
single dose administration. 
3.4.3.4  Extent of tractional retinal detachment and other ultrasound findings 
Ultrasound evaluation at enrolment and one week later on the day of surgery was 
chosen to  allow detailed description of subjects  with  fibrovascular and tractional 
retinal pathology who had vitreous haemorrhage obscuring the fundus view, and to 
evaluate the impact of ranibizumab administration on the size and extent of tractional 
retinal detachment. Previous trials have excluded subjects where fundus details are 
not visible (e.g. [106]), which may lead subject selection to be biased towards those 
with more stable disease. In each group, the number with TRD increased by one 
between injection and surgery. This may represent new disease, but may be the result 
of detection of TRD not visualised on the first scan. Measurement of the height and 
base dimensions of the detachments did not reveal any evidence of an increase in 
TRD size and equally there was no evidence of increased fibrovascular proliferation. 
 
A  surgical  complexity  score  has  previously  been  described  to  allow  objective 
comparison of difficulty between cases with different pathology and was used in this 
trial to stratify randomisation and achieve balanced groups. Other trials that have 
used this score, e.g. [194, 196], are not explicit about how this score is obtained; for 
the  first  time,  ultrasound  has  been  used  to  derive  this  complexity  score  pre-
operatively. This ultrasound-derived complexity score correlates well with the score 
reported by the surgeon based on the findings during surgery. However, ultrasound 
failed to detect a number of small retinal breaks and so more subjects had combined 
TRRD identified at  surgery. All  subjects  were graded as  having partial posterior 
vitreous detachment (PVD) by ultrasound, as there were focal attachments of the gel 
to  FVP  and  TRD,  whereas  surgeons  graded  PVD  as  absent  when  there  was  no 
detachment over these areas. Ultrasound grading in future studies should ensure that 
PVD is classified in the same way as during surgery. 
 
3.4.3.5  Vitreous and plasma cytokine levels 
Cytokine  analysis  confirmed  that  vitreous  levels  of  VEGF  were  reduced  by 
ranibizumab treatment one week previously. In addition, levels of IL-1α were also 201 
 
reduced in the group treated with ranibizumab. This cytokine was detected in no non-
diabetic samples, six untreated diabetic samples and two after ranibizumab treatment. 
It is implicated in inflammatory pathways and fibroblast activation so reduction in its 
concentration by ranibizumab, if confirmed by other studies, adds a new dimension 
to the understanding of the mechanisms by which VEGF inhibition exerts its effects. 
A change in the balance of intraocular cytokines from pro-angiogenic to pro-fibrotic 
has  been  postulated  following  VEGF  inhibition,  with  raised  levels  of  connective 
tissue  growth  factor  detected  after  bevacizumab  treatment  and  associated  with 
increased fibrosis [209]. This has been termed the “angiofibrotic switch”, and the 
discovery of reduced levels of another cytokine associated with fibrosis may provide 
another insight into this mechanism.  
 
As discussed in section 3.1, IL-6, IL-8, IP-10 and MCP-1 have been found to be 
elevated in the vitreous of subjects with proliferative retinopathy and the present 
work adds to the evidence implicating these cytokines in this condition. In addition, 
we found raised levels of IL-4, a T-helper cell associated cytokine, in the diabetic 
samples  but  did  not  detect  it  in  the  non-diabetic  controls.  Other  investigators 
analysing cytokines in diabetic vitreous have not found raised IL-4 [213-215], but 
have  reported  its  presence  in  non-diabetic  samples.  It  is  therefore  possible  that 
degradation of the non-diabetic samples in this study has led to failure to detect this 
cytokine.  
 
Two cytokines were reduced in the current set of samples, Fractalkine and IFN-α2, 
but these were only detected in a small number of samples so the significance of this 
finding is questionable. Lange et al. reported reduced IL-9 and Flt-3 ligand in their 
similar study; IL9 was not detected in any of the current samples and Flt-3 ligand 
levels were the same in the diabetic samples as in controls but with a trend towards 
reduction with ranibizumab. It is likely that some results may occur due to chance 
given  the  large  number  of  cytokines  being  simultaneously  tested.  The  relatively 
small  patient  numbers  involved  in  the  experiment  mean  that  lack  of  statistical 
significance on testing should not be interpreted as proof of absence of a difference 
between two groups; it may be that difference too small to detect with this number of 
samples. 
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Plasma levels of VEGF in this study appeared reduced after a single administration 
of  ranibizumab  but  this  did  not  reach  statistical  significance.  Other  trials  have 
reported reduced plasma levels of VEGF after repeated ranibizumab treatment [216], 
suggesting that further study of the pharmacokinetics of ranibizumab is warranted. In 
one small study of ten patients with DMO treated with different VEGF inhibitors, 
there  was  no  change  in  plasma  VEGF  concentration  after  either  ranibizumab  or 
pegaptanib, however [217]. Cytokines with altered levels in the vitreous in this study 
did not have altered levels in plasma. 
 
In summary, cytokine analysis in this small pilot study has confirmed elevated levels 
of  cytokines  previously  implicated  in  the  pathogenesis  of  proliferative  diabetic 
retinopathy and has shown that ranibizumab treatment leads to a reduction in VEGF 
and IL-1α levels; the latter of these warrants further investigation and replication by 
other investigators. 
3.4.4  Safety issues 
Ranibizumab administration prior to diabetic vitrectomy surgery appears to be safe, 
as no new safety issues have been identified in this small trial with only a single 
administration of ranibizumab. The SAEs that occurred were not related to study 
drug administration: raised intraocular pressure likely occurred as a consequence of 
intraocular gas tamponnade from surgery and a hypoglycaemic episode ten weeks 
after study enrolment was due to more proximate causes. The pattern of adverse 
events seen in both groups mirrors previous reports of adverse events seen in similar 
trials, with frequent occurrences of upper respiratory tract infections and mild ocular 
discomfort as a result of the injection procedure.  
 
During surgery, the number of iatrogenic breaks was relatively low in both groups 
and  similar  numbers  needed  tamponnade  with  gas,  although  two  subjects  in  the 
ranibizumab group required silicone oil. Thus no definite evidence of an adverse 
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3.4.5  Strengths and weaknesses of the study 
The double masked, randomised design of this study leads to a low risk of bias. 
Some  of  the  assessments  of  surgery  were  subjective  and  so  preserving  surgeon 
masking adds to the validity of these assessments. Nevertheless, it is possible that the 
behavior of the tissues during surgery could give a clue to whether the subject had 
received  ranibizumab.  However,  the  use  of  a  control  injection  that  may  cause  a 
small, harmless, subconjunctival haemorrhage prevented accidental unmasking that 
could have occurred if only one group had received an active intervention. As this is 
the second trial to have used this technique for the control group, it is hoped that this 
will continue to be accepted by ethics committees. 
 
Subjects  included in  the trial all had significant fibrovascular proliferation at  the 
retina and so visual acuity improvement is unlikely to be driven by a group of low 
complexity patients likely to respond well to surgery without adjunctive treatment. 
The study included multiple surgeons, all experienced in diabetic vitrectomy surgery, 
so that any findings could not be attributed to an effect on one surgeon’s technique 
only. However, including multiple surgeons  introduces  another variable that may 
make it more difficult to identify a small effect. The low number of subjects included 
in this pilot study and the relatively short follow-up mean that long term effects of 
this treatment cannot be evaluated. Longer follow-up after this type of surgery may 
increase the effect of confounding factors as post-vitrectomy cataract develops and 
changes to the status of diabetic retinopathy occur. 
3.4.6  Power calculation and further work 
The  results  from  this  pilot  study  showed  that  mean  (SD)  visual  acuity  in  the 
ranibizumab group at 12 months was 52.6 (21) compared to 46.7(25.4) for control. 
Assuming equal SD in the two groups and taking an average SD of 23.2 letters, a 
power calculation with an alpha of 0.05 yields the results shown in Table 32. Thus it 
can  be  seen  that  to  detect  a  difference  in  visual  acuity  of  the  same  magnitude 
(approximately 6 letters) found in this pilot study, a sample size of over 300 per 
group would be required. 
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Power 
N per group  99%  95%  90%  80%  50% 
100  14.14   11.89   10.69   9.24   6.47  
150  11.52   9.69   8.72   7.53   5.27  
200  9.97   8.39   7.54   6.52   4.56  
300  8.13   6.84   6.15   5.32   3.72  
400  7.04   5.92   5.32   4.60   3.22  
500  6.30   5.30   4.76   4.12   2.88  
1000  4.45   3.74   3.37   2.91   2.03  
 
Table 32 – Power calculation from the RaDiVit study to show required sample size 
to detect differences of varying sizes with different powers (calculated using 
GraphPad StatMate version 2.00, GraphPad Software, Inc.) 
 
It may be possible to refine this figure using a more sophisticated power calculation 
that takes into account the difference in visual acuity between groups and the slightly 
different SDs present, but nevertheless, given the rate of recruitment for this study, it 
would be difficult to perform at a single institution and would need a multi-centre, or 
possibly even multi-national set-up to ensure recruitment in a reasonable time frame. 205 
 
3.5  Conclusions 
The RaDiVit study was the first randomised controlled trial to investigate the use of 
pre-treatment with ranibizumab on the clinical outcomes of vitreoretinal surgery for 
advanced proliferative diabetic retinopathy. Its primary outcome measure was visual 
acuity at 12 weeks post-surgery, and a number of secondary outcome measures were 
evaluated. 
 
The trial showed a potential beneficial effect for giving ranibizumab one week prior 
to vitrectomy for advanced PDR, as subjects in the treated group had better visual 
acuity at the primary endpoint compared to the control group. In this pilot study, 
statistical significance was not reached, and the wide range of visual acuity outcomes 
(and hence high standard deviation of the primary outcome result) means that no 
conclusion can yet be reached on the effect of ranibizumab in this condition. 
 
There were fewer subjects with post-operative vitreous cavity haemorrhage in the 
ranibizumab group than the control group. No differences were seen in the degree of 
intra-operative  haemorrhage,  either  by  subjective  (surgeon’s  bleeding  score)  or 
objective (haemocytometry) measures. 
 
Ultrasound evaluation on the day of injection and one week later explored the effect 
of ranibizumab on existing vitreoretinal pathology. No objective evidence was found 
that ranibizumab either caused tractional retinal  detachment or worsened existing 
detachment. 
 
Investigation of vitreous cytokine levels has confirmed elevated levels of IL-1α, IL-
6, IL-8, IP-10, MCP-1 and VEGF in subjects with diabetes. Two of these cytokines, 
IL-1α and VEGF were reduced following ranibizumab treatment. In plasma, there 
was a trend towards lower VEGF levels in subjects in the ranibizumab group but this 
did not reach statistical significance. 
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4 Conclusion 
 
Vascular endothelial growth factor is now widely recognised as the most important 
cytokine  in  the  complex  pathways  leading  to  physiological  and  pathological 
angiogenesis. Knockout of the Vegf gene is embryologically lethal, a multitude of in 
vitro studies  place VEGF at  the heart of pathways  for vascular proliferation and 
permeability, but most importantly, clinical evidence shows that inhibition of VEGF 
is an effective treatment modality for neovascular diseases of the eye. 
 
In this thesis, the results of two randomised clinical trials exploring the effects of 
VEGF inhibition with ranibizumab in the setting of diabetic eye disease have been 
presented.  
 
This  final  chapter  evaluates  the  strengths  and  weaknesses  of  the  study  designs, 
examines what conclusions, if any, can be drawn from the results, and discusses 
possible future work. 207 
 
4.1  Trial design 
The randomised clinical trial design remains the gold standard for comparing a new 
treatment against an existing treatment, or where there is no satisfactory existing 
treatment, against placebo. Therefore, for these two separate investigations, selecting 
a randomised trial design offered the best possibility of generating scientifically valid 
results. 
4.1.1  The LUCIDATE study design 
At the time of designing the protocol for the LUCIDATE study, the only licensed 
treatment available in the NHS for DMO was macular laser therapy. Ranibizumab 
was under investigation in large, phase 3 trials in this condition, but was awaiting a 
UK licence. The concept  of intravitreal  injections  was  daunting for patients,  and 
carried  risks  of  loss  of  sight  that  were  much  less  likely  with  laser  treatment. 
Therefore laser was selected for the control group in this study, to allow comparison 
of the new treatment with the existing standard treatment, and because it would be 
unethical to choose a placebo treatment when the ETDRS had shown laser to be 
superior to no treatment.  
 
However,  one  significant  failing  in  the  study  design  was  the  inclusion  of  non-
treatment naïve patients. Many of the recruited patients had already received laser as 
part of their standard care for DMO, so the ongoing effects of laser in these patients 
cannot be definitively excluded. 
 
Recruitment  for  the  study  took  just  under  nine  months,  with  the  first  patient 
randomised on 11/11/10 and the final randomisation on 27/7/11. Although there was 
a high prevalence of DMO in the Medical Retina clinics, there were still considerable 
barriers to recruitment. Identifying 126 potentially eligible patients to randomise 37 
subjects gave a ratio of 3.5 potential patients required to generate one randomisation. 
This means that a significant number of patients who could have benefited from the 
treatment were not included in the trial. Equally, those not included could have been 
different in some way from randomised subjects. 
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The investigations required to be undertaken by subjects at 0, 12, 24 and 48 weeks 
placed a significant burden on them and on the resources available. Carrying out all 
the  tests  required  the  patients  to  attend  on  two  separate  days  and  was  time 
consuming. The 48 week end point was chosen as this represented the point four 
weeks  after  a  12
th  and  final  ranibizumab  injection,  which  reflected  the  funding 
available. Other studies have typically chosen one year as a final outcome measure, 
with monthly rather than four-weekly retreatment. There are advantages in selecting 
a trial design that matches wider practice in order to improve the acceptability of 
results to the medical community. As it turned out, there were sufficient visits when 
retreatment with ranibizumab was not required to have had enough remaining to 
offer a 13
th possible injection to those who required it and extend the trial to a full 52 
weeks. 
 
Justification for choice of investigations 
 
All of the investigations undertaken were designed to offer new insights into the 
effects  of  ranibizumab  on  DMO.  Visual  acuity  is  the  standard  primary  outcome 
measure in clinical trials for macular disease and OCT retinal thickness a common 
secondary outcome measure. Looking in more detail into OCT derived measures of 
retinal  thickness  and volume, together with  morphological  changes,  increases  the 
understanding of the effects of ranibizumab and laser across the whole macular area 
and in different layers of the retina. Microperimetry has been investigated in DMO 
and there are reports of the effects of laser and triamcinolone treatment. A thorough 
investigation of retinal sensitivity following ranibizumab treatment in this condition 
has not been reported previously. The same is true for colour contrast sensitivity: 
while reports of altered colour vision in DMO date from the 1970s, no previous 
investigation  of  anti-VEGF  therapy  has  explored  this  functional  measure.  The 
potential adverse effects of pan anti-VEGF therapy on an ischaemic macula were a 
topic of interest when this trial was designed. This meant that significant macular 
ischaemia was a principal exclusion criterion that led to numerous potential patients 
not  being  recruited.  Although  the  BOLT  study  reported  no  increase  in  FAZ 
dimensions or area following 12 months of bevacizumab therapy, serial fluorescein 
angiography was again performed with masked Reading Centre grading to look for 
an  increase  in  macular  ischaemia  with  ranibizumab.  Similarly,  global 209 
 
electroretinography indices might have shown an overall decrease in retinal function 
after repeated anti-VEGF treatment. 
 
The retreatment protocol in this study was designed to give maximum exposure to 
ranibizumab;  this  was  to  maximize  the  likelihood  of  a  clinical  response  and  to 
increase the chance of detecting any significant safety issues (although none were 
anticipated). There continues to be no consensus in the retina specialist community 
regarding the optimum treatment schedule for anti-VEGF therapy in diabetic eye 
disease, although certain themes are emerging. The DRCR.net protocol I trial gave 
an initial four ranibizumab injections at monthly intervals then retreated with two 
further injections if there was anything other than a complete resolution of oedema 
with good visual acuity. In the subsequent six months and in the following two year 
extension to the study, injections were given at investigator discretion when oedema 
continued to be present or there had been a drop in visual acuity. The RIDE and 
RISE  licensing  trials  for  ranibizumab  gave  monthly  injections  for  two  years. 
Although these latter two trials had the best visual acuity results, further work from 
the DRCR.net study shows that many subjects who received 7-8 injections in year 1 
only need 2-3 in year 2 and 1-2 in year 3 to preserve visual acuity. Therefore it can 
be  said  with  confidence  that  subjects  in  the  LUCIDATE  study  were  not  under-
treated. 
 
4.1.2  The RaDiVit study design 
A  pilot  randomised  trial  was  designed  to  investigate  the  impact  of  ranibizumab 
therapy prior to diabetic vitrectomy to inform a power calculation for a subsequent 
definitive clinical trial. Surgery is the only recognised intervention for this type of 
advanced  proliferative  retinopathy,  and  results  of  the  Diabetic  Vitrectomy  Study 
demonstrated  its  superiority  to  observation.  There  is  no  recognised  pre-operative 
treatment in this setting, so it was appropriate to compare ranibizumab with placebo, 
which for this trial was a harmless subconjunctival saline injection. 
 
Bevacizumab  has  been  extensively  investigated  in  this  setting  but  has  not  been 
widely  adopted  because  of  its  unlicensed  status  and  because  of  safety  concerns 210 
 
regarding exacerbation of tractional retinal detachment and pre-retinal fibrosis. Other 
trials have suffered from methodological flaws putting them at high risk of bias and 
have  often  reported  single-surgeon  outcomes,  calling  into  question  their 
generalisability.  This pilot study chose to include multiple surgeons to avoid this 
problem, to be more representative of clinical practice, and because a definitive trial 
would likely require a multi-centre and hence multi-surgeon design. Further details 
of choices made in the design of the RaDiVit trial have been discussed in section 3.3. 211 
 
4.2  Trial results and applicability 
The trials showed evidence of benefit for ranibizumab over control in DMO and in 
surgery for advanced PDR but results were not generally statistically significant. 
 
4.2.1  The LUCIDATE study 
In the LUCIDATE study, detailed indices of retinal function were measured and 
retinal structure evaluated. The results showed the following trends at the 48 week 
endpoint: 
-  Better visual acuity with ranibizumab than laser 
-  Less  reduction  in  colour  contrast  sensitivity  with  ranibizumab  treatment 
compared with laser 
-  Improvement  in  retinal  sensitivity  measured  by  microperimetry  with 
ranibizumab 
-  Less reduction in PERG P50 amplitude with ranibizumab 
-  Greater thickness reduction in retinal subfields with ranibizumab compared to 
laser 
 
In several areas where there was potential concern that ranibizumab could exacerbate 
macular ischaemia or lead to  generalised retinal electrophysiological dysfunction, 
there was no evidence that ranibizumab caused harm: 
-  No new serious adverse events were identified that could be attributed to 
ranibizumab 
-  There was no evidence of worsening of macular ischaemia with ranibizumab 
-  There  was  no  evidence  of  global  retinal  dysfunction  by  full  field 
electroretinography following ranibizumab treatment 
-  No evidence of a change in choroidal thickness with either ranibizumab or 
laser 
 
The lack of statistical significance raises the possibility that these results have arisen 
by chance, or that the study was underpowered to detect the difference that exists 
between the two treatments.  212 
 
Further study would be useful in light of the small reduction in rod function shown 
by the decreased bright flash a- and b-wave amplitude detected with ranibizumab 
therapy; again, the lack of power to detect a difference means that statistical noise is 
a possibility for this finding. The change detected was of small magnitude (10%) and 
did  not  reach  statistical  significance.  It  was  not  accompanied  by  a  decrease  in 
generalised cone function and in particular, the cone 30 Hz flicker wave, arguably 
the most sensitive of the electrophysiological tests, was not affected. 
 
The  study  had  an  exploratory  design  and  so  a  power  calculation  could  not  be 
performed as the magnitude of the effect was unknown when the study commenced. 
In addition to lack of power, the study did not employ stratified randomisation at 
baseline, resulting in two groups that had differences at baseline in visual acuity, 
type of diabetes and duration of DMO. This is a major failure of randomisation in 
this trial and raises the possibility that the two groups were not directly comparable 
at baseline. 
 
Choroidal thickness and structure-function correlation are both areas of increased 
recent interest given the ready availability of higher resolution retinal imaging in the 
form of OCT. A post-hoc exploratory analysis in this study, which benefited from 
randomisation at baseline in contrast to many other published studies in this field, 
has not shown that choroidal thickness changes over 48 weeks of treatment with 
either  ranibizumab  or  laser.  This  is  an  important  negative  finding  in  a  rapidly 
evolving  field  and  suggests  that  while  the  choroid  may  be  important  in  the 
pathophysiology  of  diabetic  retinopathy,  choroidal  vascular  changes  may  not  be 
VEGF dependent in the same way that retinal vascular changes are.  
 
The  study  also  explored  the  relationship  between  retinal  thickness  and  retinal 
sensitivity. This showed that for ranibizumab treated patients, a decrease in retinal 
thickness  coincided  with  increased  retinal  sensitivity.  Further  work  in  this  area 
should explore the presence of structural abnormalities visible on OCT with their 
effect on retinal sensitivity. 
 
Data from OCT scans at entry to the study were used to establish the repeatability of 
automated retinal thickness and volume measurements using Spectralis SD OCT in 213 
 
DMO. This study showed that changes in thickness greater than 8 µm in the central 
subfield  are  likely  to  be  indicative  of  clinical  change  rather  than  measurement 
variability. This may have implications for the design of clinical trials and making 
retreatment decisions in clinical practice in the future. 
4.2.2  The RaDiVit study 
In the RaDiVit study, ranibizumab pre-treatment and sub-conjunctival saline in the 
control group led to improved visual acuity 12 weeks after diabetic vitrectomy. The 
results suggested a benefit for ranibizumab compared with saline, as the visual acuity 
gain was greater (24 letters for ranibizumab compared with 14 for control). A larger, 
powered trial that may require 300 subjects per arm would be needed to validate this 
finding in view of the large variability in outcome seen in terms of visual acuity in 
this study. It is therefore possible that the difference in visual acuity detected was 
driven by large changes in a small number of subjects that happened to occur in the 
ranibizumab group.  
 
Other findings from the trial were: 
-  A  trend  towards  a  lower  incidence  of  post-operative  vitreous  cavity 
haemorrhage in subjects treated with ranibizumab 
-  No evidence of new tractional retinal detachments or worsening of existing 
tractional retinal detachments with subjects treated with ranibizumab 
-  No  evidence  of  a  reduced  surgical  duration  or  reduced  intraoperative 
haemorrhage with ranibizumab 
-  A  change  in  the  cytokine  profile  of  the  vitreous  following  ranibizumab 
injection, but no firm evidence of changes to plasma cytokines 
 
Evaluation  of  cytokines  in  the  vitreous  and  plasma  of  subjects  in  this  trial  has 
provided further evidence that the interleukins IL-6 and IL-8, together with IP-10 
and MCP-1 are elevated in proliferative diabetic retinopathy. These cytokines are 
involved in the white blood cell recruitment as part of the inflammatory response, 
which plays a significant part in the pathophysiology of diabetic retinopathy. VEGF 
levels were reduced one week after ranibizumab administration as were levels of IL-
1α, although in small numbers of subjects only. This cytokine is implicated also in 214 
 
the activation of leukocytes in the inflammatory response and induces TNF-α release 
as well as activating cyclo-oxygenase pathways. It may therefore play a role in the 
induction  of  vascular  permeability,  and  if  it  is  activated  downstream  of  VEGF, 
inhibitors  of  VEGF  like  ranibizumab  could  plausibly  lead  to  reduced  levels,  but 
again validation in larger studies is required. The pharmacokinetics of ranibizumab 
are  different  from  bevacizumab,  and  while  the  latter  is  readily  detectable  in  the 
serum of rabbits following intravitreal injection, ranibizumab is not. Bevacizumab 
reduced serum VEGF to a greater degree than ranibizumab in subjects in the large 
IVAN trial for AMD and in this study, levels of plasma VEGF were not significantly 
different  in  subjects  who  had  received  a  single  dose  of  ranibizumab  one  week 
previously.  Thus  while  concern  remains  about  the  possibility  of 
arteriothromboembolic  events  as  a  results  of  systemic  action  of  ranibizumab 
following intravitreal injection, this study has not shown reduced levels of VEGF 
systemically. 
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4.3  VEGF inhibition in diabetic eye disease 
Ranibizumab is a monoclonal antibody fragment that binds all isoforms of VEGF-A. 
Differential splicing of messenger RNA gives rise to different isoforms of VEGF that 
exhibit  different  properties.  To  our  knowledge,  all  of  these  are  inhibited  by  the 
currently  available  VEGF  inhibitors  with  the  exception  of  pegaptanib,  which 
selectively binds VEGF165. If this were genuinely the most important VEGF isoform 
in the setting of pathological angiogenesis, it is surprising that trial results for this 
drug in AMD and DMO have not shown it to be more effective. 
 
VEGF has been shown to be neuroprotective in the retina; for example it reduces 
retinal neuronal apoptosis as a result of ischaemia/reperfusion injury  [31], and is 
released as part of ischaemic preconditioning. This raises the possibility that VEGF 
is a critical survival factor for neurons in ocular diseases characterised by retinal 
ischaemia, such as diabetic retinopathy, and that inhibiting VEGF by ranibizumab 
and  other  pharmacological  agents  could  have  deleterious  effects  on  the  retina. 
Detailed  functional  testing  combined  with  evaluation  of  structures  such  as  the 
perifoveal capillaries in the LUCIDATE study was carried out to explore a possible 
effect of repeated VEGF inhibition on the neurovascular unit. The results did not 
support  a  conclusion  that  ranibizumab  led  to  significant  reductions  in  retinal 
function. Subjects in the RaDiVit study, with more advanced diabetic retinopathy 
and  more  retinal  ischaemia,  still  gained  vision  after  surgery  when  ranibizumab 
pretreatment had been administered. 
 
4.3.1.1  VEGFxxxb isoforms 
A  further  dimension  to  the  understanding  of  VEGF  biology  has  arisen  with  the 
discovery of new variants of the VEGFxxx molecules, such as VEGF165b. This was 
first identified in a renal cell carcinoma line and arises through a change in the distal 
splice acceptor site in exon 8 [23]. This group of VEGFs activate VEGF receptors in 
a  different  way  and  hence  may  have  different  properties,  being  associated  with 
physiological, rather than pathological angiogenesis [218]. 216 
 
Evidence that VEGF165b may inhibit angiogenesis and could have a cytoprotective 
effect by reducing the cellular insult following induced ischaemia [98] suggests that 
vascular homeostasis is maintained by a delicate balance between these isoforms. 
This could have implications for pan anti-VEGF inhibition as a treatment strategy: 
inhibiting  isoforms  of  the  molecule  that  are  responsible  for  preserving  healthy 
vasculature could have unwanted effects. 
As greater understanding of the roles of different isoforms of VEGF in the landscape 
of angiogenesis and vascular homeostasis is reached, it may become apparent that 
pan anti-VEGF inhibition is an aggressive step to take given the delicate balance 
existing between isoforms. A switch in splice variants has been reported to occur in 
diabetic  retinopathy  [219],  so  therapeutic  approaches  in  future  could  look  at  the 
molecular mechanisms behind this change in expression of VEGF isoforms that may 
underpin the development of pathological angiogenesis.  
 
In the first instance, the development of an analytical test specific to different VEGF 
isoforms including VEGF165b would mean that vitreous and plasma samples from the 
RaDiVit study could be analysed in an isoform-dependent manner to shed further 
light on the effects of ranibizumab.  
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4.4  Future work 
These trials both add to the existing literature on the place of anti-VEGF therapy in 
diabetic eye disease, and suggest a benefit for ranibizumab treatment compared to 
existing practice in two clinical scenarios. Further confirmatory work is needed. 
 
Following the LUCIDATE study: 
-  Further analysis of morphological data from OCT scans and the correlation of 
structural changes with sensitivity changes should be carried out 
-  A  powered  study  could  be  undertaken  to  validate  the  change  in  colour 
contrast sensitivity and retinal sensitivity measured by microperimetry with 
ranibizumab. This would only be of value if felt to be clinically relevant 
-  Larger  studies  examining  the  effect  of  anti-VEGF  agents  on  the  choroid 
should be undertaken to improve understanding of the role of the choroid in 
the pathogenesis of diabetic retinopathy 
 
Following the RaDiVit study: 
-  A definitive, powered trial should be undertaken to test the hypothesis that 
ranibizumab pre-treatment leads to improved visual acuity at 12 weeks post-
surgery for subjects with advanced proliferative diabetic retinopathy. 
 
This is likely to present challenges in terms of recruiting the number of patients 
needed. Ongoing trials investigating the efficacy of ranibizumab as a treatment for 
proliferative retinopathy instead of panretinal laser may show that medical treatment 
leads to improved outcomes and reduction in the rates of development of advanced 
proliferative  retinopathy.  If  this  is  the  case,  diabetic  vitrectomy  surgery  could 
become a rarely performed procedure. At present though, despite screening and in 
some cases prompt panretinal photocoagulation, there remains a subset of patients 
who  develop  advanced  retinopathy  and  are  at  risk  of  blindness  without  surgery. 
While this is the case, efforts should continue to optimise the results of that surgery 
in terms of visual outcome and post-operative complications. 
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